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Hypercholesterolemia is a major risk factor for development of coronary heart
disease.  Proper diagnosis and adequate treatment are vital to reducing
morbidity and mortality associated with elevated serum lipid levels.  The
amount of literature in this area is overwhelming.  To aid practitioners and
educators in organizing this large body of information, we compiled key articles,
guidelines, and consensus papers relative to the treatment of dyslipidemias.
Research articles were chosen based on the significance of findings, relevance to
practice, quality of research, and timeliness; recent articles were given priority
over earlier ones unless they demonstrated groundbreaking findings.
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Coronary heart disease (CHD) is the leading
cause of death in the United States and other
industrialized nations and is the chief cause of
premature, permanent disability in the
workforce.  Hypercholesterolemia is a major risk
factor for development of CHD.  Thus, it is not
surprising that cholesterol is the most
“decorated” molecule in history, having
contributed to as many as 13 Nobel prizes.1 In
the past 20 years, major strides have been made
in the understanding and treatment of
hypercholesterolemia and other dyslipidemias.
Since its inception in 1985, the National
Cholesterol Education Program (NCEP) has
battled to reduce the prevalence of high blood
cholesterol through educational campaigns and
science-based practice guidelines.2 However,
cholesterol levels are still undertreated.3
The body of literature presented here provides
a source of important references and practice
guidelines for clinicians seeking to broaden their
knowledge regarding treatment of dyslipidemias.
Research articles were chosen based on
significance of findings, relevance to practice,
quality of research, and timeliness; recent articles
were given priority over earlier ones unless they
demonstrated groundbreaking findings.  Selected
review articles were included for their compre-
hensive overview and state-of-the-art perspective.
Epidemiologic Studies
Stamler J, Wentworth D, Neaton JD. Is the
relationship between serum cholesterol and risk
of premature death from coronary heart disease
continuous and graded? Findings in 356,222
primary screenees of the multiple risk factor
intervention trial (MRFIT). JAMA 1986;256:
2827–8.
The Multiple Risk Factor Intervention Trial, a
CHD prevention trial, screened 356,222 men as
possible participants.  Overall mortality related to
CHD was examined in relation to blood pressure,
serum cholesterol levels, and cigarette smoking
in men aged 35–50 years.  The relationship
between cholesterol levels and 6-year risk of
death from CHD was steady, continuous, and
graded.  Of all CHD-related deaths, 46% were
estimated to be excess deaths attributable to
cholesterol levels of 180 mg/dl or greater, and
almost half the excess deaths involved cholesterol
levels in higher quintiles.  In other words, there
was no threshold of cholesterol level at which
high risk occurred; risk of death was progressive
with increasing total cholesterol levels.
Kronmal RA, Cain KC, Ye Z, Omenn GS. Total
serum cholesterol levels and mortality risk as
a function of age: a report based on the
Framingham data. Arch Intern Med 1993;153:
1065–73.
The Framingham Heart Study, initiated in 1948
in Framingham, Massachusetts, has been one of
the leading longitudinal cohort studies of risk for
CHD in both men and women.  In this
Framingham cohort, the relationship between
serum cholesterol levels and all-cause, CHD, and
non-CHD mortality as a function of age was
evaluated.  Elevated cholesterol levels were
associated with high all-cause and CHD mortality
at age 40 years, negligible at 50–70 years, and
negative at 80 years.  Similar results were
observed with the relationship between low- and
high-density lipoprotein cholesterol (LDL and
HDL, respectively) and all-cause and CHD
mortality in different age groups.  Non-CHD
mortality was significantly negatively related to
cholesterol levels at age 50 years or older. The
negative results at age 60 years or older for all-
cause and CHD mortality may be due to the
negative relationship with LDL levels rather than
the protective effects of elevated HDL levels.
This study demonstrated that clinicians should
be cautious about starting lipid-lowering therapy
in elderly men or women.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K,
Laakso M. Mortality from CHD in subjects with
type 2 diabetes and nondiabetic subjects with
and without prior myocardial infarction. N Engl J
Med 1998;339:229–34.
Type 2 diabetes mellitus is a major risk factor
for CHD, which is an independent risk factor
(with both strength of epidemiologic association
and biologic plausibility).  Whether patients with
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diabetes without previous CHD are at greater risk
for myocardial infarction than those without
diabetes who have CHD has been debated.  A
Finnish population-based study evaluated the 7-
year rate of fatal and nonfatal myocardial
infarction in 1059 patients with and 1373
patients without diabetes.  The 7-year rate of
myocardial infarction in patients with diabetes,
with and without previous CHD, was significant
at 45% and 20.2%, respectively (p<0.001).
However, in those without diabetes, with and
without previous CHD, the rate was 18.8% and
3.5%, respectively (p<0.002).  The hazard ratio
(HR) of death after adjustment for age, sex, total
cholesterol level, hypertension, and smoking was
close to 1.0.  This study suggests that patients
with and without diabetes (with previous CHD)
should be treated aggressively.
Lipids and Lipoprotein Metabolism
Genest J. Lipoprotein disorders and cardio-
vascular risk. J Inherit Metab Dis 2003;26:
267–87.
The pharmacotherapy for patients with lipid
disorders requires a firm understanding of
lipoprotein metabolism and underlying genetic
defects.  This article is an excellent review of
lipoprotein composition and structure, lipoprotein
transport and lipid metabolism, and genetic
disorders leading to dyslipoproteinemia.
Brewer HB. Increasing HDL cholesterol levels. N
Engl J Med 2004;350(15):1491–4.
Although LDL remains the primary target for
reducing the risk of CHD, the focus on potential
targets for raising HDL has increased in recent
years.  This report reviews the role of HDL in
reverse cholesterol transport, with a focus on a
recently identified sterol transporter, the
adenosine 5′-triphosphate (ATP)–binding
cassette transporter 1 (ABCA1).  In addition,
potential modalities for raising HDL levels are
reviewed, such as genetically engineered
apolipoprotein A-I Milano (discussed in the
Angiographic or Surrogate End Point Trials
section) and inhibitors of cholesterol ester
transfer protein.  The author concludes that
drugs being developed to increase HDL levels
hold great promise for reducing the risk of
cardiovascular disease.
Oram JF, Lawn RM. ABCA1: the gatekeeper for
eliminating excess tissue cholesterol. J Lipid Res
2001;42:1173–9.
The cellular ATP-binding cassette transporter
ABCA1 mediates the initial steps in reverse
cholesterol transport.  Genetic mutations in
ABCA1 cause severe HDL deficiency.  This article
reviews the role of ABCA1 in removing excess
cholesterol from peripheral cells, gene mutation,
regulation, and tissue expression of ABCA1.  The
authors conclude that ABCA1 is the gatekeeper
for modulating cholesterol efflux from peripheral
tissue and is an attractive target for drug
development.
Phan CT, Tso P. Intestinal lipid absorption and
transport. Front Biosci 2001;6:D299–319.
Inhibition of cholesterol absorption is an
important strategy for reducing serum cholesterol
levels.  This review is an update of our current
knowledge of the digestion, uptake, and
transport of dietary lipid.  The authors discuss
the role of intestinal lipid transporters in the
uptake of lipids by the enterocytes, how
chylomicrons are formed and packaged for
export into the lymphatic system through
exocytosis, and clinical disorders as they relate to
lipid absorption.
Atherogenesis
Libby P. Molecular basis of the acute coronary
syndromes. Circulation 1995;91:2844–50.
Research in vascular biology has surged in
recent years.  Advances have led to significant
insights into the treatment of atherosclerosis.
This article reviews the basic regulatory
mechanisms underlying vascular biology.  In
addition, it reviews research developments that
have resulted in the paradigm shift from a focus
on high-grade stenosis and revascularization to
the vascular biology of the arterial wall and
noncritically stenotic plaques (“vulnerable
plaques”).  These plaques are actually more
prone to rupture, leading to acute coronary
syndromes (ACS).  The author concludes that
increased understanding of cellular and
molecular mechanisms of the vascular wall in
patients with atherosclerosis will lead to novel
therapies aimed at stabilizing these vulnerable
plaques.
Ross R. Atherosclerosis: an inflammatory disease.
N Engl J Med 999;340:115–26.
The pathologic process of atherogenesis is
mediated and propagated by a variety of
inflammatory mediators.  This article reviews
941
PHARMACOTHERAPY  Volume 26, Number 7, 2006
factors such as lipids and lipoproteins,
homocysteine, hypertension, and infectious
microorganisms that induce and promote
inflammation.  The nature of the inflammatory
response and its role in plaque instability and
rupture are discussed.  The author concludes that
atherosclerosis is clearly an inflammatory disease
not always associated with hypercholesterolemia.
Targeting the various components of the
inflammatory process should result in promising
new therapies to reduce the risk of cardiovascular
disease.
Guidelines and Position Statements
Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults.
Third report of the national cholesterol education
program (NCEP) expert panel on detection,
evaluation, and treatment of high blood
cholesterol in adults (adult treatment panel III)
final report. Circulation 2002;106:3143-421.
The cholesterol guidelines, issued by the third
adult treatment panel (ATP III) of the NCEP in
May 2001, reflect the extension of the knowledge
base since the ATP II guidelines were issued in
1993.  The main focus of the 2001 recommen-
dations is to lower LDL further than recom-
mended previously.  The optimum LDL goal
decreased from 130 to 100 mg/dl.  Although the
optimum total cholesterol goal remained the
same, lower than 200 mg/dl is considered
desirable; HDL level should be at least 40 mg/dl,
as compared with 35 mg/dl in the earlier
guidelines.  Other changes involve treating
patients with diabetes who have elevated
cholesterol levels more aggressively, testing first
for high total cholesterol levels, determining a
new level at which low HDL becomes a major
risk factor for CHD, intensifying the use of
changes in nutrition, increased physical activity,
and weight control (therapeutic lifestyle
changes), identifying the metabolic syndrome of
risk factors linked to insulin resistance, paying
more attention to elevated triglyceride levels, and
advising against hormone replacement therapy as
an alternative to lipid-lowering drugs.
The 2001 guidelines also introduced the
concept of the Framingham risk score, or the
probability of having a CHD event within 10
years.  The score is computed based on age, sex,
tobacco use, and high blood glucose level.  This
score should be calculated for any patient with
hyperlipidemia and two or more risk factors for
CHD.  For a patient whose 10-year risk is greater
than 20%, the LDL goal would be less than 100
mg/dl.  All the changes translate to aggressive
treatment for patients with diabetes or certain
risk factor clusters, and for elderly patients, with
lipid-lowering agents as adjunct therapy for a
healthier diet and increased physical activity.
The 2001 guidelines will increase the use of
lipid-lowering agents.
Grundy SM, Cleeman JI, Bairey Merz CN, et al,
for the Coordinating Committee of the National
Cholesterol Education Program Endorsed by the
National Heart, Lung and Blood Institute,
American College of Cardiology Foundation,
and American Heart Association . Update
implications of recent clinical trials for the
national cholesterol education program adult
treatment panel III guidelines. Circulation
2004;110:227–39.
This update is based on results from the five
clinical trials of statin treatment conducted since
the release of the NCEP ATP III guidelines in
2001.  Endorsed by the American College of
Cardiology Foundation, American Heart
Association, and National Heart, Lung and Blood
Institute (ACC/AHA/NHLBI), this update offers
options for more aggressive lowering of LDL
levels for individuals at high and moderate risk
for CHD.  This update emphasizes that thera-
peutic lifestyle changes remain the cornerstone of
treatment for lowering cholesterol levels.  For
high-risk patients, the goal LDL level is still less
than 100 mg/dl; one therapeutic option sets the
goal at less than 70 mg/dl for patients at very
high risk.  The update recommends consid-
eration of lipid-lowering agents as an adjunct to
therapeutic lifestyle changes in high-risk patients
with an LDL level 100 mg/dl or greater, and
consideration of drug treatment as an option for
patients whose LDL level is less than 100 mg/dl.
For patients at moderately high risk, the update
recommends keeping the overall LDL goal of less
than 130 mg/dl.  One therapeutic option for
patients whose LDL level is 100–129 mg/dl is to
set the LDL goal below 100 mg/dl, with drug
treatment.  The update advises that the intensity
of LDL-lowering drug treatment in patients at
high risk or moderately high risk be sufficient to
achieve at least a 30% decrease in LDL level.
Finally, for patients at moderate or low risk, the
update does not modify the ATP III recommen-
dations.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et
al. ACC/AHA/NHLBI advisory on the use and
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safety of statins. J Am Coll Cardiol 2002;40:
568–73.
These guidelines from the ACC/AHA/NHLBI
committee are the first recommendations
specifically directed toward health care profes-
sionals regarding the use and safety of statins.
The committee defined and summarized the
current understanding of statin use, including
cautions, contraindications, and safety monitoring
for statin therapy.  More specifically, the
committee provides information regarding
myopathy compiled by the United States Food
and Drug Administration (FDA), clinical trials,
and a brief summary from ATP III.  These
guidelines were released in response to the
voluntary withdrawal of cerivastatin from the
U.S. market on August 8, 2001, by the
manufacturer, in agreement with the FDA.  The
withdrawal of cerivastatin prompted concerns on
the part of physicians and patients regarding the
safety of statin therapy. Of note, statins are the
most commonly prescribed lipid-lowering agents
worldwide, often cited as over 25 million
prescriptions.  Because of the life-saving potential
of statins, the committee’s purpose was to
enhance the prescribing of statins and dispel any
misunderstanding about the safety of these
agents.
Haffner SM; American Diabetes Association.
Dyslipidemia management in adults with
diabetes. Diabetes Care 2004;27(suppl 1):S68–71.
The recommendations in this article are based
on the earlier American Diabetes Association
technical review, Management of Dyslipidemia in
Adults with Diabetes, by the same authors
(Diabetes Care 2003;26(suppl 1):S83–6).  That
article was a concise review of relevant literature
focusing on both drug and nondrug therapy for
patients with type 2 diabetes, a disease associated
with a 2–4-fold excess risk of CHD.  This 2004
article presents screening and diagnoses based on
expert opinions.  Treatment-goal recommen-
dations based on levels of evidence (A, B, and C)
are summarized.
Meta-Analyses of Clinical Trials
LaRosa JC, He J, Vupputuri S. Effect of statins
on risk of coronary disease: a meta-analysis of
randomized controlled trials. JAMA 1999;282:
2340–6.
Although reducing LDL levels lowers the risk
of recurrent CHD in middle-aged men, whether
this is true with women and elderly individuals is
less certain.  The goal of this meta-analysis was to
determine the risk reduction of CHD and all-
cause mortality associated with statin therapy in
women and the elderly.  Studies included in the
analysis involved patients who were randomized
to treatment with a statin or control for at least 4
years; primary outcome was death or a major
clinical event.  Overall, statin treatment reduced
the risk of major clinical events by 31% and all-
cause mortality by 21%.  No difference in risk
reduction of major clinical events was noted
between men and women, or between patients
aged 65 years or older and those younger than 65
years.  The authors concluded that statin therapy
for at least 5 years provides risk reduction for
middle-aged and elderly men and women.
Amarenco P, Labreuche J, Lavallee P, Touboul
PJ. Statins in stroke prevention and carotid
atherosclerosis: systematic review and up-to-date
meta-analysis. Stroke 2004;35:2902–9.
Previous studies had shown that statin therapy
reduces the risk of stroke; however, the effects of
reducing LDL levels on stroke occurrence were
not clear.  These authors provided a systematic
review and meta-analysis of all randomized trials
evaluating statin therapy before August 2003.
The primary goal of this analysis was to
determine the effects of statins and LDL level
reduction on stroke occurrence in more than
90,000 patients.  The authors evaluated the effect
of statins on type and rate of stroke as well as
carotid atherosclerosis, measured by intimal
medial thickness according to LDL level
reduction.  Relative risk reduction for stroke was
21%, with no heterogeneity between trials, and
with reduction in fatal stroke and no increase in
hemorrhagic stroke.  Each 10% reduction in LDL
level was associated with relative risk reduction
of 15.6% and carotid intimal medial thickness of
0.73%/year.  Results from this analysis suggest
that statin therapy, by decreasing LDL levels, may
reduce the rate of stroke.  In addition, the results
indicate that LDL level reduction is strongly
correlated with progression of carotid intimal
medial thickness.
Goldberg AC. A meta-analysis of randomized
controlled studies on the effects of extended-
release niacin in women. Am J Cardiol 2004;94:
121–4.
The aim of this meta-analysis was to determine
the LDL-lowering effects of extended-release
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niacin in women compared with men.  In five
trials involving 432 patients, the difference in
LDL level reductions were significantly greater in
women than men at all evaluated dosages of
extended-release niacin 1000–2000 g/day.  In
addition, effects on triglyceride level reduction
were greater in women and reached significance
with 1500 g/day.  No difference was noted
between men and women regarding lipoprotein(a)
and HDL levels.  Although the NCEP ATP III
does not recommend different guidelines for
women and men, HDL and triglyceride levels
appear to be stronger risk factors in women than
in men.  Hence, the metabolic syndrome may be
of special concern in women.  This is
compounded by the fact that LDL and total
cholesterol levels as risk predictors are as
powerful in women as in men.  Niacin is unique
in that it substantially improves all major lipid
parameters, and the extended-release formulation
has been associated with fewer episodes of
flushing.  This meta-analysis confirms that
women respond well to extended-release niacin,
which is safe for treatment of mixed
hyperlipidemia.
Balk EM, Lau J, Goudas LC, et al. Effects of
statins on nonlipid serum markers associated
with cardiovascular disease: a systematic review.
Ann Intern Med 2003;139:670–82.
The clinical benefits of statins are largely due
to lipid-lowering effect; however, these benefits
also are due to nonlipid effects on endothelial
function, inflammation, thrombosis, and smooth
muscle proliferation (often collectively called
pleiotropic effects).  These effects have been
identified in numerous experiments, and changes
have reportedly occurred within weeks or
months of the start of therapy.  The authors
provide a systematic review in an attempt to
evaluate the effects of statins on nonlipid serum
markers, particularly with lipid levels and CHD
outcomes.  When appropriate, a meta-analysis
was performed.  Among the nonlipid markers
evaluated, only high-sensitivity C-reactive
protein (hs-CRP) levels were significantly
lowered by statin therapy.  However, no
correlation was observed between statin effects
on hs-CRP and lipid levels or CHD outcomes.  Of
note, hs-CRP level was independently associated
with premature development of CHD.  The
findings from this trial, along with those from
other clinical trials, indicate that screening for
hs-CRP level is appropriate in those at high risk
for CHD and that statin therapy may provide an
antiinflammatory effect, potentially contributing
to reduction of CHD outcomes.
Corvol JC, Bouzamondo A, Sirol M, Hulot JS,
Sanchez P, Lechat P. Differential effects of lipid-
lowering therapies on stroke prevention: a meta-
analysis of randomized trials. Arch Intern Med
2003;163:669–76.
A number of risk factors for first stroke can be
addressed, such as having experienced
myocardial infarction.  The incidence of stroke
after myocardial infarction is 1–2%/year, with the
greatest risk in the first month.  Although
antiplatelet therapy (e.g., aspirin) is the mainstay
of treatment, trials have suggested that statin
therapy may reduce the risk of stroke after
myocardial infarction.  The authors evaluated 38
trials involving a total of 83,161 patients, with
follow-up of about 5 years.  The meta-analysis
showed a significant relative risk reduction
(17%) of stroke with lipid-lowering agents,
without significant heterogeneity between trials
and between subgroups, according to type of
patient or lipid-lowering agent.  Statins showed a
significant relative risk reduction (26%) in the
rate of stroke.  This analysis demonstrated that
lipid-lowering therapy, particularly statins,
reduces the occurrence of stroke in patients with
CHD when their total cholesterol level is lowered
to less than 232 mg/dl.  These results further
support statin therapy, along with aspirin, to
reduce the occurrence of stroke after myocardial
infarction in patients with previous high
cholesterol levels.
Prospective Primary Prevention Trials
Statins
Downs JR, Clearfield M, Weis S, et al, for the
AFCAPS/TexCAPS Research Group. Primary
prevention of acute coronary events with
lovastatin in men and women with average
cholesterol levels: results of AFCAPS/TexCAPS.
JAMA 1998;270:1615–22.
The Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS) was the
first landmark statin trial to show reduction of
CHD morbidity and mortality in a cohort of
generally healthy individuals without clinical
evidence of coronary artery disease (CAD).  This
randomized, double-blind, placebo-controlled
trial investigated the benefits of long-term
lovastatin therapy in men and women with
average LDL and total cholesterol levels, and
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lower-than-average HDL levels.  The study
randomized 6605 participants to receive either
placebo or lovastatin 20 mg/day, which could be
titrated to 40 mg/day to maintain LDL levels of
110 mg/dl or lower.  Baseline mean total
cholesterol and LDL levels were 221 and 150
mg/dl, respectively.  The primary end point was a
composite of sudden cardiac death, fatal and
nonfatal myocardial infarction, and unstable
angina.  Participants receiving lovastatin
experienced a 37% relative risk reduction for the
first acute major coronary event compared with
those receiving placebo (Cox proportional
hazards model, 95% confidence interval [CI]
21–50%, p<0.001).  Also, AFCAPS/TexCAPS
showed that benefit with lovastatin therapy
extended to Hispanics, African-Americans, and
older persons.  This study was the first large-scale
primary prevention trial to include a substantial
number of women and to include unstable
angina in the primary end point.
Shepherd J, Cobbe SM, Ford I, et al, for the
West of Scotland Coronary Prevention Study
Group. Prevention of coronary heart disease with
pravastatin in men with hypercholesterolemia. N
Engl J Med 1995;333:1301–7.
The West of Scotland Coronary Prevention
Study (WOSCOPS) was the first landmark trial to
demonstrate the benefit and safety of lipid-
lowering therapy with a statin in patients with
hypercholesterolemia for prevention of CHD.
The authors evaluated the effectiveness of
pravastatin in preventing coronary events in men
with moderate hypercholesterolemia, a baseline
LDL level of 155 mg/dl or greater, and no history
of myocardial infarction.  The study randomized
6595 men aged 45–64 years to receive either
placebo or pravastatin 40 mg every evening.  The
combined primary end point was the occurrence
of nonfatal myocardial infarction or death from
CHD as a first event.  Other end points were the
effect of treatment on death from cardiovascular
causes, death from any cause, and frequency of
coronary revascularization procedures.
Pravastatin produced a 31% risk reduction of the
combined primary end point (95% CI 17–43%,
p<0.001) compared with placebo after 4.9 years
of follow-up.  This study also showed that
pravastatin reduced the risk of coronary
angiography, percutaneous transluminal coronary
angiography, coronary artery bypass grafting, and
death from all cardiovascular causes.
Sever PS, Dahlof B, Poulter NR, et al. Prevention
of coronary and stroke events with atorvastatin in
hypertensive patients who have average or lower-
than-average cholesterol concentrations, in the
Anglo-Scandinavian cardiac outcomes trial–lipid
lowering arm (ASCOT-LLA): a multicentre
randomised controlled trial. Lancet 2003;361:
1149–58.
This study reported the results from the Anglo-
Scandinavian Cardiac Outcomes Trial–Lipid
Lowering Arm (ASCOT-LLA), a multicenter,
randomized trial comparing two antihypertensive
treatment strategies for primary prevention of
CHD.  Results showed that adding statins to
antihypertensive therapy reduced CHD risk in
patients with hypertension and moderate
cardiovascular risk who were not conventionally
considered to have dyslipidemia.  The ASCOT-
LLA results support the benefit of early treatment
of patients at high risk of cardiovascular events.
In this double-blind, two-by-two factorial
comparison, 10,305 patients with hypertension
from ASCOT were randomized to receive
atorvastatin 10 mg/day or placebo.  Study
patients had total cholesterol levels of 250 mg/dl
or lower and at least three risk factors for
cardiovascular disease.  The primary end point
was the combination of nonfatal myocardial
infarction, silent myocardial infarction, and fatal
CHD.
The study was terminated early on recommen-
dation of the data safety monitoring board
because atorvastatin therapy had resulted in a
highly significant reduction in the primary end
point of CHD events and in the rate of stroke
compared with placebo.  Relative risk of the
primary end point was reduced by 36% (HR 0.64,
95% CI 0.50–0.83, p=0.0005) after 1 year of
follow-up.  Four of the secondary end points
(total cardiovascular events, total coronary
events, and fatal or nonfatal stroke) and the
primary end point (except for silent myocardial
infarction) were also significantly reduced.  Other
than the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial
(ALLHAT), ASCOT-LLA was the only trial to
study the effects of lipid-lowering therapy
specifically in patients with hypertension.  The
results support the trend to treat numerous
cardiovascular risks in patients with hyper-
tension because statin therapy conveyed benefits
in addition to good blood-pressure control.
The ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group. Major
outcomes in moderately hypercholesterolemic,
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hypertensive patients randomized to pravastatin
vs usual care: the antihypertensive and lipid-
lowering treatment to prevent heart attack trial
(ALLHAT-LLT). JAMA 2002;288:2998–3007.
This randomized, nonblinded trial was the
lipid-lowering component of ALLHAT.  The
purpose of the study was to determine the effects
of pravastatin versus usual care in a subset of
patients with hypertension, moderate hyper-
cholesterolemia, and at least one other CHD risk
factor.  The study also assessed CHD reduction
and other benefits in populations that have been
excluded or underrepresented in previous trials,
such as older patients, women, and racial and
ethnic minority groups.  The study randomized
10,355 participants to receive pravastatin 40
mg/day or usual care, which was at the discretion
of primary care physicians.  The primary end
point was all-cause mortality, the secondary
outcome a composite of fatal or nonfatal CHD
events.
After a mean of 4.8 years, calculated LDL levels
decreased by 27.7% and 11.0% in the pravastatin
and usual-care groups, respectively. The primary
end point of all-cause mortality was not
significantly different between the two groups
(relative risk [RR] 0.99, 95% CI 0.89–1.11,
p=0.88), nor was the secondary end point (RR
0.91, 95% CI 0.79–1.04, p=0.16).  Failure to
detect mortality and morbidity benefits with
pravastatin was attributed to several reasons.
One reason was a decline in adherence to the
prescribed treatment over time; another was a
high rate of crossover of patients from the usual-
care group to the pravastatin group, and a third
was a modest differential in total cholesterol
levels (9.6%) between the pravastatin and usual-
care groups.  In a subgroup analysis, however,
pravastatin significantly reduced CHD events in
African-Americans.  The authors suggested that
achieving larger reductions in total cholesterol
and LDL levels is needed to achieve reduced
CHD risk.
Colhoun HM, Betteridge DJ, Durrington PN, et
al. Primary prevention of cardiovascular disease
with atorvastatin in type 2 diabetes in the
collaborative atorvastatin diabetes study
(CARDS): multicentre randomised placebo-
controlled trial. Lancet 2004;364:685–96.
The Collaborative Atorvastatin Diabetes Study
(CARDS) was the first primary prevention study
to show reduction of major cardiovascular events
in a population with type 2 diabetes and a
moderate LDL level.  This randomized, double-
blind, placebo-controlled study investigated the
effectiveness of atorvastatin versus placebo in the
primary prevention of cardiovascular disease in
patients with type 2 diabetes.  The study enrolled
2838 men and women aged 40–75 years with
type 2 diabetes and at least one of the following
other risk factors:  hypertension, retinopathy,
macroalbuminuria, microalbuminuria, or
smoking.  Study patients had baseline LDL levels
of 160 mg/dl or lower and triglyceride levels of
600 mg/dl or lower.  Eligible patients were
randomized to receive either atorvastatin 10
mg/day or placebo, but investigators were
allowed to prescribe treatment in addition to the
study drug if further lipid-lowering therapy was
needed.  Additional treatment could include
atorvastatin 10 mg/day, simvastatin up to 40
mg/day, pravastatin up to 40 mg/day, fluvastatin
up to 80 mg/day, and cerivastatin 0.3 mg/day.
The primary end point was a composite of an
acute CHD event, coronary revascularization
procedures, and stroke.  Atorvastatin treatment
was associated with a 37% reduction in
occurrence of the primary end point (HR 0.63,
95% CI 0.48–0.83, p=0.001).  Separate assess-
ment of each component revealed reductions of
36% in acute coronary events, 31% in coronary
revascularization events, and 48% in stroke.
Overall, CARDS was the first trial to study the
effects of a statin exclusively in patients with
diabetes, unlike other studies that performed
only subgroup analyses of patients with diabetes.
Fibrates
World Health Organization Committee of
Principal Investigators. WHO cooperative trial
on primary prevention of ischaemic heart disease
with clofibrate to lower serum cholesterol: final
mortality follow-up. Report of the committee of
principal investigators. Lancet 1984;2:600–4.
This is the final report of the World Health
Organization (WHO) cooperative trial that
investigated the effects of clofibrate versus
placebo on ischemic heart disease (IHD) in
healthy men without evidence of heart disease.
The study compared a high-risk group of men
receiving clofibrate with a high-risk control
group and a low-risk control group.  The results,
first published in 1978, showed a 25% reduction
(p<0.05) in nonfatal myocardial infarction among
men with plasma cholesterol levels in the upper
third of the distribution who were given
clofibrate.  However, mortality from all causes
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and causes other than IHD was significantly
higher in the clofibrate group.  The first posttrial
follow-up report showed 25% more deaths in the
clofibrate group than in the high-cholesterol
control group (p<0.01).
This warranted a follow-up of mortality for an
additional 4 years.  After an average of 13.2 years
from time of study entry to the end of the final
follow-up, 1788 deaths occurred in 208,000
patient-years of observation.  A total of 720
deaths (8.6/1000 patients/yr) occurred from all
causes in the clofibrate group, 650 (7.9/1000/yr)
in the high-risk control group, and 418
(5.7/1000/yr) in the low-risk control group.
Differences in the total numbers and rates/1000
patients/year of deaths between the clofibrate
group and the high-risk control group were not
statistically significant.  Excess deaths in the
clofibrate group were more numerous during the
treatment phase than after treatment ended.  The
final report of the WHO cooperative study
showed an excess mortality in patients treated
with clofibrate, but this was confined to the
clofibrate treatment period and did not continue
during follow-up.  Clofibrate reduced the
occurrence of nonfatal myocardial infarction, but
not mortality, from IHD.
Frick MH, Elo O, Haapa K, et al. Helsinki heart
study: primary prevention trial with gemfibrozil
in middle-aged men with dyslipidemia: safety of
treatment, changes in risk factors, and incidence
of coronary heart disease. N Engl J Med
1987;317:1237–45.
The Helsinki Heart Study was the first primary
prevention trial to show that lipid-lowering
treatment with gemfibrozil reduces the risk of
CHD in men with dyslipidemia.  This double-
blind, placebo-controlled trial investigated the
effects of gemfibrozil on fatal and nonfatal
myocardial infarction and cardiac death.  The
study randomized 4081 middle-aged men
without CAD, and whose non-HDL (defined as
total cholesterol minus HDL) level was 200 mg/dl
or greater, to receive either gemfibrozil 600 mg
twice/day or placebo.  In the gemfibrozil group,
HDL levels increased by 10%, whereas LDL, non-
HDL, total cholesterol, and triglyceride levels
were reduced by 10%, 14%, 11%, and 43%,
respectively.  After a mean follow-up of 60.4
months, 56 cardiac events had occurred in the
gemfibrozil group compared with 84 in the
placebo group (p<0.02).  This represents a
reduction of 34.0% (95% CI 8.2–52.6) in cardiac
end points.  The greatest reduction was seen in
the rate of nonfatal myocardial infarction.  The
gemfibrozil group experienced 45 nonfatal
myocardial infarctions compared with 71
(p<0.02) in the placebo group (37% reduction,
p<0.05).  Kaplan-Meier curves for occurrence of
definite cardiac end points showed that the
curves began to separate after the first 2 years of
treatment, and continued to decrease in the
gemfibrozil group.  However, no differences
between the two groups were noted regarding
mortality.
In the safety analysis, the gemfibrozil group
experienced a higher rate of moderate-to-severe
upper gastrointestinal symptoms (11.3% vs 7.0%
in placebo group, p<0.0001).  Overall, the
Helsinki Heart Study—the one major study
evaluating gemfibrozil in patients undergoing
primary preventive treatment—demonstrated
that gemfibrozil reduced the risk of fatal and
nonfatal myocardial infarction and sudden death,
but not overall mortality.
Keech A, Simes RJ, Barter P, et al, for the FIELD
Study Investigators . Effects of long-term
fenofibrate therapy on cardiovascular events in
9795 people with type 2 diabetes mellitus (the
FIELD study): randomised controlled trial.
Lancet 2005;366:1849–61.
The Fenofibrate Intervention and Event
Lowering in Diabetes study, a prospective,
randomized, placebo-controlled trial, was the
first to investigate the effects of a fibrate on
cardiovascular events in patients with type 2
diabetes with and without previous myocardial
infarction.  A total of 9795 patients aged 50–75
years not receiving statin therapy at study entry
were randomized to receive micronized fenofi-
brate 200 mg/day (4895 patients) or matching
placebo (4900 patients) for 5 years, after a
fenofibrate and placebo run-in phase.  The
primary outcome was coronary events (CHD
death or nonfatal myocardial infarction).  The
outcome for prespecified subgroup analyses was
total cardiovascular events (a composite of
cardiovascular death, myocardial infarction,
stroke, and coronary and carotid revascularization).
Mean baseline LDL, HDL, and triglyceride
levels were 118.7, 42.5, and 153.3 mg/dl,
respectively. Coronary events were not
significantly reduced (5.9% of patients receiving
placebo, 5.2% of those receiving fenofibrate;
relative reduction 11%, p=0.16).   However,
nonfatal myocardial infarctions were significantly
reduced (24%, p=0.010), as were revascular-
ization procedures (21%, p=0.003).  Total
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cardiovascular mortality and overall mortality
were not significantly reduced.  Significant
increases in the rate of pancreatitis (0.5% with
placebo vs 0.8% with fenofibrate, p=0.031) and
pulmonary embolism (0.7% vs 1.1%, p=0.022)
were seen in the fenofibrate group.
The authors concluded that because a number
of patients in the placebo group started receiving
statin therapy, the benefits of fenofibrate may
have been masked.  In addition, baseline
triglyceride and HDL levels were not in ranges in
which benefits from fibrate therapy would
typically be seen.  The FIELD study further
emphasizes that statins should be primary
therapy and that fibrates could be administered
in selected patients with atherogenic dyslipidemia.
The incremental benefits of a fibrate added to
statin therapy are being investigated in the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial.
Resins
Lipid Research Clinics Coronary Primary
Prevention Trial Investigators. The lipid research
clinics coronary primary prevention trial results:
the relationship of reduction in incidence of
coronary heart disease to cholesterol lowering.
JAMA 1984;251:365–74.
The lipid research clinics coronary primary
prevention trial (LRC-CPPT) was one of the first
studies to show that lipid-lowering therapy
reduces risk of CHD in men with primary
hypercholesterolemia.  This multicenter, double-
blind, clinical trial randomized 3806 men aged
35–59 years, without signs of CHD and with
plasma cholesterol levels 256 mg/dl or greater, to
receive either cholestyramine 24 g/day or
placebo.  The primary end point was the
combination of definite CHD-related death
and/or definite nonfatal myocardial infarction.
Other end points were all-cause mortality,
positive exercise test result, angina pectoris,
atherothrombotic brain infarction, peripheral
vascular disease, and transient cerebral ischemic
attack.
After 7 years of follow-up, average plasma total
cholesterol and LDL level reductions were 13.4%
and 20.3%, respectively, in the cholestyramine
group; these levels were significantly greater
(p<0.001) than in the placebo group.  The
cholestyramine group experienced risk
reductions of 24% for CHD death and 19% for
the primary end point of CHD death or nonfatal
myocardial infarction (p<0.05).  Cholestyramine
also resulted in reductions of 20% (p<0.01) in
the frequency of development of angina, 25%
(p<0.001) in the development of a positive
exercise test result, and 21% (p=0.06) in the
frequency of coronary artery bypass surgery.  The
rate of all-cause mortality was not statistically
different between the two groups.
Additional analysis of data from LRC-CPPT
provided more information regarding the
relationship between lipid lowering and
occurrence of CHD.  An 18.8% reduction in
occurrence of CHD corresponded to decreases of
7.9% in total cholesterol level and 10.8% in LDL
level.  A clear dose-response relationship was
noted between lipid changes and reported
cholestyramine intake.  Also, analysis showed
that increased HDL levels were independently
related to reduced CHD occurrence in the
cholestyramine group.
Overall, LRC-CPPT was the first primary
prevention study to conclusively show reduction
in CHD risk with cholestyramine resin treatment.
Other major trials conducted at the time of LRC-
CPPT were either secondary prevention trials or
studies evaluating diet intervention.  The LRC-
CPPT authors concluded that the degree of lipid
lowering achieved with cholestyramine 24 g/day
potentially reduces CHD risk by nearly 50%.
Secondary Prevention Trials
Statins
Scandinavian Simvastatin Survival Study
Group. Randomised trial of cholesterol lowering
in 4444 patients with coronary heart disease: the
Scandinavian simvastatin survival study (4S).
Lancet 1994;344:1383–9.
The Scandinavian Simvastatin Survival Study
was the first landmark statin trial and the first to
demonstrate a statistically significant reduction
in overall mortality secondary to lipid
intervention.  The study also answered questions
as to whether statin therapy could improve
survival because of increases in non-CHD deaths
seen in other studies.  The study was a double-
blind trial that randomized 4444 men and
women with CHD to receive simvastatin 20–40
mg/day or placebo.  The primary end point was
total mortality, and the secondary end point was
time to major coronary events.  After a median
follow-up of 5.4 years, 256 (12%) patients in the
placebo group had died, compared with 182 (8%)
in the simvastatin group.  Relative risk of total
mortality with simvastatin was 0.70 (95% CI
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0.58–0.85, p=0.0003).  Relative risk of major
coronary events, also lower in the simvastatin
group, was 0.88 (95% CI 0.59–0.75, p<0.0001).
Benefits of simvastatin were seen in both sexes
and in all age groups; no significant between-
group differences were noted in noncardio-
vascular deaths.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect
of pravastatin on coronary events after
myocardial infarction in patients with average
cholesterol levels: cholesterol and recurrent
events trial investigators. N Engl J Med
1996;335:1001–9.
The Cholesterol and Recurrent Events trial
(CARE) trial was the first secondary prevention
study to evaluate the effectiveness of lipid
lowering in a population with average plasma
lipid levels.  This double-blind study randomized
4159 patients with previous myocardial
infarction to receive either pravastatin 40 mg/day
or placebo.  The primary end point was CHD
death or a symptomatic, nonfatal myocardial
infarction.  Mean LDL level at baseline was 139
mg/dl, and the pravastatin group experienced an
LDL level reduction of 32%.  Compared with the
placebo group, pravastatin-treated patients had
lower LDL (28%), total cholesterol (20%), and
triglycerides (14%) levels; HDL level was higher
(5%; p<0.001 for all comparisons).  The
frequency of the primary end point was 24%
lower with pravastatin than placebo (p=0.003).
Rates of nonfatal myocardial infarction, coronary
artery bypass surgery, angioplasty, and stroke
were all significantly lower with pravastatin than
placebo.  No between-group difference in CHD
mortality was noted.  Baseline LDL level
influenced the extent of CHD risk reduction in
the pravastatin group.  Patients with higher LDL
levels at baseline had greater reduction in major
coronary events with pravastatin, whereas those
with lower LDL levels at baseline had smaller, if
any, reduction.  Among the notable adverse
effects observed, significantly more breast cancer
developed in the pravastatin group than in the
placebo group.  The CARE trial demonstrated
that lowering cholesterol levels in patients with
typical or average LDL levels reduced the risk of
recurrent coronary events.
Heart Protection Study Collaborative Group.
MRC/BHF Heart protection study of cholesterol
lowering with simvastatin in 20,536 high-risk
individuals: a randomised placebo-controlled
trial. Lancet 2002;360:7–22.
The Medical Research Council/British Heart
Foundation Heart Protection Study (HPS)
evaluated the benefits of lipid-lowering therapy
in high-risk patients largely underrepresented in
other clinical trials, such as those with diabetes
or noncoronary occlusive arterial disease, elderly
or female patients, and those with below average
cholesterol levels.  Also, the HPS provided more
information regarding the effects of statins on
site-specific cancers.  The study enrolled over
20,000 patients, the largest number in a statin
trial.  Study patients had a substantial 5-year risk
of death due to history of coronary disease,
noncoronary occlusive arterial disease, diabetes,
or treated hypertension.  Patients were randomized
to a 2 x 2 factorial design consisting of
simvastatin 40 mg/day or matching placebos, as
well as antioxidant vitamins or matching
placebos.  Primary outcomes were total, coronary,
and noncoronary mortality; secondary outcomes
were major coronary and vascular events, such as
stroke.
After a mean follow-up of 5 years, reductions
in the simvastatin group were 17% in all-cause
mortality (p<0.0001), 18% in coronary death
(p=0.0005), and 16% in death from other
vascular causes (p=0.07).  In addition, simvastatin
significantly reduced the relative risk of major
coronary events by 27%, stroke by 25%, and any
revascularization by 24% (p<0.0001 for all).
Benefit from simvastatin therapy was seen in all
age subgroups, including 75–85 years, and all
baseline LDL level subgroups, even patients with
baseline LDL levels less than 116 mg/dl.  Risk
reduction with simvastatin was independent of
treatment with angiotensin-converting enzyme
(ACE) inhibitors, b-blockers, and aspirin.  No
significant differences were noted in rate or type
of cancer between the two groups.
The HPS demonstrated that lowering
cholesterol levels with statin therapy substan-
tially reduced the frequency of coronary and
noncoronary vascular events in a wider range of
high-risk patients than had been demonstrated
before.  The study enrolled a large number of
patients from subgroups, such as those with
diabetes, cerebrovascular disease, or peripheral
arterial disease.  High-risk patients with relatively
low baseline LDL levels (< 116 mg/dl) also
benefitted from simvastatin therapy, which
contributes to the NCEP optional LDL level goal
of less than 70 mg/dl for patients at highest risk.
Long-Term Intervention with Pravastatin in
Ischemic Disease (LIPID) Study Group.
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Prevention of cardiovascular events and death
with pravastatin in patients with coronary heart
disease and a broad range of initial cholesterol
levels. N Engl J Med 1998;399:1349–57.
The LIPID study investigated the effects of
pravastatin on CHD death in patients with a
history of myocardial infarction or unstable
angina and a broad range of cholesterol levels.
This study differs from the 4S and CARE studies
in that it involved patients with lower initial
cholesterol levels and evaluated the primary end
point of CHD death alone instead of a composite
end point.  Over 9000 patients with a history of
myocardial infarction or unstable baseline and
total cholesterol levels of 155–271 mg/dl were
randomized to receive pravastatin 40 mg/day or
matching placebo.  The primary end point, death
from CHD, was further subclassified into
categories.  Secondary outcomes included all-
cause mortality, myocardial infarction, stroke,
and coronary revascularization.  After a mean
follow-up of 6 years, a 24% relative risk
reduction in the primary outcome of CHD death
was noted with pravastatin therapy compared
with placebo (95% CI 12–35%, p<0.001).
Overall rate of mortality was 22% lower (95% CI
13–31%, p<0.001) and mortality from
cardiovascular causes 25% lower (p<0.001) in
the pravastatin group.  Fewer patients died of
cancer, trauma, or suicide in the pravastatin than
placebo group, but the differences were not
statistically different.
Results from the LIPID study extend the
benefits of statin therapy to high-risk patients
with low baseline LDL levels and to all patients
with CHD, including those with a history of
unstable angina or stroke.  This study also
showed that pravastatin reduces CHD mortality
and all-cause mortality without increasing the
risk of death due to trauma, suicide, or cancer.
Cannon CP, Braunwald E, McCabe CH, et al.
Intensive versus moderate lipid lowering with
statins after acute coronary syndromes. N Engl J
Med 2004;350:1495–504.
The Pravastatin or Atorvastatin Evaluation and
Infection Therapy–Thrombolysis in Myocardial
Infarction (PROVE IT–TIMI) 22 study
demonstrated that intensive lipid level reduction
of LDL to a target level of approximately 70
mg/dl in patients with recent ACS provides
additional CHD risk reduction beyond standard
lipid level reduction to an LDL goal of
approximately 100 mg/dl.  The study randomized
4162 patients hospitalized within the preceding
10 days for unstable angina or acute myocardial
infarction to receive either pravastatin 40 mg/day,
considered standard lipid-lowering therapy, or
atorvastatin 80 mg/day, considered intensive
lipid-lowering therapy.  (Patients were also
randomized to receive gatifloxacin or placebo in
a 2 x 2 factorial design, but those results are
reported elsewhere.)  The primary efficacy end
point of PROVE IT–TIMI 22 was time to the first
occurrence of a composite of all-cause mortality,
myocardial infarction, unstable angina requiring
rehospitalization, revascularization, or stroke.
The secondary end point was risk of CHD death,
nonfatal myocardial infarction, or
revascularization.  At the time of randomization,
median LDL level was 106 mg/dl for both groups.
The pravastatin group achieved a median LDL
level of 95 mg/dl during treatment, whereas this
level was 62 mg/dl in the atorvastatin group
(p<0.001).
After 2 years, the event rate in the standard-
therapy pravastatin group was 26.3% versus
22.4% in the intensive-therapy atorvastatin
group, representing a 16% hazard ratio reduction
with atorvastatin (95% CI 5–26%, p=0.005).  The
secondary end point was reduced by 14% in the
atorvastatin group as well (p=0.029).  The benefit
of high-dose atorvastatin was consistent across
the prespecified subgroups, which included men
and women, patients with unstable angina, those
with myocardial infarction, and those with and
without diabetes.  However, patients with
baseline LDL levels above 125 mg/dl had greater
reductions in hazard ratio than those with
baseline LDL levels below 125 mg/dl.  In terms of
safety, the atorvastatin group had a significantly
greater rate of elevated alanine aminotransferase
level (3.3%) than the pravastatin group (1.1%,
p<0.001).
Overall, the PROVE IT–TIMI 22 study showed
that intensive therapy with a high-dose statin to
lower LDL level to approximately 70 mg/dl
reduced the risk of another cardiovascular event
compared with standard therapy with a
moderate-dose statin to lower LDL level to
approximately 100 mg/dl.  This study
demonstrated that patients with recent ACS may
benefit from further lipid-lowering therapy
beyond the standard LDL goal of less than 100
mg/dl.
De Lemos JA, Blazing MA, Wiviott SD, et al.
Early intensive vs a delayed conservative
simvastatin strategy in patients with acute
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coronary syndromes: phase Z of the A to Z trial.
JAMA 2004;292:1307–16.
Phase Z of the Aggrastat to Zocor (A to Z) Trial
evaluated the benefits of intensive simvastatin
treatment started soon after an ACS event
compared with conservative simvastatin
treatment started in a delayed manner.  A second
component of the study, phase A, compared
enoxaparin and unfractionated heparin in
patients with ACS treated with tirofiban and
aspirin; the results were published elsewhere.  In
phase Z, patients with non–ST-elevation ACS or
ST-elevation myocardial infarction and a total
cholesterol level less than 250 mg/dl were
randomized to receive either simvastatin 40
mg/day for 30 days and then simvastatin 80
mg/day, or placebo for 4 months and then
simvastatin 20 mg/day.  The primary end point
was a composite of cardiovascular death, nonfatal
myocardial infarction, readmission for ACS, and
stroke.  Secondary end points were revascular-
ization, all-cause mortality, new-onset heart
failure, and others.
After a median follow-up of 721 days, rates of
primary end point events did not differ
significantly between the two groups.  The
simvastatin-plus-placebo group incurred 343
cases (in 16.7% of patients) of cardiovascular
death, myocardial infarction, readmission for
ACS, and stroke, compared with 309 (14.4%) in
the simvastatin-only group (HR 0.89, 95% CI
0.76–1.04, p=0.14).  Among the secondary end
points, only cardiovascular death and new-onset
heart failure were significantly lower in the
simvastatin-only than placebo-plus-simvastatin
group.  In terms of safety and tolerability, the
simvastatin-only treatment group had greater
rates of aspartate aminotransferase and alanine
aminotransferase elevations and myopathy with
creatine kinase elevations.
Overall, starting intensive simvastatin therapy
soon after ACS did not reduce the composite
primary end point compared with delayed start of
conservative simvastatin therapy.  However, rates
of cardiovascular death and new-onset heart
failure were lower.  The failure to detect between-
group differences in primary outcome could have
been caused by less statistical power than
predicted and by a small between-group
difference in LDL levels.  Compared with the
Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering (MIRACL) study, a larger
population in the A to Z trial received
glycoprotein IIb-IIIa inhibitor therapy or had
planned revascularization procedures, which may
have competed with statin therapy to reduce
cardiovascular events.  In addition, patients in
the A to Z trial were randomized several days
earlier than those in the PROVE IT–TIMI 22
study, representing a less stable and higher risk
patient group.  These explanations could
contribute to understanding why the intensive-
treatment group did not experience benefits over
the conservative-treatment group, as seen in
other studies.
Schwartz GG, Olsson AG, Ezekowitz MD, et al,
for the Myocardial Ischemia Reduction With
Aggressive Cholesterol Lowering (MIRACL)
Study Investigators. Effects of atorvastatin on
early recurrent ischemic events in acute coronary
syndromes: the MIRACL study: a randomized
controlled trial. JAMA 2001;285:1711–18.
The MIRACL study was the first to investigate
whether statin therapy begun soon after recent
unstable angina or non–Q-wave acute myocardial
infarction reduces deaths and recurrent ischemic
events.  Previously, these high-risk patients were
excluded from large trials.  The MIRACL study
randomized 3086 patients with ACS to receive
either atorvastatin 80 mg/day or placebo for 16
weeks, with treatment starting 24–96 hours after
hospitalization.  The primary combined end
point was death, nonfatal acute myocardial
infarction, cardiac arrest with resuscitation, or
recurrent symptomatic myocardial ischemia.
Secondary end points were the occurrence of
each primary end point component plus nonfatal
stroke, new or worsening heart failure, worsening
angina requiring hospitalization, or other
cardiovascular end points.
During the study, no statistically significant
difference was noted between the two groups in
primary end point.  There were 228 occurrences
(14.8% of patients) of primary end point events
in the atorvastatin group and 269 (17.4%) in the
placebo group (RR 0.84, 95% CI 0.70–1.00,
p=0.48).  Of the primary end point components,
only recurrent symptomatic myocardial ischemia
was reduced in the atorvastatin group.  Regarding
secondary outcomes, atorvastatin significantly
reduced the risk of fatal and nonfatal stroke but
not of other outcomes, such as coronary
revascularization or worsening angina.  In
addition, more patients in the atorvastatin than
placebo group had elevated liver transaminase
levels (2.5% vs 0.6%, p<0.001).
Overall, the MIRACL study showed that
treatment with atorvastatin 80 mg/day started
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soon after a coronary event reduced recurrent
ischemic events.  However, the study did not
show statistically significant benefits in reducing
the risk of death or the combined primary end
point after ACS in atorvastatin-treated patients.
The study duration may have been too short to
detect such a difference.
Pitt B, Waters D, Brown WV, et al. Aggressive
lipid-lowering therapy compared with angioplasty
in stable coronary artery disease: atorvastatin
versus revascularization treatment investigators.
N Engl J Med 1999;341:70–6.
This study tested the hypothesis that lipid-
lowering treatment with atorvastatin can delay or
prevent the need for revascularization without
increasing the risk of ischemic events in patients
with one- or two-vessel CAD, relatively normal
left ventricular function, and no severe symptoms
of angina pectoris.  The study randomized 341
patients with stable CAD who had been
recommended for percutaneous revascularization
to receive either lipid-lowering treatment with
atorvastatin 80 mg/day or the recommended
revascularization procedure (angioplasty)
followed by usual care.  The primary end point
was ischemic events, defined as death from
cardiac causes, resuscitation after cardiac arrest,
nonfatal myocardial infarction, cerebrovascular
accident, coronary artery bypass graft, angioplasty,
or worsening angina.
After 18 months of follow-up, 22 (13%)
patients in the atorvastatin group and 37 (21%)
in the angioplasty group had ischemic events
(p=0.048).  However, this difference did not
reach a level of significance after adjustment for
interim analysis.  In addition, fewer revascular-
ization procedures were performed in the
atorvastatin than angioplasty group (20 [12%] vs
29 [16%] patients).  Treatment with atorvastatin
was also associated with a significantly longer
time to a first ischemic event (p=0.03).  However,
angina symptoms improved in a significantly
larger percentage of angioplasty patients,
although this may have been due to increased
administration of nitrates in this group.
Overall, this study found a lower frequency of
ischemic events over 18 months and a longer
time to a first event in patients receiving
intensive lipid-lowering therapy than in those
who underwent angioplasty.  Fewer atorvastatin-
treated patients were hospitalized with worsening
angina or underwent bypass surgery or
angioplasty during the follow-up period.  The
authors concluded that aggressive treatment with
atorvastatin appears to be as safe and effective as
angioplasty and usual care in reducing ischemic
events in patients with stable one- or two-vessel
CAD.
Athyros VG, Mikhailidis DP, Papageorgiou AA,
et al, for the GREACE Study Collaborative
Group. Relationship between LDL-c and
non–HDL-C levels and clinical outcome in the
greek atorvastatin and coronary-heart-disease
evaluation (GREACE) study. Curr Med Res Opin
2004;20:1385–92.
The GREACE study was performed because of
the controversy surrounding the relationship
between baseline LDL level and the extent of
cholesterol reduction.  Some studies
demonstrated a linear relationship, whereas
others demonstrated a threshold or no
relationship.  The GREACE study sought to
determine whether cholesterol levels and the
extent of LDL level reduction have a direct
relationship on the primary outcomes of
coronary mortality and nonfatal myocardial
infarction.  The study enrolled men and women
younger than 75 years recently hospitalized for
an ACS event, with baseline LDL levels below100
mg/dl and triglyceride levels below 400 mg/dl.
Patients were randomized either to usual care or
to structured care with atorvastatin 10 mg/day
titrated until achievement of an LDL level below
100 mg/dl.
In the usual-care group, a direct relationship
was noted between the primary end points and
baseline LDL levels (R=0.273, p<0.0001) or LDL
levels during the study (R=0.318, p<0.0001).  A
trend toward greater CHD event rates was
observed in the higher baseline LDL level
quartiles.  However, in the structured-care group,
no relationship was noted between LDL or non-
HDL levels and the primary end points.  Patients
in the upper two quartiles according to baseline
LDL levels needed greater atorvastatin dosages to
achieve LDL levels lower than 100 mg/dl and had
disproportionately higher relative risk reductions
than patients in the lower two quartiles.  Overall,
the GREACE study demonstrated a linear
relationship between LDL levels and cardio-
vascular outcomes.  It also showed that patients
with the highest baseline LDL levels benefitted
the most from reductions to less than 100 mg/dl
in cardiovascular events.  Therefore, a target-
oriented strategy for lowering cholesterol may be
better than a single-dose strategy for all patients.
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Serruys PW, de Feyter P, Macaya C, et al, for the
Lescol Intervention Prevention Study (LIPS)
Investigators. Fluvastatin for prevention of
cardiac events following successful first percu-
taneous coronary intervention: a randomized
controlled trial. JAMA 2002;287:3215–22.
The LIPS was the first prospective trial to
evaluate the effects of a statin on clinical end
points in patients undergoing their first
percutaneous coronary intervention (PCI).  This
study investigated whether fluvastatin versus
placebo prolongs survival time free of cardiac
disease after successful completion of first PCI,
with or without stenting.  This double-blind trial
included 1677 men and women after PCI of one
or more lesions in native coronary arteries; their
total cholesterol levels were 135–170 mg/dl.
Patients were randomized to receive either
fluvastatin 40 mg twice/day or placebo for 3–4
years.  The primary outcome was a composite of
cardiac death, nonfatal myocardial infarction, and
a reintervention procedure (defined as coronary
artery bypass graft, repeated PCI, or PCI for a
new lesion).
After a median follow-up of 3.9 years, survival
time free of cardiac events was significantly
longer in the fluvastatin group (first quartile of
time to first event 1558 days) than in the placebo
group (1227 days, p=0.01).  Also, 21.4% of the
fluvastatin group and 26.7% of the placebo group
had at least one primary end point, resulting in a
significant risk reduction of cardiac events (RR
0.78, 95% CI 0.64–0.95, p=0.01).  Overall, LIPS
showed that early lipid-lowering therapy with
fluvastatin 80 mg/day after PCI reduced absolute
risk of fatal and nonfatal cardiac events by 5.3%,
and relative risk by 22%.  In addition, results
from LIPS also suggest that benefits are equal and
significant regardless of baseline cholesterol
levels, unlike the CARE study. This adds support
to the use of aggressive approaches to lowering
cholesterol levels and treating patients based on
risk instead of baseline cholesterol levels.
LaRosa JC, Grundy SM, Waters DD, et al, for
the Treating to New Targets (TNT) Investi-
gators. Intensive lipid lowering with atorvastatin
in patients with stable coronary disease. N Engl J
Med 2005;352:1425–35.
The TNT study investigated whether intensive
lipid-lowering therapy with atorvastatin 80
mg/day is associated with better outcomes than
moderate lipid-lowering therapy with atorvastatin
10 mg/day in patients with stable nonacute CHD.
This double-blind, parallel-group study
randomized 10,001 patients to the two treatment
groups.  The primary outcome was occurrence of
a major cardiovascular event, defined as CHD
death, nonfatal myocardial infarction, and fatal
and nonfatal stroke.  Mean LDL levels during the
study were 77 and 101 mg/dl for patients
receiving atorvastatin 10 and 80 mg/day,
respectively.  Total cholesterol and triglyceride
levels were also significantly lower with
atorvastatin 80 mg/day, but HDL levels were
similar in the two groups.  The event rate of the
composite primary outcome was 8.7% and 10.9%
with atorvastatin 80 and 10 mg/day, respectively,
representing a 22% relative risk reduction (HR
0.78, 95% CI 0.69–0.89, p<0.001).  Although no
between-group difference was noted in all-cause
mortality, patients receiving atorvastatin 80
mg/day experienced significant risk reductions
for any major coronary event, a cerebrovascular
event, any cardiovascular event, and any
coronary event.  However, significantly more
adverse events occurred in patients receiving
atorvastatin 80 mg/day, including more
atorvastatin discontinuations and cases of
persistently elevated liver enzyme levels.  The
rate of treatment-related myalgia was similar
between the groups.
Overall, the TNT study demonstrated that
more aggressive treatment of hypercholes-
terolemia to target levels below the current NCEP
ATP III guidelines provided additional clinical
benefit over moderate treatment to a goal of less
than 100 mg/dl.  Just as the PROVE IT–TIMI 22
study helped lower LDL level goals for patients
with ACS, the TNT study may provide evidence
that lower LDL level goals could be beneficial for
patients with stable CHD.
Pedersen TR, Faergeman O, Kastelein JJ, et al,
for the Incremental Decrease in End Points
Through Aggressive Lipid Lowering (IDEAL)
Study Group. High-dose atorvastatin vs usual-
dose simvastatin for secondary prevention after
myocardial infarction: the IDEAL study: a
randomized controlled trial. JAMA 2005;294:
2437–45.
The IDEAL study is one of the few final studies
testing the hypothesis that there is further benefit
of reducing LDL levels to less than 100 mg/dl.
This prospective, randomized, open-label study
randomized 8888 adults with a history of acute
myocardial infarction to receive atorvastatin 80
mg/day or simvastatin 20 mg/day. The primary
outcome measure was a major coronary event
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(coronary death, confirmed nonfatal myocardial
infarction, or cardiac arrest with resuscitation) at
a median follow-up of 4.8 years.  Mean baseline
LDL level was 121 mg/dl in both groups and was
reduced to 80.0 and 99.8 mg/dl in the
atorvastatin and simvastatin groups, respectively.
A major coronary event occurred in 411 (9.3%)
atorvastatin patients and 463 (10.4%) simvastatin
patients, resulting in a relative risk reduction of
11% (p=0.07).  The rate of nonfatal myocardial
infarction was reduced by 17% (p=0.02);
however, rates of coronary deaths and all-cause
mortality were similar in both treatment groups.
Myalgia, liver function abnormalities, and
adverse events resulting in permanent drug
discontinuation were significantly higher in
patients receiving atorvastatin.  Although this
study did not demonstrate a reduction in major
coronary events with more aggressive lowering of
LDL levels, several of the prespecified end points
did.  The authors offered several reasons to
explain why statistical significance was not
reached for the primary end point.  However, the
important findings of this study show consistency
with the total body of evidence that more
aggressive lowering of LDL levels is beneficial.
The increased risk of statin-associated adverse
events with higher dosages also is consistent with
findings of other similar studies.
Fibrates
Rubins HB, Robins SJ, Collins D, et al.
Gemfibrozil for the secondary prevention of
coronary heart disease in men with low levels of
high-density lipoprotein cholesterol: Veterans
Affairs high-density lipoprotein cholesterol
intervention trial study group. N Engl J Med
1999;341:410–18.
The Veterans Affairs high-density lipoprotein
cholesterol intervention trial (VA-HIT) was the
first large-scale intervention trial to focus on
patients with CHD and low levels of HDL but
relatively normal LDL.  This study demonstrated
that increasing HDL levels and lowering
triglyceride levels with gemfibrozil significantly
reduces the risk of nonfatal myocardial infarction
or coronary death.  The VA-HIT randomized
2531 men with HDL levels of 40 mg/dl or less
and LDL levels of 140 mg/dl or less to receive
gemfibrozil 1200 mg/day or placebo.  The
primary outcome was the combined rate of
nonfatal myocardial infarction and death from
CHD.  In the gemfibrozil group, mean HDL level
was 6% higher than in the placebo group, mean
total cholesterol was 4% lower, and mean
triglycerides were 31% lower.  Mean LDL levels
were not significantly different between the two
groups.  After a mean of 5 years of follow-up,
gemfibrozil reduced the rate of the primary
outcome by 22% (95% CI 7–35%, p=0.006).
Gemfibrozil also significantly reduced the risk of
transient ischemic attacks and carotid endarterec-
tomy.  Dyspepsia was the only adverse event to
occur more often in the treatment group.
Overall, VA-HIT demonstrated that increasing
low HDL levels in patients with CHD without
affecting LDL levels can reduce recurrent
coronary events.
Bezafibrate Infarction Prevention Study Group.
Secondary prevention by raising HDL cholesterol
and reducing triglycerides in patients with
coronary artery disease: the bezafibrate infarction
prevention (BIP) study. Circulation 2000;102:
21–7.
The BIP study evaluated whether bezafibrate
reduces CAD mortality and nonfatal myocardial
infarction in patients with established CAD, HDL
level less than 45 mg/dl, and moderately elevated
cholesterol levels.  The study randomized 3090
men and women aged 45–74 years to receive
either bezafibrate 400 mg/day or placebo.  The
primary end point was fatal or nonfatal
myocardial infarction, or sudden death, occurring
within 24 hours of symptom onset.  Secondary
end points were hospitalization for unstable
angina, percutaneous transluminal coronary
angiography, and coronary artery bypass grafting.
After a mean duration of 6.2 years, bezafibrate
therapy resulted in an 18% increase in HDL and a
21% reduction in triglyceride levels, whereas
total cholesterol and LDL levels remained
relatively unchanged.  No statistically significant
differences between the two groups were noted
for the primary or secondary end points.  The
frequencies of the primary outcome were similar
in the two groups:  211 (13.6%) events in the
bezafibrate group and 232 (15%) in the placebo
group (p=0.26).  Rates of all-cause mortality and
cardiac-related mortality also were similar in the
two groups.  However, in a post hoc analysis, a
small group of patients with baseline triglyceride
levels of 200 mg/dl or greater had a 39.5%
reduction in the probability of a primary end
point (p=0.02), whereas the reduction was not
significant in patients with triglycerides less than
200 mg/dl.  Unlike VA-HIT and the Helsinki
Heart Study, the BIP study did not demonstrate
an overall reduction in occurrence of myocardial
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infarction or death with fibrate therapy.  This
may be due to differences in characteristics of the
study populations as well as the lower frequency
of the primary event in the BIP placebo group
than in the VA-HIT placebo group.  However, the
BIP study identified a subgroup of patients with
high triglyceride levels who may benefit from
long-term therapy with bezafibrate.
Coronary Drug Project Research Group.
Clofibrate and niacin in coronary heart disease.
JAMA 1975;231:360–81.
The Coronary Drug Project was the only
secondary prevention trial to demonstrate
coronary risk reduction with niacin monotherapy.
This double-blind study evaluated whether lipid-
modifying agents could prevent new CHD events
in patients with established CHD, and whether
these interventions would be safe for long-term
therapy. The study was discontinued before
completion for three of the six original treatment
groups (conjugated estrogens 2.5 mg/day,
conjugated estrogens 5 mg/day, or dextro-
thyroxine 1.8 g/day) due to excess mortality or
morbidity.  Only those randomized to receive
niacin 3 g/day, clofibrate 1.8 g/day, or placebo
completed the study. Participants were men aged
30–64 years with at least one previous
myocardial infarction.  The primary end point
was total mortality; other major end points were
cause-specific mortality and nonfatal cardio-
vascular events.
After 5 years, all-cause mortality and coronary
mortality rates were similar in the clofibrate and
placebo groups.  Compared with the placebo
group, the clofibrate group had higher rates of
heart failure, new hypertension, new angina
pectoris, intermittent cerebral ischemic attacks,
pulmonary embolism, thromboembolism,
thrombophlebitis, and atrial fibrillation.  In
addition, a higher percentage of clofibrate-treated
patients were hospitalized.  Overall mortality and
coronary mortality did not differ significantly
between the niacin and placebo groups, but the
occurrence of nonfatal myocardial infarction
alone and in combination with coronary death
was significantly lower in the niacin than in the
placebo group.  Based on these data, clofibrate
showed no benefit with regard to mortality or
nonfatal cardiovascular events.  Compared with
placebo, however, niacin significantly decreased
the risk of nonfatal myocardial infarction but not
total mortality.
Group of Physicians of the Newcastle upon
Tyne Region. Trial of clofibrate in the treatment
of ischaemic heart disease. Br Med J 1971;4:
767–75.
This double-blind trial evaluated the effects of
clofibrate on morbidity and mortality in patients
with ischemic heart disease.  The study
randomized 497 men and women with a history
of angina or myocardial infarction to receive
either clofibrate or placebo containing corn oil.
The primary end point was death (defined as
sudden death, fatal infarction, or death from
heart failure) and nonfatal myocardial infarction
(defined as angina or infarction).  After at least
3.5 years of follow-up, the cardiac death rate was
significantly lower in the clofibrate group than in
the placebo group (11.1% and 19.0%, respec-
tively, p=0.02).  This difference was mostly
attributable to the significantly fewer sudden
deaths in the clofibrate group.  The rate of
nonfatal myocardial infarction was also lower in
the clofibrate group than in the placebo group,
but this difference did not reach statistical
significance (11.9% and 18.2%, respectively,
p=0.055).  When the groups were further divided
according to baseline cardiac history, patients
with angina or both angina and myocardial
infarction benefitted from clofibrate therapy,
whereas those with a history of myocardial
infarction (no angina) did not.  In addition, these
findings were independent of baseline lipid levels
or extent of cholesterol reduction by clofibrate.
This early study, performed when the impact of a
lipid-lowering drug on long-term morbidity and
mortality was unknown, demonstrated that
clofibrate treatment could protect patients with
CHD from sudden death and future ischemic
events.
Research Committee of the Scottish Society of
Physicians. Ischaemic heart disease: a secondary
prevention trial using clofibrate. Br Med J
1971;4:775–84.
Similar to the Newcastle study, this Scottish
study evaluated whether reducing serum lipid
levels with clofibrate would affect mortality and
morbidity in patients with established ischemic
heart disease.  The study included 717 patients
with a history of myocardial infarction, angina, or
both.  Patients were divided into a double-blind
group, which included those not receiving
anticoagulants, and an anticoagulant group,
which included a small subgroup of patients also
receiving warfarin.  In both groups, patients were
randomized to receive clofibrate or placebo (olive
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oil capsules).  Study end points were sudden
death, fatal myocardial infarction, and nonfatal
definite or probable myocardial infarction.
After 6 years of follow-up, no significant
overall differences in rates of morbidity and
mortality were noted between the clofibrate
group and the placebo group in either the
double-blind group or the anticoagulant group.
However, a trend was noted in favor of clofibrate.
A subgroup analysis showed that significantly
more fatal infarctions occurred in men in the
clofibrate group with a history of myocardial
infarction only.  Similar findings were also seen in
the increased rates of sudden death and fatal
infarction in the overall clofibrate group.  In
terms of nonfatal infarction, rates were similar in
the clofibrate and placebo groups.  The only
benefit from clofibrate therapy seen in this study
was reduced mortality in the subgroup of patients
with a history of myocardial infarction and
angina or angina alone at study entry. Overall,
this Scottish study demonstrated that clofibrate
reduced the rate of fatal CHD events in patients
with a history of angina, which is similar to the
Newcastle study results.  In the Scottish study,
the benefits of clofibrate did not extend to the
overall group, especially patients with a history
of myocardial infarction.
Carlson LA, Rosenhammer G. Reduction in
mortality in the Stockholm ischaemic heart
disease secondary prevention study by combined
treatment with clofibrate and nicotinic acid. Acta
Med Scand 1988;223:405–18.
The Stockholm Ischaemic Heart Disease
Secondary Prevention Study evaluated the effects
of combination lipid-lowering therapy with
clofibrate plus nicotinic acid on IHD in patients
discharged from a Stockholm hospital after
treatment for myocardial infarction.  This open-
label study randomized 555 patients into either
the clofibrate–nicotinic acid group or the control
group.  At the end of 5 years, in the clofibrate–
nicotinic acid group, mean serum cholesterol
level was lowered by 13% (p<0.001) and
triglyceride level by 19% (p<0.001).  Also in the
clofibrate–nicotinic acid group, the rate of total
mortality was reduced by 26% (p<0.05) and IHD
mortality by 36% (p<0.01).  In addition, major
nonfatal cardiovascular events were reduced by
33%.  The benefits of lipid-lowering therapy were
confined to patients with fasting triglyceride
levels greater than 1.5 mmol/L (133 mg/dl) since
no treatment effect was observed in patients with
triglyceride levels of 1.5 mmol/L (133 mg/dl) or
lower. In addition, the effects seemed to be
related to degree of triglyceride level reduction
but not to cholesterol reduction.  In patients with
at least 30% reduction in triglyceride levels, IHD-
related mortality was 9.9% compared with 26.4%
in the control group, which reflects a 60% risk
reduction (p<0.01).  Overall, the Stockholm IHD
study demonstrated morbidity and mortality
benefits of clofibrate– nicotinic acid combination
therapy in patients after myocardial infarction.
Most of the benefit was seen in patients with
elevated baseline triglyceride levels and those
who achieved larger reductions in triglyceride
levels due to the lipid-lowering therapy.
Niacin
Canner PL, Berge GK, Wenger NK, et al.
Fifteen-year mortality in coronary drug project
patients: long-term benefit with niacin. J Am Coll
Cardiol 1986;18:1245–55.
This study was the 15-year follow-up to the
Coronary Drug Project (discussed in the previous
section); it was conducted to detect any long-
term adverse effects of the study interventions.
The primary objective was to determine the vital
status of all 8341 patients in the Coronary Drug
Project nearly 9 years after termination of the
study. The total mortality rate in patients
randomized to high- and low-dose estrogen,
dextrothyroxine, and clofibrate was 57.0–59.7%
compared with 58.2% in the placebo group, and
in each of these treatment groups, no statistical
difference in mortality was noted compared with
placebo.  Only the niacin treatment group had a
statistically significant lower mortality rate
(52.0%) than the placebo group (56.2%;
p=0.004).  Niacin-treated patients also had a
longer median survival time from entry into the
study (11.40 vs 13.03 yrs, p=0.0012).  This
survival benefit was primarily due to the
reduction of deaths from CHD.  Overall, this
follow-up study showed no evidence of long-
term adverse effects in patients treated with
estrogens, dextrothyroxine, or clofibrate beyond
the study time frame.  More important, the study
demonstrated that the mortality rate in the niacin
group was lower than in the placebo group after a
mean follow-up of 6.2 years even though it was
slightly higher at the termination of the Coronary
Drug Project.  This delayed benefit took place
even after niacin was discontinued; life table
curves showed that the niacin group began to
diverge in the beneficial direction at month 72.
This finding of long-term survival benefit may be
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due to the greater cholesterol level reductions
seen in niacin-treated patients compared with the
other interventions, or an improved survival rate
after myocardial infarction in these patients.
Surgical Methods
Buchwald H, Varco RL, Matts JP, et al. Effect of
partial ileal bypass surgery on mortality and
morbidity from coronary heart disease in patients
with hypercholesterolemia: report of the program
on the surgical control of the hyperlipidemias
(POSCH). N Engl J Med 1990;323:946–55.
The Program on the Surgical Control of the
Hyperlipidemias (POSCH) study was the only
prospective, randomized, secondary prevention
trial to use partial ileal bypass as the method of
reducing cholesterol levels.  This study evaluated
whether the resulting lipid level changes would
affect CHD morbidity and mortality.  Patients
with a history of one myocardial infarction were
randomized to either the control group (i.e.,
treated with diet instruction) or the surgery
group (treated with diet instruction plus partial
ileal bypass).  The primary end point was all-
cause mortality; secondary end points were
cause-specific death or other cardiovascular and
atherosclerotic events.
The trial ended after a mean follow-up of 9.7
years (range 7.0–14.8 yrs).  Five years after
randomization, total cholesterol levels in the
surgery group were 23.3% lower than in the
control group, LDL levels 37.7% lower, HDL
levels 4.3% higher, very low-density lipoprotein
cholesterol (VLDL) levels1 8.3% higher, and
triglyceride levels 19.8% higher.  Surgery reduced
total mortality by 21.7% and CHD mortality by
28.0% compared with controls, but this was not
statistically significant.  However, patients in the
surgery group had significantly lower rates of
CHD mortality and nonfatal myocardial
infarction combined, peripheral vascular disease,
coronary artery bypass grafting, percutaneous
transluminal coronary angiography, and disease
progression as determined by coronary
arteriography.  Patients in the surgery group also
had more adverse events, such as diarrhea,
kidney stones, gallstones, and bowel obstruction.
Overall, POSCH provided strong evidence that
large, sustained decreases in cholesterol levels
resulted in significant reduction of nonfatal CHD
events as well as reduced atherosclerotic
progression on sequential coronary arteriography.
Buchwald H, Varco RL, Boen JR, et al. Effective
lipid modification by partial ileal bypass reduced
long-term coronary heart disease mortality and
morbidity: five-year posttrial follow-up report
from the POSCH: program on the surgical
control of the hyperlipidemias. Arch Intern Med
1998;158:1253–61.
This study was a 5-year follow-up study to
POSCH.  After the formal completion of POSCH,
patients consented to annual follow-up by
telephone interview.  Mean follow-up for this
study was 14.7 years (range 12.2–20 yrs) from
original randomization.  Five years after formal
trial closure, 12.1% of the surgery group and
34.8% of the control group were taking
cholesterol-lowering agents, but patients in the
surgery group still had significantly lower total
cholesterol levels than controls.  Of 421 patients
assigned to undergo partial ileal bypass, 23
underwent reversal of the surgery due to
intolerable diarrhea or recurrent nephrolithiasis.
At the 5-year follow-up, 106 (25.4%) control
patients had died compared with 84 (20%)
surgery patients (RR 0.75, 95% CI 0.56–1.00,
p=0.49).  In terms of deaths from CHD, 70
(16.8%) control and 49 (11.6%) surgery patients
died (RR 0.66, 95% CI 0.46–0.96, p=0.03).
When nonfatal myocardial infarction and other
clinical end points were combined with mortality,
risk reduction in the surgery group was
significant as well.  Overall, this follow-up study
showed that lipid-lowering intervention with
partial ileal bypass 5 years after the trial resulted
in statistically significant reductions in total
deaths, CHD deaths, and nonfatal cardiovascular
events, thus providing evidence of long-term
benefits in the management of CHD.
Buchwald H, Williams SE, Matts JP, Nguyen PA,
Boen JR. Overall mortality in the program on the
surgical control of the hyperlipidemias. J Am Coll
Surg 2002;195:327–31.
This was a follow-up study to POSCH after
patients had been followed for a mean of 18 years
(range 15.5–23.0 yrs).  Investigators followed
patients through 1998, and analysis showed that
the overall mortality rate in the control group
exceeded that in the surgery group (who had
undergone partial ileal bypass).  During the
follow-up period, overall mortality increased in
both groups but was consistently lower in the
surgery group (120 deaths, 28.5%) than in the
control group (144, 34.4%; p=0.05).  Risk was
reduced by 20% due to surgical intervention
compared with control (RR 0.799, 95% CI
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0.628–1.018, p=0.07).  The authors calculated a
gain of 2.7 years in life expectancy in the surgery
group.  This follow-up study to POSCH
confirmed that lipid-lowering therapy decreased
overall mortality and increased life expectancy.
Angiographic or Surrogate End Point Trials
Post Coronary Artery Bypass Graft Trial
Investigators. The effect of aggressive lowering of
low-density lipoprotein cholesterol levels and
low-dose anticoagulation on obstructive changes
in saphenous-vein coronary-artery bypass grafts.
N Engl J Med 1997;336:153–62.
This study tested two hypotheses:  that
aggressive LDL level reduction to a goal of 60–85
mg/dl is more effective in delaying progression of
atherosclerosis in grafts than moderate reduction
to 130–140 mg/dl, and that low-dose anticoagu-
lation reduces obstruction of bypass grafts.  The
study randomized 1351 patients to receive either
lovastatin 2.5–5 mg/day with or without
cholestyramine 8 g/day (moderate-treatment
group) or lovastatin 40–80 mg/day with or
without cholestyramine 8 g/day (aggressive-
treatment group) for a mean duration of 4.3
years.  Evaluation was by quantitative coronary
angiography (QCA).  The primary end point was
the per-patient percentage of initially patent
major grafts showing substantial progression
(defined as a decrease of ≥ 0.6 mm in lumen
diameter) at the site of greatest change noted at
follow-up.  Most patients were Caucasian men
with a mean age of 61.5 years.  After 1 year of
follow-up, mean LDL level was 93 mg/dl in the
aggressive-treatment group versus 136 mg/dl in
the moderate-treatment group.  The aggressive-
treatment group achieved 37–40% reduction in
LDL concentration during the study versus
13–15% in the moderate group.  Therefore, this
study actually compared LDL levels below 100
mg/dl with those below 140 mg/dl.  A statistically
significant decrease was seen in the primary
outcome of per-patient percentage of grafts with
substantial disease progression (27% with
aggressive treatment vs 39% with moderate
treatment, p<0.001).  No significant benefit was
seen with warfarin versus placebo.  This study
indicates that patients treated with a statin with
or without cholestyramine to achieve an LDL
level less than 100 mg/dl have significantly less
progression of atherosclerosis as measured by
QCA compared with those who achieve more
modest LDL level reductions.
Blankenhorn DH, Azen SP, Kramsch DM, et al.
Coronary angiographic changes with lovastatin
therapy: the monitored atherosclerosis regression
study (MARS). Ann Intern Med 1993;119:969–76.
This was the first angiographic trial to
investigate the effects of a statin, lovastatin 40 mg
twice/day, versus placebo on progression of
coronary atherosclerosis.  Inclusion criteria were
age younger than 70 years, total cholesterol level
190–295 mg/dl, and CAD in at least two
segments, with at least one segment having a
diameter stenosis of 50% or more.  Patients with
diabetes and candidates for coronary artery
bypass grafting were excluded.  The study
randomized 270 patients, mostly men, of whom
247 had follow-up angiography at 2 years.
Assessment was by QCA.  The primary end point
was the average per-patient change from baseline
in percent diameter stenosis in all lesions that
showed 20% stenosis at baseline or follow-up.
Secondary end points were average per-patient
change in minimum lumen diameter, the global
change score, and the proportion of patients with
disease progression or regression (defined as a
change in diameter stenosis of ≥ 12%).
Mean baseline LDL level in the lovastatin
group was 151 mg/dl, which decreased 38% ±
12.3% to 93 mg/dl; LDL level in the placebo
group decreased by only 0.9% ± 13.8%.
Lovastatin caused a modest increase in HDL level
(8.5% ± 10.3%).  The primary end point did not
reach statistical significance; mean per-patient
diameter stenosis increased in both groups
(lovastatin 1.6% ± 6.7% vs placebo 2.2% ± 6.8%,
p>0.20).  The only statistically significant
difference between groups was in lesions with
stenosis of 50% or greater at baseline; lovastatin
caused a mean decrease of 4.1% ± 11.0% versus
an increase of 0.9% ± 11.0% with placebo
(p=0.005).  Fewer patients demonstrated progres-
sion and more demonstrated regression with
lovastatin, as measured by global change score
and change in percent diameter stenosis; these
differences were statistically significant.  No
statistically significant differences were noted in
clinical events, although a trend toward fewer
events was noted in the lovastatin group (22
events) versus the placebo group (31 events).
Brensike JF, Levy RI, Kelsey SF, et al. Effects of
therapy with cholestyramine on progression of
coronary arteriosclerosis: results of the NHLBI
type II coronary intervention study. Circulation
1984;69:313–24.
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This study from the National Heart, Lung and
Blood Institute was the first published
angiographic trial designed to determine whether
lowering cholesterol levels by diet and drug
therapy reduced the rate of progression of CAD.
The study randomized 143 patients with type II
hyperlipidemia and CAD to a low-cholesterol,
low-fat diet with or without cholestyramine 24
g/day; dosage was adjusted for adverse effects.
Assessment by coronary angiography, which was
a relatively new research methodology at the
time, was available for the 5-year follow-up in
116 patients (extended from the initially
intended 2 yrs due to lower-than-expected rate of
progression).  Mean± SD LDL level was 251.5 ±
4.3 mg/dl before the diet (at study entry) and 236
± 4.8 mg/dl after the diet; cholestyramine
treatment resulted in an additional 26% LDL
level reduction.  Therefore, LDL levels remained
quite elevated in most study patients.  Although
not statistically significant, a trend toward less
progression was noted in the cholestyramine
group.  This study was small, and LDL level
reduction from the drugs was limited; however,
the study was important in that it provided some
support for a beneficial effect of LDL lowering on
atherosclerotic progression.
Brown BG, Zhao XQ, Chait A, et al. Simvastatin
and niacin, antioxidant vitamins, or the
combination for the prevention of coronary
disease. N Engl J Med 2001;345:1583–92.
The hypothesis for the HDL–Atherosclerosis
Treatment Study (HATS) was that lipid-altering
and antioxidant therapy provide independent and
additive benefits for patients with CAD and low
HDL levels.  Study patients were men younger
than 63 years and women younger than 70 years
with clinical coronary disease who had at least
three stenoses 30% or greater or one stenosis
50% or greater of the lumen, HDL level less than
35 mg/dl in men or less than 40 mg/dl in women,
LDL level 145 mg/dl or greater, and triglyceride
level less than 400 mg/dl.  A total of 160 patients
were randomized to receive one of four
treatments:  simvastatin 10 mg/day, adjusted to
an LDL level less than 90 mg/dl and greater than
40 mg/dl, plus sustained-release niacin 2.0 g/day,
adjusted to an HDL level increase by changing to
a crystalline product if necessary and increasing
the dosage to 3–4 g/day; antioxidants (vitamins A
and C, b-carotene, and selenium); simvastatin-
niacin combination plus antioxidants; or placebo
(niacin placebo was active, with 50 mg/tablet).
Placebo patients could be treated with
simvastatin 10 mg/day to maintain an LDL level
of 130 mg/dl or less.
The primary end point was the mean per-
patient change from initial to final arteriogram in
the percent stenosis caused by the most severe
lesion in each of the nine proximal coronary
segments.  Average age of the patients was 53
years, 13% were women, 55% had a previous
myocardial infarction, and 16% had diabetes.
Mean ± SD doses were simvastatin 13 ± 6 mg/day
and niacin 2.4 ± 2.0 g/day.  Mean LDL level
during treatment in the simvastatin-niacin group
was 75 mg/dl, representing a 43% reduction,
versus 116 mg/dl in the placebo group.
Antioxidant therapy reduced the cardioprotective
HDL2 fraction by 15% when given alone and
blunted the expected HDL level increase when
given with simvastatin-niacin.  The vitamins had
no effect on the other lipoprotein fractions.  The
simvastatin-niacin group demonstrated a
decrease from baseline in mean percent stenosis,
which was significantly different from that of the
placebo group.  The simvastatin-niacin-antioxi-
dant group did not demonstrate atherosclerotic
regression, although progression was less than in
the placebo group.  A significant decrease in
composite clinical event rate was evident with
simvastatin-niacin treatment (90% reduction vs
placebo, p=0.03).  Risk in other treatment groups
did not differ significantly from that in the
placebo group.
This study demonstrated a significant benefit
in atherosclerotic regression and a lack of
progression with aggressive LDL reduction and
HDL elevation by low-dose simvastatin combined
with moderate-dose niacin therapy.  Consistent
with large-scale studies of antioxidant vitamins,
no benefit was seen when these agents were
administered alone; in fact, they appeared to
blunt the beneficial effects of the lipid-lowering
regimen.
Crouse JR III, Byington RP, Bond MG, et al.
Pravastatin, lipids, and atherosclerosis in the
carotid arteries (PLAC-II). Am J Cardiol
1995;75:455–9.
Designed to test whether pravastatin would
retard progression of carotid intimal medial
thickness, this was the first trial to use B-mode
ultrasonography to monitor intimal medial
thickness progression as a surrogate for coronary
disease.  Enrolled patients had coronary disease,
LDL levels in the 60th–90th percentile for age,
and at least one extracranial carotid lesion with
an intimal medial thickness of 1.3 mm or greater.
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Pravastatin 10–40 mg/day, adjusted to maintain
an LDL level of 90–110 mg/dl, was compared
with placebo, and ultrasound assessments were
performed at 6-month intervals beginning at 1
year of follow-up and ending at 3 years.  The
primary end point was growth or progression of
the mean maximum intimal medial thickness.
Data were adjusted for baseline cardiovascular
risk factors, mean intimal medial thickness, and
reader effects because a change was demonstrated
in reading patterns by some readers over time.
No significant difference was found between
groups in mean intimal medial thickness for all
segments or those at the bifurcation or internal
carotid artery.  A statistically significant reduction
in progression was noted at the common carotid
artery (reduction of 0.0161 mm/yr with
pravastatin vs placebo, p=0.03).  A 61% decrease
in the combined end point of any coronary event
and any death was seen in the pravastatin group
(p=0.04).  This study is of interest because of the
methodology used, which is less invasive than
coronary angiography and predicts coronary
atherosclerosis progression.  Although the degree
of angiographic change was of questionable
clinical significance, a decrease in coronary
events was demonstrated.
Frick MH, Syvanne M, Nieminen MS, et al.
Prevention of angiographic progression of
coronary and vein-graft atherosclerosis by
gemfibrozil after coronary bypass surgery in men
with low levels of HDL cholesterol. Lopid
coronary angiography trial (LOCAT) study
group. Circulation 1997;96:2137–43.
This trial studied the effect of treating men
with a history of coronary bypass surgery whose
primary lipid abnormality was a low HDL level.
Three hundred ninety-five men aged 70 years or
younger with an HDL level of 42.5 mg/dl or
lower, LDL level 174 mg/dl or lower, and
triglyceride level 354 mg/dl or lower were
randomized to slow-release gemfibrozil 1200
mg/day or placebo.  Those with diabetes or who
smoked more than 20 cigarettes/day were
excluded.  Change in average diameter of
segments from baseline to follow-up angiogram
and mean luminal diameter were assessed;
changes in primary segments (unaffected and
graft-dependent native coronary segments) were
the main end point of the study.  All patients had
an exercise tolerance test at baseline and at
follow-up angiography at a mean of 32 months.
Fewer than one third of patients in each group
demonstrated ischemic signs.  In the gemfibrozil
group, mean ± SD HDL level increased 21% from
baseline to 38 ± 7 mg/dl, triglyceride level
decreased 36% to 92 ± 34 mg/dl, and LDL level
decreased 4.5% to 130 ± 21 mg/dl.  In the
placebo group, mean ± SD HDL level increased
7% from baseline to 34 ± 6 mg/dl, triglyceride
level increased 4.6% to 154 ± 62 mg/dl, and LDL
level increased 5.3% to 148 ± 23 mg/dl.  All
differences were statistically significant.  No
statistically significant difference was noted in
the primary end point; however, significantly less
progression was seen in segments unaffected by
or influenced by grafts than in graft-dependent
segments.  No between-group differences in
clinical event rates were noted.  Although HDL
was increased in this study, the levels remained
low, and LDL levels during treatment remained
elevated.
Haskell WL, Alderman EL, Fair JM, et al. Effects
of intensive multiple risk factor reduction on
coronary atherosclerosis and cardiac events in
men and women with coronary artery disease:
the Stanford coronary risk intervention project
(SCRIP). Circulation 1994;89:975–90.
This study tested the hypothesis that intensive
multiple risk factor reduction over 4 years
significantly reduces the rate of progression of
atherosclerosis in the coronary arteries of men
and women compared with patients randomly
assigned to the usual care provided by their
physician.  Three hundred patients (259 men, 41
women, mean ± SD age 56 ± 7.4 yrs) with
angiographically defined coronary atherosclerosis
were randomized to receive intensive multifactor
risk reduction or usual care.  The risk reduction
intervention consisted of individualized
programs involving a low-fat and low-cholesterol
diet, exercise, weight loss, smoking cessation,
and drug therapy to favorably alter lipoprotein
profiles.  Patients were started with a bile
acid–binding resin (colestipol) and, depending
on response, other drugs, such as niacin,
gemfibrozil, lovastatin (available only during
second half of the study), and probucol were
added or substituted.  The LDL target level was
110 mg/dl instead of the 130 mg/dl advocated by
the NCEP at the time.
At baseline, 6.3% and 12.6% of patients in the
usual care and risk reduction groups, respectively,
were taking lipid-lowering agents.  At the 4-year
follow-up, these percentages rose to 22.6% and
89.9% of patients, respectively.  The main
angiographic outcome was the rate of change in
the minimal diameter of diseased segments at 4
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years, as measured by computer-assisted QCA.
Intensive risk reduction resulted in significant
improvements in LDL (-22%), apolipoprotein
B (-22%), HDL (+12%), plasma triglycerides (-
20%), body weight (-4%), exercise capacity
(+20%), and intake of dietary fat (-24%) and
cholesterol (-40%) compared with relatively small
changes in the usual-care group.  The mean ± SD
change in minimal coronary artery diameter was
smaller in the risk reduction group than in the
usual-care group (-0.024 ± 0.066 vs -0.045 ±
0.073 mm/yr, p<0.02).  The risk reduction group had
25 hospitalizations due to clinical cardiac events
compared with 44 in the usual-care group (rate
ratio 0.61, 95% CI 0.4–0.9, p=0.05).  This study
is of interest in that it incorporated aggressive
risk factor modification other than lipid
lowering.  However, it was unable to differentiate
among interventions to determine which were
most effective in improving angiographic
outcomes and reducing risk of coronary events.
Jukema JW, Bruschke AVG, van Boven AJ, et al.
Effects of lipid lowering by pravastatin on
progression and regression of coronary artery
disease in symptomatic men with normal to
moderately elevated cholesterol levels: the
regression growth evaluation statin study
(REGRESS). Circulation 1995;91:2528–40.
This study assessed the effects of pravastatin
on progression and regression of coronary
atherosclerosis after 2 years of treatment in men
with normal to moderately elevated cholesterol
levels.  The study enrolled 885 patients with a
total cholesterol level of 155–310 mg/dl.  Patients
included had clinical evidence of CAD and a
coronary arteriogram showing at least one lesion
that narrowed the lumen diameter by at least
50%.  Patients with diabetes were excluded; those
who were to undergo percutaneous transluminal
coronary angiography or coronary artery bypass
grafting were allowed to participate.  Primary
outcome, assessed by QCA, was the per-patient
change in mean segment diameter and mean
minimum obstruction diameter.  Mean ± SD LDL
level at baseline was 167 ± 30 mg/dl for both
groups; at 24 months, it was 127 ± 34.8 and 172
± 33.6 mg/dl in the pravastatin and placebo
groups, respectively.  Both groups showed
progression in that mean segment and minimum
obstruction diameters at follow-up were smaller
than at baseline.  Statistically significantly less
change was seen in the pravastatin group, but the
difference was small, with a mean segment
diameter decrease of 0.10 and 0.06 mm in the
placebo and pravastatin groups, respectively
(p=0.019).  The frequency of clinical events did
not differ between groups, except for a
nonscheduled percutaneous transluminal
coronary angiography that was needed in 47 and
20 placebo and pravastatin-treated patients,
respectively (p=0.004).  No difference in primary
outcome was noted in patients who received
pravastatin and underwent coronary artery
bypass grafting or percutaneous transluminal
coronary angiography or were medically
managed.
Kane JP, Malloy MJ, Ports TA, Phillips NR,
Diehl JC, Havel RJ. Regression of coronary
atherosclerosis during treatment of familial
hypercholesterolemia with combined drug
regimens. JAMA 1990;264:3007–12.
This 2-year study of 72 men and women
investigated the effect of LDL level reduction on
regression of coronary atherosclerosis.  Patients
were randomized to receive colestipol up to 30
g/day and niacin up to 7.5 g/day; when lovastatin
became available, it was added to the regimen.
The control group was offered colestipol up to 15
g/day.  Assessment was by QCA, and progression
and regression were defined as a 10% change in
lesion diameter stenosis.  Mean ± SD LDL levels
at baseline were 275 ± 52 and 283 ± 58 mg/dl in
the control and treatment groups, respectively,
and during the study were 243 ± 67 and 172 ± 63
mg/dl (38.1% decrease from baseline).  In the
treatment group, HDL levels increased 28%.  The
mean per-patient change in percent area stenosis
was +0.80 in the control group versus -1.53 in
the treatment group (95% CI -4.55 to -0.11,
p=0.039).  These changes were consistent in men
and women.  Of note, LDL levels in the treatment
group remained relatively high during the study.
Watts GF, Lewis B, Brunt JN, et al. Effects on
coronary artery disease of lipid-lowering diet, or
diet plus cholestyramine, in the St Thomas’
atherosclerosis regression study (STARS). Lancet
1992;339:563–9.
This study assessed the effects of a “practicable”
lipid-lowering diet on coronary atherosclerosis,
and the effects of greater cholesterol level
reduction with diet plus cholestyramine.  Ninety
men older than 66 years with total cholesterol
levels greater than 240 mg/dl (mean 280 mg/dl)
were randomized to receive usual care, diet (total
fat intake 27% of dietary energy, saturated fats
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8–10%, cholesterol 100 mg/1000 kcal, omega-6
and omega-3 polyunsaturated fats 8%, and
increased plant-derived soluble fiber), or diet
plus cholestyramine 8 g twice/day.  Overweight
patients were prescribed 1000–1200 kcal/day to
achieve a body mass index of 25 kg/m2. The
primary outcome was change in mean absolute
width of segments as determined by angiography.
At a mean of 39 months, angiograms of 74
patients were suitable for analysis.  Patients’ LDL
levels decreased 16.2% in the diet group and
35.7% in the diet-drug group; triglyceride levels
decreased significantly in the diet group but were
unchanged in the diet-drug group.  Change in
mean absolute width of segments was -0.201 mm
in the usual-care group, +0.003 mm in diet
group, and +0.103 mm in the diet-drug group
(p<0.012 for trend).  Overall progression was less
in the diet and diet-drug groups, and regression
occurred significantly more often in these groups.
Similar results were seen in the frequency of
clinical events.  The lipid-lowering diet in STARS
resulted in improvement in angiographic
measurements compared with usual care, and
addition of cholestyramine to this diet improved
angiographic outcomes further.
Taylor AJ, Kent SM, Flaherty PJ, Coyle LC,
Markwood TT, Vernalis MN. ARBITER: arterial
biology for the investigation of the treatment
effects of reducing cholesterol: a randomized trial
comparing the effects of atorvastatin and
pravastatin on carotid intimal medial thickness.
Circulation 2002;106:2055–60.
This study was a prospective, randomized,
open-label comparison of the effects of
pravastatin 40 mg/day or atorvastatin 80 mg/day
on carotid intimal medial thickness.  Eligible
patients were adults who met the NCEP ATP II
criteria for pharmacologic lipid lowering.  The
primary end point was change in mean common
carotid intimal medial thickness after 1 year, and
the secondary end point was a composite of
clinical cardiovascular events.  Investigators
randomized 161 patients to the two treatment
groups.  Mean patient age was 60 years, 71.4%
were men, 46% had known cardiovascular
disease, and mean ± SD baseline LDL level was
152 ± 34 mg/dl.  During therapy, mean ± SD LDL
level was 76 ± 23 mg/dl in the atorvastatin group
(48.5% decrease from baseline) versus 110 ± 30
mg/dl in the pravastatin group (27.2% decrease,
p<0.001).  Mean carotid intimal medial thickness
was stable in the pravastatin group (mean ± SD
change from baseline 0.025 ± 0.017 mm) versus
regression in the atorvastatin group (-0.034 ±
0.021 mm).  This study is of interest in that it
compared two levels of LDL level reduction, and
added to the evidence supporting lower LDL
goals.  However, since the study used two
different drugs, it also raised the question of
whether the variability seen was due solely to
degree of LDL level reduction versus other effects
that differed between drugs.
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK,
Grace KA. Arterial biology for the investigation
of the treatment effects of reducing cholesterol
(ARBITER) 2:  a double-blind, placebo-controlled
study of extended-release niacin on athero-
sclerosis progression in secondary prevention
patients treated with statins. Circulation
2004;110:3512–17.
This study investigated the effect on carotid
intimal medial thickness of extended-release
niacin 1 g/day or placebo added to statin
monotherapy in patients with known CHD.
Eligible patients had LDL levels less than 130
mg/dl and HDL levels less than 45 mg/dl; patients
with diabetes or metabolic syndrome were
included.  The primary predefined end point was
change in mean common carotid intimal medial
thickness after 1 year.  Mean age of the 167
randomized patients was 67 years, and 91% were
men.  Mean ± SD LDL level at baseline was 89 ±
20 mg/dl, which remained unchanged during the
study.  Mean ± SD baseline HDL level was 40 ± 7
mg/dl, which increased significantly in the niacin
group to 47 ± 16 mg/dl but remained unchanged
in the placebo group.  Fasting glucose levels
increased significantly in both groups.  Increased
carotid intimal medial thickness progression in
the niacin group was not statistically significant
(from 0.892 ± 0.259 mm at baseline to 0.907 ±
0.235 mm, p=0.23).  In the placebo group,
however, carotid intimal medial thickness
increased significantly from 0.868 ± 0.207 to
0.912 ± 0.202 mm (p<0.001).  About 25% of
patients had diabetes and 50% had metabolic
syndrome.  An interesting nonprespecified
subgroup analysis suggested that the beneficial
effect of niacin was somewhat lessened in
patients with diabetes or metabolic syndrome.
No difference in clinical coronary outcomes was
noted between treatment groups.  This study
indicated that adding a low dose of extended-
release niacin to the statin monotherapy of
patients with moderately low HDL and desirable
LDL levels can reduce progression of athero-
sclerosis as measured by carotid intimal medial
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thickness.  However, the study did not intend to
establish the beneficial effect on clinical
outcomes.
Nissen SE, Tuzcu EM, Schoenhagen P, et al, for
the REVERSAL Investigators. The effect of
atorvastatin 80 mg vs pravastatin 40 mg on the
progression of coronary atherosclerotic lesions as
measured by intravascular ultrasound. JAMA
2004;291:1071–80.
This study, called the Reversal of Atherosclerosis
with Aggressive Lipid Lowering (REVERSAL)
trial, compared the effects of aggressive LDL level
reduction with atorvastatin 80 mg/day, with those
of moderate reduction with pravastatin 40
mg/day, on the rate of atherosclerotic disease
progression as measured by intravascular
ultrasound over 18 months.  Study patients were
men and women aged 30–75 years who had an
LDL level of 125–210 mg/dl and required
coronary angiography for clinical reasons.  Mean
patient age was approximately 56 years, more
than 70% were men, and most patients were
Caucasian.  Mean LDL level at baseline was 150
mg/dl; final mean LDL was 110 mg/dl (25%
reduction) in the pravastatin group and 79 mg/dl
(46% reduction) in the atorvastatin group
(p<0.001).  The primary outcome was the
percent change in atheroma volume.  The
pravastatin group demonstrated an increased
volume of 2.7% (95% CI 0.24–4.67, p<0.001),
whereas the atorvastatin group demonstrated no
progression (change -0.4%, 95% CI -2.35–1.49).
In the subsegment with the greatest disease
burden, both treatment groups showed
statistically significant regression compared with
baseline; a statistically significantly greater
decrease in atheroma volume was noted in
patients treated with atorvastatin than with
pravastatin.  This study is of interest because it
compared two intensities of LDL level reduction.
However, it tested two different drugs, so the
question remains as to whether the effect was due
to drug therapy versus LDL level reduction, or
whether higher doses of pravastatin (not
available at the start of the study) would have
demonstrated responses similar to those seen
with high-dose atorvastatin.  In addition,
intravascular ultrasound is a relatively new
analytic method, and its correlation with clinical
outcomes has not been established.
Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of
recombinant apo A-I Milano on coronary
atherosclerosis in patients with acute coronary
syndromes: a randomized controlled trial. JAMA
2003;290:2292–300.
This randomized, double-blind, multicenter,
parallel-treatment study assessed the effect of two
different doses of recombinant apolipoprotein A-I
Milano–phospholipid complex (ETC-216) versus
placebo on coronary atheroma volume as
measured by intravascular ultrasound.  Patients
who were within 14 days of ACS and required
diagnostic coronary angiography were treated
with  infusions of saline placebo or ETC-216 15
or 45 mg/kg/week for 5 weeks.  This was a pilot
study and was not powered to compare treatment
groups; the primary outcome measure was the
percent change in atheroma volume as measured
by intravenous ultrasound in both treatment
groups combined.  Of 57 patients, 12 were
randomized to placebo, 23 to low-dose ETC-216,
and 22 to high-dose ETC-216.  The combined
treatment group demonstrated a mean ± SD
change in atheroma volume of -1.06% ± 3.17%,
median value 0.81% (95% CI -1.53–0.34%,
p=0.02 compared with baseline).  Total atheroma
volume in the combined treatment group
decreased 14.1 mm3 (p<0.001).  The effect of
ETC-216 was predominantly seen in the most
severely diseased 10-mm subsegments.  No
change was noted in mean coronary luminal
diameter as measured by coronary angiography.
Two patients in the high-dose ETC-216 group
were withdrawn from the study due to adverse
drug effects.  This trial suggests that ETC-216
may have a rapid effect on decreasing athero-
sclerotic disease burden in patients with recent
ACS.  However, larger studies with clinical
outcomes are needed to determine the efficacy
and safety of this approach.
Whitney EJ, Krasuski RA, Personius BE, et al. A
randomized trial of a strategy for increasing high-
density lipoprotein cholesterol levels: effects on
progression of coronary heart disease and clinical
events. Ann Intern Med 2005;142:95–104.
To determine the effect on coronary athero-
sclerosis of combination drug therapy with
gemfibrozil 600 mg twice/day plus niacin 3 g/day
plus cholestyramine up to 16 g/day, this study
increased HDL level in patients with fairly
normal LDL and low HDL levels.  Fairly normal
LDL level was defined as up to 160 mg/dl, low
HDL level was below 40 mg/dl.  The study was
performed in 1993, when using a placebo control
was still permissible; however, all patients were
prescribed the AHA step II diet.  Patients with
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diabetes were excluded from participation.  The
primary outcome was percent change in global
angiographic stenosis from baseline to the end of
treatment, as assessed by QCA at baseline and 30
months.  The secondary outcome was a composite
measure of clinical events.
Mean age of the 143 randomized patients was
63 years, and more than 90% of the patients were
men.  Mean ± SD LDL level was 126 ± 28.7 mg/dl
in the treatment group and 130.5 ± 24 mg/dl in
the control group.  Mean HDL level in both
groups was approximately 34 mg/dl at baseline.
Relative to the control group, the treatment
group experienced reductions of 26.4% in LDL
level, 49.8% in triglycerides, and 4% in weight,
and increases of 35.9% in HDL and 9.5% in
fasting glucose.  Mean ± SD global stenosis
decreased from 54.5% ± 6.8% to 53.7% ± 5.9% in
the treatment group and increased from 53.4% ±
7.3% to 54.8% ± 7.1% in the placebo group.  Of
the treatment patients, 70% were unchanged or
improved versus 50% of placebo patients
(p=0.03).  Major cardiovascular end points
(death, hospitalization for angina, revascular-
ization procedure, and cardiovascular accident or
transient ischemic attack) occurred in 26.4% of
placebo patients versus 12.7% of treated patients
(difference of 13.7%, 95% CI 0.9–26.5%, p=0.04).
Flushing, rash, and abdominal symptoms were
more common in the treatment group.  Fasting
glucose levels increased significantly more in the
treatment group, but no additional diagnoses of
diabetes were made.  Although the study
purported to show that the benefits seen were
due primarily to increasing the HDL level, LDL
reduction of almost 22% in the treated group
would have resulted in a mean LDL level during
treatment of just under 100 mg/dl.
Pasternak RC, Brown LE, Stone PH, et al. Effect
of combination therapy with lipid-reducing drugs
in patients with coronary heart disease and
“normal” cholesterol levels: a randomized,
placebo-controlled trial. Harvard atherosclerosis
reversibility project (HARP) study group. Ann
Intern Med 1996;125:529–40.
This portion of the Harvard Atherosclerosis
Reversibility Project (HARP) study reports the
lipid-lowering efficacy and tolerability of
multidrug therapy to improve LDL and HDL
levels in patients with CHD and average lipid
levels.  Stepped-care therapy with pravastatin 40
mg/day, slow-release nicotinic acid 1.5–3.0 g/day,
cholestyramine resin 4–24 g/day, and gemfibrozil
600–1200 mg/day was sequentially added until
the treatment goal of total cholesterol less than
160 mg/dl and an LDL:HDL ratio less than 2.0
were reached.  If LDL reached 80 mg/dl or less,
subsequent steps were not introduced.  The study
randomized 91 patients to treatment or placebo.
The patients (primarily men, mean age 60 yrs)
had CHD, a total cholesterol level below 250
mg/dl at baseline, and a total cholesterol:HDL
ratio greater than 4.0 at baseline.  Mean lipid
levels at baseline were total cholesterol 214
mg/dl, LDL 140 mg/dl, HDL 42 mg/dl, and
triglycerides 159 mg/dl.
With pravastatin, changes in lipid levels from
baseline were -22% for total cholesterol, -32% for
LDL, +8% for HDL, and -15% for triglycerides
(p<0.001 for all comparisons).  With the addition
of 1.5 g of nicotinic acid, further lipid level
changes were -6% for total cholesterol (p<0.002),
-11% for LDL, +8% for HDL, and -10% for
triglycerides (p<0.001 for all comparisons).  With
nicotinic acid 2.25–3.00 g, lipid changes were -
7% for total cholesterol (p=0.007), -14% for LDL
(p<0.001), +6% for HDL (p=0.02), and -13% for
triglycerides (p=0.03).  With cholestyramine,
total cholesterol and LDL levels were unchanged
from the previous step; lipid level changes were -
8% for HDL (p=0.03) and +46% for triglycerides
(p<0.001).  With gemfibrozil, additional lipid
changes were LDL +12% (p=0.09), HDL +12%
(p=0.03), and triglycerides -37% (p<0.001).  In
50% of patients whose baseline LDL levels were
greater than 130 mg/dl, pravastatin decreased
LDL level to 100 mg/dl or less by 6 weeks, but
maintained that level in only 30% of patients.
Eventually, 70% of patients needed combination
therapy to reach this goal during the 2.5 years of
the study.  Adding nicotinic acid to pravastatin
produced LDL levels of 100 mg/dl or less in 15
more of these 35 patients; thus, 94% of the
patients receiving these two drugs reached this
goal.  Although small, this study is useful in that
it evaluated the sequential effects of adding drugs
that were the standard therapies at the time.
Also, it demonstrated that many patients need
combination drug therapy to reach the LDL goal
of less than 100 mg/dl.
Serum Lipid, Lipoprotein, and Apolipoprotein
Levels:  Role in Cardiovascular Risk
Triglycerides
Jeppesen J, Hein HO, Suadicani P, Gyntelberg F.
Triglyceride concentration and ischemic heart
disease: an eight-year follow-up in the Copenhagen
male study. Circulation 1998;97:1029–36.
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To assess the potential of triglyceride levels to
function as an IHD risk factor, this Danish study
measured fasting lipid levels and assessed risk
factors for IHD in 2906 Caucasian men.  The
men did not have IHD at baseline; at their
assessment 8 years later, 229 first IHD events had
occurred.  The study population was divided into
three tertiles according to triglyceride concen-
tration.  Triglyceride levels were 1.09 mmol/L
(96.5 mg/dl) or less in the first tertile, 1.10–1.59
mmol/L (97–141 mg/dl) in the second, and 1.60
mmol/L (142 mg/dl) or greater in the third.
Starting with the low triglyceride concentration
tertile and increasing through the middle and
high tertiles, the three groups demonstrated
significant (p<0.001) trending increases in total
cholesterol level, LDL level, physical inactivity,
body mass index, systolic and diastolic blood
pressure, percentage of patients in low social
class, age, and percentage of patients with
hypertension, non–insulin-dependent diabetes
mellitus, and glucosuria.  Also noted was a
significant trending decrease in HDL level with
the increasing triglyceride tertile concentrations.
Within each triglyceride tertile, patients were
separated across HDL level tertiles to minimize
the confounding role of HDL level in
determining the risks attributed to triglyceride
concentrations.  The HDL level tertile categories
were 1.18 mmol/L (45 mg/dl) or less, 1.19–1.47
mmol/L (46–56.5 mg/dl), and 1.48 mmol/L (57
mg/dl) or greater. After controlling for potential
confounders, including alcohol consumption and
tobacco use, an increase was noted in IHD risk
with increasing triglyceride levels in each HDL
level tertile.  In the high triglyceride concen-
tration tertile (mean 2.45 mmol/L [217 mg/dl]),
the IHD frequency was 12.2%, 9.5%, and 12.5%
in the low, middle, and high HDL level tertiles,
respectively.
The authors hypothesized that perhaps HDL
loses its protective effect in the setting of high
triglyceride levels.  Fasting hypertriglyceridemia
was associated with an increased IHD risk
regardless of HDL concentration, even though
levels were not greatly elevated according to
contemporary guidelines (the NCEP ATP II
guidelines called for triglyceride levels less than
200 mg/dl).  Therefore, fasting triglyceride level
is an important screening parameter in patients at
risk of IHD.  However, the fact that patients with
high triglyceride levels also had more risk factors
for IHD (and metabolic syndrome) should still be
considered, even though this was adjusted for in
the analysis.  Two criteria that were absent and
significant—fasting serum glucose level and LDL
pattern size—also may have contributed to IHD
development, especially in patients with high
triglyceride levels.
Austin MA, McKnight B, Edwards KL, et al.
Cardiovascular disease mortality in familial forms
of hypertriglyceridemia: a 20-year prospective
study. Circulation 2000;101:2777–82.
This study, which assessed the effects of
familial forms of hypertriglyceridemia on
cardiovascular disease mortality, was based on
two studies from the 1970s that involved 101
families.  In the study cited, first-degree relatives
of the families were study subjects and spouses
were controls for familial combined hyper-
lipidemia (FCHL, 287 relatives, 195 spouses) and
familial hypertriglyceridemia (FHTG, 148
relatives, 88 spouses).  From 1993–1997, vital
status and cause of death were determined
among the study subjects.  Although the rate of
total mortality increased 40% in the FCHL group
and decreased 12% in the FHTG group, no
statistically significant changes were noted.  The
FCHL group had a statistically significant
increase in cardiovascular mortality of 70%
(p=0.02).  The FHTG group also had a 70%
increase in cardiovascular mortality but this did
not achieve statistical significance (p=0.39),
probably because of this group’s lower number of
cardiovascular-related deaths (21 patients).
Triglyceride level was an independent risk factor
of 20-year cardiovascular disease mortality
among first-degree relatives for FHTG (RR 2.7,
95% CI 1.7–5.2, p=0.02) but not for FCHL (RR
1.5, 95% CI 0.87–2.4, p=0.16).  Therefore, FCHL
relatives had a higher frequency of cardiovascular
mortality, but only the FHTG relatives had
triglyceride concentration as an independent
predictor of cardiovascular disease mortality.
This may be because patients with FCHL have
overproduction of apolipoprotein B and
formation of small, dense LDL particles, which
may contribute to cardiovascular mortality.
Brown DF, Kinch SH, Doyle JT. Serum
triglycerides in health and in ischemic heart
disease. N Engl J Med 1965;273:947–52.
This 4-year follow-up study assessed the effects
of serum cholesterol or triglyceride concentration
on frequency of IHD in 1851 men.  Of these men,
140 were known to have IHD.  Mean triglyceride
levels were not significantly different between
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healthy subjects and patients with IHD.  As
triglyceride concentrations increased, IHD rates
increased as well.  The same was true with
cholesterol levels, and determining an independent
effect of triglyceride or cholesterol level was
difficult.  Patients with high cholesterol (> 246
mg/dl) and triglyceride levels (> 541 mg/dl) had
the highest IHD rates.  A major finding was that
patients with high triglyceride levels had high
IHD rates, until total cholesterol levels reached
275 mg/dl or greater.  At that point, IHD rates
were similar despite triglyceride concentration.
Secondary to this finding, the authors determined
that fasting triglyceride concentrations were not
useful in predicting  IHD events in this study, but
that more investigation should be conducted to
further characterize this phenomenon.  The
hypothesis that elevated triglyceride level is
linked to insulin and carbohydrate metabolism
was also discussed in this study.
Assmann G, Schulte H. Relation of high-density
lipoprotein cholesterol and triglycerides to
incidence of atherosclerotic coronary artery
disease (the PROCAM experience). Am J Cardiol
1992;70:733–7.
This prospective study assessed the incidence
of CAD over a 6-year period in 4559 men aged
40–65 years with no history of myocardial
infarction or stroke.  Over the 6 years, 186 events
were recorded:  134 definite nonfatal myocardial
infarctions, 31 fatal myocardial infarctions, and
21 sudden cardiac deaths.  The groups who
experienced CAD had significantly elevated total
cholesterol, LDL, and triglyceride levels, as well
as significantly elevated blood pressure and body
mass index, and a high percentage of cigarette
smokers.  The group with CAD also had
significantly lower HDL levels.  After controlling
for multivariate risk factors, low HDL level
remained a significant predictor of CAD, whereas
triglyceride level did not.  However, hyper-
triglyceridemia (triglyceride level ≥ 200 mg/dl)
was associated with more CAD events in
subgroups with elevated total cholesterol, LDL,
and LDL:HDL ratio, and in men with decreased
HDL levels.  In those with LDL levels 160 mg/dl
or greater, concomitant hypertriglyceridemia
increased the frequency of CAD 2.5-fold.
Although a statistical correlation was not proven
through multivariate analyses, hypertriglyc-
eridemia remains a risk for CAD in patients with
concomitant lipid abnormalities.
High-Density Lipoprotein Cholesterol
Gotto AM Jr, Brinton EA. Assessing low levels of
high-density lipoprotein cholesterol as a risk
factor in coronary heart disease: a working group
report and update. J Am Coll Cardiol 2004;43:
717–24.
This article is based on the meeting of the
Working Group who discussed the latest research
on decreased HDL levels as a risk factor for CAD.
The group concluded that increasing HDL levels
can reduce the frequency of CAD, and that more
research is needed to identify ways to improve
our ability to increase HDL levels.  Data suggest
that for every 1-mg/dl increase in HDL level,
CAD risk decreases 2–3%.  Currently, the best
way to raise HDL levels is by administration of
niacin or fibric acids.  In a head-to-head study of
extended-release niacin versus gemfibrozil,
niacin raised HDL and apolipoprotein A-I levels
more significantly than gemfibrozil.  Apolipoprotein
A-I is a major protein component of HDL.
Statins may raise HDL levels to varying degrees,
and more research is needed to differentiate
which statins are preferred for raising HDL levels.
Other possible therapies for raising HDL levels
are omega-3 fatty acids, which are found in fish
oils, grape-seed oil, and thiazolidinediones
(glitazones).  Newer therapies on the horizon are
recombinant apolipoprotein A-I Milano, which
stimulates apolipoprotein A-I production;
cholesteryl ester transfer protein inhibitors,
which block cholesteryl ester efflux from HDL
particles to very low-density lipoprotein and low-
density lipoprotein particles in exchange for
triglycerides; and targeted gene therapy, which
involves using macrophages to induce
apolipoprotein A-I production.
Brousseau ME, Schaefer EJ, Wolfe ML, et al.
Effects of an inhibitor of cholesteryl ester transfer
protein on HDL cholesterol. N Engl J Med
2004;350:1505–15.
This single-blind, placebo-controlled study
assessed the effects of torcetrapib, a novel
cholesteryl ester transfer protein inhibitor, in 19
subjects.  Nine of the 19 subjects received
concomitant atorvastatin 20 mg/day; all 19 were
given placebo for 4 weeks followed by torcetrapib
120 mg/day.  Six subjects not receiving
atorvastatin went on to receive torcetrapib 120
mg twice/day.  No serious adverse events or
withdrawals due to adverse events occurred.
Minor-to-moderate adverse events, such as
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headache, dyspepsia, and sweating, were reported
during the study.  Cholesteryl ester transfer
protein activity was significantly reduced in both
groups of subjects (i.e., those receiving and not
receiving atorvastatin), and across both dosing
regimens of torcetrapib versus placebo.
Torcetrapib 120 mg/day increased HDL levels in
subjects receiving concomitant atorvastatin (61%
increase, p<0.001) and in those not receiving
atorvastatin (46% increase, p=0.001).  In subjects
who went on to receive torcetrapib 120 mg
twice/day, HDL levels were increased 106%
(p<0.001).  Apolipoprotein A-I levels were also
increased in all groups.  Torcetrapib alone did not
produce significant decreases in either
triglyceride or LDL levels.  The HDL2 subclass
was significantly increased in all groups.  Levels
of large low-density lipoprotein particles were
significantly increased in the torcetrapib
monotherapy groups, but not in the atorvastatin
group.  Therefore, trials with hard clinical end
points are needed to further characterize the
effects of raising HDL levels on atherosclerosis.
Yokota H, Hashimoto Y, Okubo S, et al.
Apolipoprotein A-I deficiency with accumulated
risk for CHD but no symptoms of CHD.
Atherosclerosis 2002;162:399–407.
This case study describes a 69-year-old
Japanese woman with extremely low HDL levels
(0.10–0.18 mmol/L [3.9–7.0 mg/dl]) and no
detectable apolipoprotein A-I (< 0.6 mg/dl).
Apolipoprotein A-I is a major protein of HDL
particles that carries HDL, and both
apolipoprotein A-I and HDL are inversely related
with occurrence of CHD.  Despite low levels, the
patient described did not develop CHD despite
numerous risk factors, such as elevated LDL
levels, hypertension, and impaired glucose
tolerance.  Perhaps CHD development was
avoided due to concomitant treatment with
pravastatin 10 mg/day, consumption of about 30
ml of wine/day, or HDL particles rich in
apolipoprotein E.  Of 22 patients with
homozygous deficiencies in apolipoprotein A-I,
only nine developed CHD.  More research is
needed to determine what types of apolipoprotein
A-I mutations confer a higher risk for CHD.
Weverling-Rijnsburger AW, Jonkers IJ, van Exel
E, Gussekloo J, Westendorp RG. High-density vs
low-density lipoprotein cholesterol as the risk
factor for coronary artery disease and stroke in
old age. Arch Intern Med 2003;163:1549–54.
This study assessed how well total cholesterol,
LDL, and HDL levels served as a predictor of
CAD in 599 subjects during a 4-year follow-up
period after they reached 85 years of age.
Subjects in the lowest tertile of total cholesterol
(median 179 mg/dl), LDL (median 106 mg/dl),
and HDL (median 36 mg/dl) levels had higher
mortality than those in the highest tertiles due to
a 2.4–2.7-fold increased risk of infection.
Increased risk of mortality due to CAD or stroke
was not predicted by either total cholesterol or
LDL level across the three strata.  However, the
lowest HDL level strata predicted CAD risk (RR
2.0, 95% CI 1.0–3.9, p=0.04) and stroke (RR 2.6,
95% CI 1.0–6.6, p=0.05).  In these elderly
subjects, therefore, only HDL level predicted
cardiovascular events.  Cholesterol-lowering
therapy arguably is not necessary in the elderly
since it may lead to increased risk of mortality
due to infection; however, therapies that increase
HDL level should be further studied in this
population.
Non–High-Density Lipoprotein Cholesterol
Frost P, Havel R. Rationale for the use of
non–high-density lipoprotein cholesterol rather
than low-density lipoprotein cholesterol as a tool
for lipoprotein cholesterol screening and
assessment of risk and therapy. Am J Cardiol
1998;81:26B–31.
Measuring LDL level is the gold standard for
estimating risk of cardiovascular disease.
However, using LDL levels has limitations.
Patients must be fasting, and LDL concentration
determined by the Friedewald equation is not
useful when triglyceride level exceeds 400 mg/dl.
Also, measuring LDL level takes into account
LDL, intermediate-density lipoprotein cholesterol,
and lipoprotein(a), but not VLDL, which is
atherogenic.  Therefore, the authors proposed
using non-HDL levels as an alternative to LDL
levels for screening, risk assessment, and
determining the effectiveness of therapy.
Measuring non-HDL levels does not require the
patient to be fasting, is useful when triglyceride
level exceeds 400 mg/dl, and takes into account
all atherogenic particles.  Non-HDL level is
calculated by subtracting HDL level from total
cholesterol level.  Correlation of non-HDL level
with a wide variety of lipid components is better
than with LDL level, and correlation with LDL
level is low at an LDL concentration less than
160 mg/dl.  This shows that non-HDL levels
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provide additional information regarding risk
compared with LDL levels alone.  Measuring
non-HDL levels is useful in patients for whom
hypertriglyceridemia is a problem, such as those
with diabetes.  The recommended cutoff point is
30 mg/dl above a patient’s LDL goal level.
Cui Y, Blumenthal RS, Flaws JA, et al.
Non–high-density lipoprotein cholesterol level as
a predictor of cardiovascular disease mortality.
Arch Intern Med 2001;161:1413–19.
This study assessed whether non-HDL level is
a good predictor of cardiovascular disease risk,
and how non-HDL level fared compared with
LDL level in predicting risk in 2406 men and
2056 women.  After follow-up for an average of
19 years, 234 men and 113 had died due to
cardiovascular disease.  Increases in non-HDL
level (RR 2.14, 95% CI 1.50–3.04), LDL level (RR
1.77, 95% CI 1.22–2.59), and total cholesterol
level (RR 2.07, 95% CI 1.39–3.08) significantly
predicted cardiovascular disease risk.  Increases
in HDL level significantly reduced risk (RR 0.41,
95% CI 0.27–0.61).  Only increases in non-HDL
level and decreases in HDL level significantly
predicted cardiovascular disease risk in women.
Every 30-mg/dl increase in non-HDL and LDL
levels translated to an increased risk of 19% and
11%, respectively, in men, 15% and 8% in
women.  A 10% increase in HDL level led to a
decreased risk of 23% in both men and women.
Non-HDL level was also a significant predictor of
all-cause mortality at levels exceeding 220 mg/dl,
whereas LDL level did not predict all-cause
mortality.  Thus, non-HDL level may be better
than LDL level as a predictor of cardiovascular
disease and all-cause mortality.
Ballantyne CM, Andrews TC, Hsia JA, Kramer
JH, Shear C, for the ACCESS Study Group.
Atorvastatin comparative cholesterol efficacy and
safety study. Correlation of non–high-density
lipoprotein cholesterol with apolipoprotein B:
effect of 5 hydroxymethylglutaryl coenzyme A
reductase inhibitors on non–high-density
lipoprotein cholesterol levels. Am J Cardiol
2001;88:265–9.
This 54-week study randomized 3916 patients
to receive one of five statins:  atorvastatin,
fluvastatin, lovastatin, pravastatin, or simvastatin.
The purpose was to determine how well non-
HDL level correlated with apolipoprotein B
concentrations versus LDL level.  Apolipoprotein
B is a marker of all the atherogenic lipoproteins
and has been a better marker of CHD than LDL
level.  Non-HDL level correlated better with
apolipoprotein B than LDL level at baseline and
at 54 weeks, although both were statistically
significant.  As triglyceride concentrations
increased, non-HDL level correlated better across
all triglyceride concentration strata as opposed to
LDL level; the greatest difference was seen in
patients with triglyceride levels exceeding 250
mg/dl (r=0.908 for non-HDL, r=0.855 for LDL).
Also, patients with CHD showed better
correlation between apolipoprotein B and non-
HDL levels (r=0.929) versus LDL levels
(r=0.810).  Thus, non-HDL level may be a better
marker of CHD risk than LDL level since it
correlates more closely with apolipoprotein B.
Atorvastatin reduced non-HDL and LDL levels
more significantly than the other statins, and
more patients taking atorvastatin reached their
respective goals.  However, dosages used in this
study were not equally potent, which may have
affected the outcomes.
von Muhlen D, Langer RD, Barrett-Connor E.
Sex and time differences in the associations of
non–high-density lipoprotein cholesterol versus
other lipid and lipoprotein factors in the
prediction of cardiovascular death (the Rancho
Bernardo study). Am J Cardiol 2003;91:1311–15.
This study analyzed the effects of total
cholesterol, triglyceride, LDL, HDL, and non-
HDL levels, as well as total cholesterol:HDL ratio
in predicting CHD mortality or cardiovascular
mortality in 1094 men and 1386 women.  After
10 years, 310 men and 268 women had died;
similar proportions of the deaths in each group
were due to CHD and cardiovascular mortality.
Also after 10 years, total cholesterol:HDL ratio
(p=0.01), triglyceride levels (p=0.01), and non-
HDL levels (p=0.05) predicted CHD and
cardiovascular mortality (p=0.04, 0.05, and 0.05,
respectively) after adjusting for age.  However,
after adjusting for all other risk factors, the
associations were lost in all lipid indexes.  In
women, no predictors of mortality were noted in
10 years, and only total cholesterol:HDL ratio
predicted CHD mortality at 3 years (p=0.001)
and 5 years (p=0.005), and predicted cardio-
vascular mortality only at 3 years (p=0.05) after
adjusting for age and for other risk factors
(p=0.001, 0.01, and 0.02, respectively).  Total
cholesterol level predicted cardiovascular
mortality at 5 years and at no other time point.
Thus, non-HDL level was not superior to other
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lipid indexes in predicting CHD mortality or
cardiovascular mortality in this study.
Small, Dense Low-Density Lipoprotein
Austin MA, King MC, Vranizan KM, Krauss RM.
Atherogenic lipoprotein phenotype: a proposed
genetic marker for coronary heart disease risk.
Circulation 1990;82:495–506.
This study described the differences between
two distinct phenotypes (A and B) of LDL in 301
subjects from 61 nuclear families.  The LDL
particle diameter of phenotype A was greater
than 255 angstroms (large, buoyant LDL), and of
phenotype B was generally 255 angstroms or less
(small, dense LDL).  Compared with subjects
expressing phenotype A, those with phenotype B
were associated with increased total cholesterol
(p<0.001), triglyceride(p<0.001), LDL (p<0.05),
and apolipoprotein B  levels (p<0.001); increased
VLDL mass (p<0.001); smaller low-density
lipoprotein particles (p<0.001); and decreased
HDL (p<0.001), apolipoprotein A-I (p<0.05), and
HDL2 mass (p<0.001).  In a study assessing
phenotype B, subjects expressing that phenotype
had an odds ratio (OR) of 3.0 for development of
myocardial infarction.  Thus, phenotype B is also
known as the atherogenic lipoprotein phenotype.
Griffin BA, Freeman DJ, Tait GW, et al. Role of
plasma triglyceride in the regulation of plasma
low-density lipoprotein (LDL) subfractions:
relative contribution of small, dense LDL to
coronary heart disease risk. Atherosclerosis
1994;106:241–53.
This study assessed the effects of triglyceride
levels on small, dense LDL (LDL-III) as well as
the effects of LDL-III on the rates of CAD  in four
groups of patients:  patients with CAD, patients
without CAD, patients with previous myocardial
infarction, and healthy controls.  At triglyceride
concentrations below 1.5 mmol/L (133 mg/dl),
LDL-III was not significantly correlated with
triglyceride levels, but larger, more buoyant LDL
(LDL-II) was significantly correlated (r=0.51,
p<0.001).  The largest LDL subclass (LDL-I) also
was not significantly correlated.  However, once
triglyceride concentrations exceeded 1.5 mmol/L
(133 mg/dl), both LDL-I and LDL-II were
significantly negatively correlated with
triglyceride levels (p<0.001), and LDL-III was
significantly positively correlated with
triglyceride levels (r=0.54, p<0.001).  Thus,
triglyceride concentrations play an important role
in the formation of small, dense LDL.  Two
proposed mechanisms are the increase in
production of large, triglyceride-rich VLDL or
increased triglyceride-rich VLDL exchanging
triglycerides for cholesteryl esters with LDL
through cholesteryl ester transfer protein.  This
study also found a 4-fold risk of developing CAD
with LDL-III and a 6-fold risk of experiencing
myocardial infarction with LDL-III.  Thus, small,
dense LDL not only is related to triglyceride
levels but is highly atherogenic as well.
Lamarche B, Tchernof A, Moorjani S, et al.
Small, dense low-density lipoprotein particles as
a predictor of the risk of ischemic heart disease in
men: prospective results from the Quebec
cardiovascular study. Circulation 1997;95:69–75.
Of 2103 men in the Quebec Cardiovascular
Study, 114 developed IHD during the 5-year
follow-up period.  These 114 patients were
matched to healthy controls for age, body mass
index, smoking habits, and alcohol intake.
Small, dense LDL was defined as having a peak
particle diameter (PPD) of 25.64 nm or less.
Patients in the first LDL-PPD tertile (≤ 25.64 nm)
had an increased risk of IHD compared with
those in the third LDL-PPD tertile (> 26.05 nm)
(RR 3.6, 95% CI 1.5–8.8).  Therefore, the small,
dense LDL phenotype translated to an increased
risk of IHD.  Also, apolipoprotein B concen-
trations were the strongest predictor of IHD risk.
Patients with an apolipoprotein B concentration
less than 120 mg/dl had no increased risk of IHD
regardless of LDL-PPD.  However, patients with
an apolipoprotein B concentration 120 mg/dl or
greater had an increased risk of IHD if LDL-PPD
was greater than 25.64 nm (OR 2.0) and an even
greater risk if LDL-PPD was 25.64 nm or less
(OR 6.2, p<0.001).  Thus, increasing LDL-PPD
reduced the risk of IHD, but lowering total
apolipoprotein B concentration to less than 120
mg/dl was more important and provided greater
risk reduction.
Gardner CD, Fortmann SP, Krauss RM.
Association of small low-density lipoprotein
particles with the incidence of coronary artery
disease in men and women. JAMA 1996;276:
875–81.
This nested, case-control study assessed the
ability of small, dense LDL particles to predict
CAD in 124 matched pairs (90 men, 34 women).
Between the two groups (cases and controls), the
patients with CAD (cases) had an LDL particle
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size 0.51 ± 1.37 nm smaller than that of controls
(p<0.001).  When LDL particle size was broken
down into quintiles, 61% of the cases were in the
two lowest quintiles.  The significance of the
difference in LDL particle size for cases and
controls remained after controlling for other lipid
parameters, systolic blood pressure, smoking,
and body mass index.  However, the difference
was no longer statistically significant after
adjusting for total cholesterol:HDL ratio.
Triglyceride concentrations and body mass index
had an impact on LDL particle size.  The increase
in CAD occurrence with decreased LDL particle
size lends further evidence to the hypothesis that
small, dense LDL particles predict CAD risk.
Apolipoproteins
Bhatnagar D, Durrington PN. Clinical value of
apolipoprotein measurement. Ann Clin Biochem
1991;28:427–37.
This article reviews all the major apolipo-
proteins, their main functions, and their possible
clinical relevance.  Apolipoprotein B is associated
with chylomicrons, VLDL, intermediate-density
lipoprotein, and LDL.  Each chylomicron, VLDL,
intermediate-density lipoprotein, and LDL
contains one apolipoprotein B molecule.
Chylomicrons express an apolipoprotein B
having 48% the molecular weight of normal;
thus, two apolipoprotein B molecules exist:
apolipoprotein B48 and apolipoprotein B100.
The LDL accounts for 90% of the total apolipo-
protein B100, except in patients with severe
hypertriglyceridemia.  Apolipoprotein(a), also
known as lipoprotein(a), is homologous to
plasminogen and links to apolipoprotein B
through a disulfide bond.  It has contributed to
CAD, usually in the setting of increased LDL
levels.  Many isoforms of apolipoprotein(a) exist,
making it difficult to quantify. Apolipoprotein A-
I is the main apolipoprotein on HDL and may be
responsible for reverse cholesterol transport.
Also, apolipoprotein A-I stimulates lecithin:acyl
transferase, which brings cholesterol into the
HDL particle.  Not much is known about
apolipoprotein A-II except that it is also
associated with HDL.  Apolipoprotein C-II
activates lipoprotein lipase, which is essential for
utilizing triglycerides.  Apolipoprotein E is
associated with polymorphisms that may increase
cardiovascular risk.  Most patients express E3-E3
or E2-E3 genotypes, which are common and
unremarkable.  However, E2-E2 or E4-E4
genotypes may be associated with increased CAD risk.
Lamarche B, Moorjani S, Lupien PJ, et al.
Apolipoprotein A-I and B levels and the risk of
ischemic heart disease during a five-year follow
up of men in the Quebec cardiovascular study.
Circulation 1996;94:273–8.
This study assessed the ability of apolipo-
protein B and apolipoprotein A-I to predict the
frequency of IHD in 2155 men over a 5-year
period.  At the end of the study, 116 patients
developed IHD.  Compared with those who did
not develop IHD, significant increases were noted
in age and systolic blood pressure, and in the
frequency of patients with diabetes and smokers.
Significant predictors of IHD were increased
apolipoprotein B, total cholesterol, and HDL
levels, as well as total cholesterol:HDL ratio.
Elevated apolipoprotein A-I level did not
significantly predict IHD, and no significant
differences were noted between survival
probabilities among the three tertiles of
apolipoprotein A-I concentration.  Survival was
significantly higher (p<0.0005) in the lowest
tertile of apolipoprotein B concentration than in
the highest tertile.  Increased apolipoprotein B
level remained a significant predictor of IHD
despite controlling for total cholesterol, LDL,
HDL, and apolipoprotein A-I levels, as well as
total cholesterol:HDL ratio.  Patients with
elevated apolipoprotein B concentrations and
total cholesterol:HDL ratio were at the highest
risk for IHD.  Thus, patients with elevated
apolipoprotein B levels are clearly at high risk for
IHD development, whereas elevated apolipoprotein
A-I levels did not significantly predict IHD.
Tomkin GH, Owens D. Abnormalities in apo
B–containing lipoproteins in diabetes and
atherosclerosis [review]. Diabetes Metab Res Rev
2001;17:27–43.
This article reviewed the interrelationship of
diabetes and atherosclerosis and identified causes
of increased atherosclerosis in patients with
diabetes.  One potential mechanism is the
overexpression of apolipoprotein C-III in patients
with type 1 diabetes mellitus.  Apolipoprotein C-
III inhibits activity of lipoprotein lipase, leading
to hypertriglyceridemia.  Also, apolipoprotein C-
III interferes with apolipoprotein E binding to the
apolipoprotein B-E receptor, which clears
atherogenic particles from the circulation.
Accumulation of atherogenic particles leads to an
increased risk of atherogenesis.  Insulin also
suppresses the release of free fatty acids from
adipose tissue.  When free fatty acids are
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released, they are taken to the liver and used for
promotion of VLDL assembly.  The VLDL
particles are potentially atherogenic, so patients
with decreased insulin production demonstrate
an increase of atherogenic particles.  Patients
with diabetes also have increased total fatty acids
in their LDL particles, which may increase the
susceptibility of LDL to oxidation.  Oxidized LDL
particles are more readily taken up by macrophage
scavenger receptors and may lead to atherogenesis.
Walldius G, Jungner I, Holme I, Aastveit AH,
Kolar W, Steiner E. High apolipoprotein B, low
apolipoprotein A-I, and improvement in the
prediction of fatal myocardial infarction
(AMORIS study): a prospective study. Lancet
2001;358:2026–33.
The AMORIS study assessed the power of
apolipoprotein B, apolipoprotein A-I, and the
apolipoprotein B:apolipoprotein A-I ratio in
predicting fatal myocardial infarction.
Information about smoking, hypertension,
diabetes, and concomitant diseases or treatments
were not recorded or adjusted for.  Low-density
lipoprotein level was calculated using a new
equation that was highly correlated with the
Friedewald equation (r=0.97–0.99).  In this
study, 98,722 men and 76,831 women
experienced 864 and 359 fatal myocardial
infarctions, respectively (a 2.5-fold increase in
risk for men).  The highest rate of fatal
myocardial infarction was in men aged 60–69
years and women aged 70–79 years.  The
apolipoprotein B:apolipoprotein A-I ratio was the
strongest predictor of risk in men and women in
univariate analysis.  Increased apolipoprotein B
level was the strongest predictor of risk in men
and women in multivariate analyses that
included other lipid indexes (RR 1.43, p<0.0001
in men, RR 1.34, p=0.0033 in women); increased
apolipoprotein A-I also had strong predictive
value.  Thus, apolipoprotein B and apolipo-
protein A-I levels are important in assessing risk
for myocardial infarction, possibly because the
apolipoprotein B:apolipoprotein A-I ratio
measures the number of atherogenic particles
divided by the number of antiatherogenic
particles.
Lipoprotein(a)
Danesh J, Collins R, Peto R. Lipoprotein(a) and
coronary heart disease: meta-analysis of
prospective studies. Circulation 2000;102:
1082–5.
This meta-analysis of 27 published prospective
studies assessed the association of lipoprotein(a)
with 5436 cases of CHD death or nonfatal
myocardial infarction.  The weighted mean
follow-up was 10 years.  In 18 population-based
study cohorts, increased lipoprotein(a) level was
associated with a significant 70% increase in
CHD death or nonfatal myocardial infarction
(2p<0.00001) when comparing patients in the
third tertile of lipoprotein(a) concentration with
those in the first tertile.  Using the same method
of comparison, a significant 30% increase was
seen in CHD death or nonfatal myocardial
infarction (2p<0.001) in the nine studies
involving patients with previous disease.
Unfortunately, cutoff numbers were not reported,
nor were the concentrations of classic lipid
indexes.  Lipoprotein(a) concentration has not
been correlated with other classic lipid level risk
factors and thus may provide information about
independent risk for CHD.  This meta-analysis
showed a strong association between elevated
lipoprotein(a) level and CHD, but more research
is needed to determine causality.
Moliterno DJ, Jokinen EV, Miserez AR, et al. No
association between plasma lipoprotein(a)
concentrations and the presence or absence of
coronary atherosclerosis in African-Americans.
Arterioscler Thromb Vasc Biol 1995;15:850–5.
This study assessed the association between
lipoprotein(a) and CAD in 140 African-American
patients (62 men, 78 women).  Patients were
defined as CAD-negative if coronary angiography
showed less than 10% diameter stenosis of one or
more major epicardial arteries, and as CAD-
positive if greater than 70% diameter stenosis.
There were no major differences between the two
groups regarding age, sex, estrogen replacement
supplements, or other atherosclerotic risk factors.
The CAD-positive group had significantly
increased total cholesterol (p=0.02), triglyceride
(p<0.001), VLDL (p<0.001), and LDL levels
(p=0.02), and significantly decreased HDL levels
(p<0.001).  Lipoprotein(a) was not significantly
different between the two groups with regard to
concentration across the total groups (CAD-
negative 54 ± 47 mg/dl vs CAD-positive 52 ± 38
mg/dl) or various subsets, or with regard to
lipoprotein(a) allele size.  Lipoprotein(a) was not
a significant predictor of CAD risk, but age, total
cholesterol level, and HDL level were.  This study
was consistent with two other studies that
reported no increased risk of CAD due to
elevated lipoprotein(a) levels in African-
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American patients.  Therefore, lipoprotein(a)
level may not be useful for risk assessment in this
population.
Shlipak MG, Simon JA, Vittinghoff E, et al.
Estrogen and progestin, lipoprotein(a), and the
risk of recurrent coronary heart disease events
after menopause. JAMA 2000;283:1845–52.
This subset of the Heart and Estrogen/
Progestin Replacement Study (HERS) assessed
the value of lipoprotein(a) concentration for
predicting CHD, and the ability of estrogen-
progestin therapy to lower lipoprotein(a) levels
and reduce future CHD risk.  Lipoprotein(a)
levels were available for 2759 women at baseline
and at 1 year.  When the baseline data were
stratified to quartiles of lipoprotein(a) concen-
trations, patients in the highest quartile had
significantly higher LDL (p<0.001) and HDL
levels (p=0.01), and significantly lower
triglyceride levels (p<0.001) and rates of
smoking (p=0.03).  Women in the highest
lipoprotein(a) concentration quartile were at a
significantly increased risk of 54% for primary
CHD events and 61% for revascularization
procedures compared with the lowest quartile.
Estrogen-progestin therapy significantly reduced
lipoprotein(a) levels compared with placebo
(p<0.001), but there was no overall effect of this
therapy on primary CHD events.  Estrogen-
progestin resulted in fewer primary CHD events
in women in the two highest quartiles.  Mortality
increased in year 1 of the study, but decreased in
years 2–5.  Lipoprotein(a) levels predicted CHD
events in women.  The effect of estrogen-
progestin on decreasing lipoprotein(a) levels to
reduce future CHD events was not strong in all
women.  Therefore, this therapy should not be
considered for those with elevated lipoprotein(a)
levels, especially in light of the Women’s Health
Initiative data.
Ariyo AA, Thach C, Tracy R, for the Cardio-
vascular Health Study Investigators. Lp(a)
lipoprotein, vascular disease, and mortality in the
elderly. N Engl J Med 2003;349:2108–15.
This study assessed the ability of lipoprotein(a)
to predict vascular events in 3972 patients (2375
women) aged 65 years or older with no baseline
history of CHD.  Lipoprotein(a) was divided into
equal quintiles, and results were reported as the
highest versus lowest quintile.  Men were more
likely than women to smoke tobacco and have
diabetes, whereas women were more likely to
have elevated lipid indexes, except for
triglyceride levels, and were more likely to have a
family history of myocardial infarction.
Lipoprotein(a) was a significant predictor of
stroke (RR 3.00, 95% CI 1.59–5.65, p=0.003),
death from vascular causes (RR 2.54, 95% CI
1.59–4.08, p=0.004), and death from all causes
(RR 1.76, 95% CI 1.31–2.36, p=0.01).
Lipoprotein(a) did not predict CHD events in
men.  Of interest, lipoprotein(a) did not
significantly predict any events in women.  Thus,
lipoprotein(a) is an independent predictor of
stroke risk, death due to vascular causes, and
death from all causes, in men but not in women.
von Eckardstein A, Schulte H, Cullen P,
Assmann G. Lipoprotein(a) further increases the
risk of coronary events in men with high global
cardiovascular risk. J Am Coll Cardiol 2001;37:
434–9.
This prospective study assessed lipoprotein(a)
as a coronary risk factor in 820 men aged 35–65
years who were followed for 10 years.  The men
were divided into two groups:  those with and
those without a history of major coronary events
(MCE+ and MCE-, respectively).  The group with
major coronary events had significantly increased
age; cholesterol, LDL, and triglyceride levels;
systolic blood pressure; fasting blood glucose
levels; history of angina; history of smoking; they
had significantly lower HDL levels.  The group
with major coronary events also had significantly
increased lipoprotein(a) levels (p=0.001).  When
lipoprotein(a) concentrations were divided into
quintiles, patients in the highest quintile (≥ 0.2
g/L) had a significantly increased rate of major
coronary events compared with those in the
lowest quintile (RR 2.7, 95% CI 1.4–5.2).
Elevated lipoprotein(a) levels were associated
with an increased risk for a major coronary event
in patients with hypertension, elevated LDL
levels, and low HDL levels.  Lipoprotein(a) levels
predicted the occurrence of major coronary
events in the two highest quintiles, which
accounted for 83% of total coronary events.
Therefore, lipoprotein(a) level is an important
independent coronary risk factor.
Kim C, Gau GT, Allison TG. Relation of high
lipoprotein(a) to other traditional atherosclerotic
risk factors in patients with coronary heart
disease. Am J Cardiol 2003;91:1360–3.
This study assessed lipoprotein(a) level as a
cardiovascular risk factor in 200 patients after an
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index CHD event.  The patients were stratified
into two groups:  those with lipoprotein(a) levels
greater than 30 mg/dl and those with
lipoprotein(a) levels 30 mg/dl or less.  Patients
with the higher lipoprotein(a) level at the time of
their index CHD event had significantly more
coronary angioplasty (p=0.027) and stent
procedures (p=0.002).  The higher lipoprotein(a)
group also had significantly fewer patients with
hypertension (p=0.002) or dyslipidemia
(p=0.018), and significantly more patients with a
family history of premature CHD (p=0.001).
Lipid indexes were not significantly different
between the two groups except for triglyceride
level (p=0.041), which was lower in the elevated
lipoprotein(a) group.  Patients in the elevated
lipoprotein(a) group had significantly fewer
traditional CHD risk factors than those in the
lower lipoprotein(a) group (1.53 ± 0.88 vs 2.12 ±
0.96, p=0.0001).  Thus, lipoprotein(a) level is an
independent risk factor for CHD and may
precipitate CHD events in patients with few
traditional risk factors.
Maher VM, Brown BG, Marcovina SM, Hillger
LA, Zhao XQ, Albers JJ. Effects of lowering
elevated LDL on the cardiovascular risk of
lipoprotein(a). JAMA 1995;274:1771–4.
Lipoprotein(a) concentration has been
associated with an increased risk of CAD in
patients with elevated LDL levels.  This post hoc
analysis of the Familial Atherosclerosis Treatment
Study (FATS) assessed the effects of LDL
lowering on the atherogenicity of lipoprotein(a).
The 120 patients involved had a history of CAD,
elevated apolipoprotein B concentration, and a
family history of premature cardiovascular
events.  Patients were divided into groups for
minimal (≤ 10%) and substantial (> 10%) LDL
lowering.  Twenty-nine patients had lipo-
protein(a) concentrations above the 90th
percentile (46.2 mg/dl).  Lipoprotein(a) concen-
tration was the most significant correlate of CAD
from baseline in univariate (p<0.001) and
multivariate (p<0.005) analyses.  Patients with
lipoprotein(a) concentration in the 90th
percentile had a 3.1% increase in percent stenosis
in proximal segments with minimal LDL level
reduction versus a 0.6% decrease in percent
stenosis in proximal segments with substantial
LDL level reduction (p<0.05).  Also, patients
with lipoprotein(a) concentration in the 90th
percentile had 77% decreased frequency of
clinical events in the substantial versus minimal
LDL level lowering groups (9% vs 39%, p<0.05).
Thus, lipoprotein(a) concentration is strongly
associated as a risk factor for CAD, but lowering
LDL level can minimize the effects of lipo-
protein(a) concentration on the coronary
vasculature and CAD events.
van Wissen S, Smilde TJ, Trip MD, de Boo T,
Kastelein JJ, Stalenhoef AF. Long term statin
treatment reduces lipoprotein(a) concentration in
heterozygous familial hypercholesterolemia.
Heart 2003;89:893–6.
Lipoprotein(a) concentrations were assessed in
325 patients with heterozygous familial hyper-
cholesterolemia who received either atorvastatin
80 mg/day (160 patients) or simvastatin 40
mg/day (165 patients) for 2 years.  The two
treatment groups were similar at baseline except
for lipoprotein(a) concentrations (327 and 531
mg/L for atorvastatin- and simvastatin-treated
patients, respectively, p=0.032).  After 2 years,
lipoprotein(a) concentration was significantly
reduced by both atorvastatin (to 263 mg/L,
p<0.001), and simvastatin (to 417 mg/L,
p<0.001); however, lipoprotein(a) levels were not
significantly different between the two groups
(p=0.53).  Baseline lipoprotein(a) concentration
was not correlated significantly with LDL level,
prevalent cardiovascular disease, age, baseline
intimal medial thickness, or change in intimal
medial thickness at any time point.  Also, change
in lipoprotein(a) concentration was not
correlated significantly with change in intimal
medial thickness but was significantly (although
weakly) correlated with change in LDL
concentrations (r=0.20, p=0.001).  Thus, long-
term statin treatment reduced lipoprotein(a)
concentrations in patients with heterozygous
familial hypercholesterolemia over a 2-year
period, but lipoprotein(a) concentration was not
correlated with the presence or change of
cardiovascular disease, so its utility is limited.
Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a)
as a predictor of coronary heart disease: the
PRIME study. Atherosclerosis 2002;163:377–84.
This study assessed lipoprotein(a) concentration
as a risk factor for CHD, as a predictor of hard
CHD or angina, and as possibly interacting with
other lipid indexes in 9133 French and Northern
Irish men aged 50–59 years with no history of
CHD.  Over a 5-year follow-up period, 288 CHD
events occurred.  The group of patients who
experienced an event had significantly more
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smokers, diabetes, hypertension, and elevated
lipid indexes, except for significantly decreased
HDL levels.  Lipoprotein(a) concentration
significantly predicted CHD after controlling for
numerous lipid and nonlipid variables (p<0.002).
Also, the highest quartile of lipoprotein(a)
concentration significantly predicted more CHD
events than the lowest quartile (RR 1.56, 95% CI
1.10–2.21, p=0.01).  The highest lipoprotein(a)
quartile also predicted more events, such as fatal
and nonfatal myocardial infarction and angina
compared with the lower quartiles (p<0.05).
Relative risk of CHD was significantly increased
across LDL level quartiles; patients in the highest
LDL level quartile and the quartile with greater
lipoprotein(a) concentration (≥ 33 mg/dl) had
the highest risk (RR 3.95, 95% CI 2.42–6.42).
This risk decreased across the lower quartiles of
LDL level.  Thus, increased lipoprotein(a)
concentration is an independent risk factor of
CHD and is useful for predicting CHD events.
Also, it appears that CHD risk with lipoprotein(a)
concentration increases with increasing LDL
concentration.  Since it is difficult to lower
lipoprotein(a) concentration with conventional
therapy, perhaps aggressively lowering LDL level
is a reasonable strategy.
Cantin B, Gagnon F, Moorjani S, et al. Is
lipoprotein(a) an independent risk factor for
ischemic heart disease in men? The Quebec
cardiovascular study. J Am Coll Cardiol
1998;31:519–25.
This 5-year prospective follow-up study in
2156 men aged 47–76 years without clinical
evidence of IHD determined whether
lipoprotein(a) concentration is a risk factor for
IHD and how it relates to other lipid indexes.
During the follow-up period, 116 IHD events
occurred.  Results indicated that increased
lipoprotein(a) concentration was not an
independent predictor of IHD; however, the
traditional risk factors (advanced age, smoking,
hypertension, elevated total cholesterol and LDL
levels, and decreased HDL level) were predictors.
Lipoprotein(a) concentration significantly
correlated with total cholesterol, LDL, and
apolipoprotein B levels (p<0.0001 for each
correlation).  Lipoprotein(a) concentration was
divided into low (< 30 mg/dl) and high (≥ 30
mg/dl) categories.  Higher lipoprotein(a)
concentrations increased the risk of IHD in
traditional risk factors, such as total cholesterol,
LDL, and apolipoprotein B levels, and removed
the protective effect of HDL.  Thus, increased
lipoprotein(a) concentration is not an
independent predictor of IHD risk but seems to
increase the risk associated with traditional risk
factors.
Nonlipid Serum Markers Associated with
Cardiovascular Disease
Hackam DG, Anand SS. Emerging risk factors in
atherosclerotic vascular disease: a critical review
of the evidence [review]. JAMA 2003;290;932–40.
This review identified 373 articles, including
randomized controlled trials, prospective cohort
studies, systematic overviews, case-control
studies, cross-sectional trials, and mechanistic
studies that evaluated C-reactive protein,
lipoprotein(a), fibrinogen, and homocysteine as
risk factors for atherosclerotic vascular disease.
The authors provided a concise overview of each
risk marker and the available evidence.
Information regarding C-reactive protein is, to a
degree, somewhat dated.  However, the article is
still useful for understanding the risk associated
with the markers discussed and the evidence
supporting their use as risk markers.
Balk EM, Karas RH, Jordan HS, Kupelnick B,
Chew P, Lau J. Effects of statins on vascular
structure and function: a systematic review. Am J
Med 2004;117:775–90.
This literature review evaluated the effects of
statins on coronary artery stenosis, carotid
intimal medial thickness, and endothelial
function.  In addition, the authors attempted to
determine whether the effects of statins on
vascular structure and function are a class effect,
and whether a correlation exists between these
effects and lipid concentrations.  Meta-analyses
were performed when appropriate.  This article
provides a good overview and discussion
regarding the effects of statins on these surrogate
markers.
Oxidation and Antioxidants
Heinecke JW. Oxidants and antioxidants in the
pathogenesis of atherosclerosis: implications for
the low oxidized low-density lipoprotein
hypothesis [review]. Atherosclerosis 1998;141:
1–15.
Oxidation of the LDL molecule is thought to
be an important factor in the development and
progression of atherosclerosis.  This review
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article examines the mechanisms of LDL
oxidation and the potential role of antioxidants.
Mechanisms the author explored were LDL
oxidation by metal ions, superoxide, thiols,
lipoxygenase, reactive nitrogen species, and
myeloperoxidase.  Review of the role of
antioxidants, especially animal data, was also
examined.  The strength of this review, for the
most part, is the proposed mechanisms of LDL
oxidation.
Yusuf S, Dagenais G, Pogue J, et al. Vitamin E
supplementation and cardiovascular events in
high-risk patients: the heart outcomes prevention
evaluation study investigators. N Engl J Med
2000;342:154–60.
Oxidation of the LDL molecule is thought to
be an important factor in the development and
progression of atherosclerosis.  Based on this
rationale, antioxidants may be important in the
treatment of cardiovascular disease.  The Heart
Outcomes Prevention Evaluation (HOPE) study
evaluated the role of antioxidants (vitamin E) in
patients at high risk for cardiovascular events.
Observational studies have suggested benefit
with vitamin E; however, results from
randomized trials have been conflicting in part
due to study limitations such as dosage, duration,
and limited event rates.  The HOPE study
addressed these concerns.  Study patients were
aged 55 years or older and at high risk for
cardiovascular events secondary to either
cardiovascular disease or diabetes and one other
risk factor.  Patients were randomly assigned by a
two-by-two factorial design to receive either
vitamin E 400 IU/day or placebo, and either an
ACE inhibitor or placebo.  Primary outcome was
a composite of myocardial infarction, stroke, and
death from cardiovascular disease.  Secondary
outcomes were unstable angina, chronic heart
failure, revascularization or amputation, death
from any cause, complications of diabetes, and
cancer.  Vitamin E was given to 4761 patients and
placebo to 4780.
After a mean follow-up of 4.5 years, no
significant difference was noted in the primary
end point (RR 1.05, 95% CI 0.95–1.16, p=0.33).
In addition, no significant differences in
secondary outcomes were observed.  This study
demonstrated that vitamin E 400 IU/day had no
benefit based on the outcome parameters
measured in patients at risk for cardiovascular
events over a 4.5-year period.  This relatively
definitive trial demonstrated that vitamin E has
no apparent benefit in patients at high risk for
cardiac events.  The strengths of the trial include
its large number of patients and sufficient power
to detect differences in outcome.  Also, the
vitamin E dose was high, and the follow-up
period probably was long enough for meaningful
conclusions.  Questions may remain regarding
whether a higher dose of vitamin E or treatment
with a combination of antioxidants would be
beneficial, and whether a longer study period
would have made a difference.  This study does
not address the issue of primary prevention.
Heart Protection Study Collaborative Group.
MRC/BHF Heart protection study of antioxidant
vitamin supplementation in 20,536 high-risk
individuals: a randomised placebo-controlled
trial. Lancet 2002;360:23–33.
Similar to the HOPE trial, this study evaluated
the role of antioxidant therapy in patients at risk
for cardiovascular events.  A total of 20,536
patients were randomized to receive antioxidant
vitamin supplementation with vitamin E 600
mg/day [sic], vitamin C 250 mg/day, and b-
carotene 20 mg/day, or placebo.  Patients were
followed for a scheduled 5-year treatment period.
Primary outcomes were major coronary events.
Subcategory analysis included fatal and nonfatal
vascular events.  No significant differences were
noted in the outcomes measured between
antioxidants and placebo.  Measured antioxidant
levels were increased in the group that received
the vitamin regimen.  This study demonstrated
that a daily antioxidant regimen had no benefit
based on the outcome parameters measured in
patients at risk for cardiovascular events over a 5-
year period.  This antioxidant regimen appeared
to be safe.  Results of this study mirror those of
the HOPE study, confirming that antioxidant
therapy in patients at high risk for cardiovascular
events is unlikely to be beneficial.  This study
also addressed the question of whether combi-
nation antioxidant therapy would be beneficial
compared with single-antioxidant therapy such
as vitamin E.  The study’s strengths were its large
number of patients and long-term follow-up; in
addition, it demonstrated increased antioxidant
levels.
Lee IM, Cook NR, Gaziano JM, et al. Vitamin E
in the primary prevention of cardiovascular
disease and cancer: the women’s health study: a
randomized controlled trial. JAMA 2005;294:
56–65.
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The overall purpose of this study was to
determine whether long-term administration of
vitamin E in healthy women would decrease the
risk of cardiovascular disease or cancer.  In a 2 x
2 factorial design, 39,876 women were randomized
to receive either vitamin E 600 IU or placebo,
and aspirin 100 mg or placebo every other day.
Average follow-up was 10.1 years.  Results
demonstrated a nonsignificant 7% risk reduction
(RR 0.93, 95% CI 0.82–1.05, p=0.26) for the
primary composite end point of nonfatal
myocardial infarction, nonfatal stroke, or
cardiovascular death.  No significant reduction
was noted for the individual components except
for cardiovascular death (24% reduction, RR
0.76, 95% CI 0.59–0.98, p=0.03).  However, no
difference in total mortality was seen.  A
subgroup analysis indicated a 26% reduction in
major cardiovascular events in women aged 65
years or older.  Finally, no significant difference
between groups was noted regarding frequency of
cancer.
The authors concluded that this study does not
support administration of vitamin E for primary
prevention of cardiovascular disease or cancer in
healthy women.  Further studies may be
warranted in women older than 65 years.  Of
note, this trial has a number of important
aspects, such as the number of patients studied,
long observation period, and relatively high dose
of vitamin E administered.  Based on these
factors, this study is relatively definitive with
regard to vitamin E and primary prevention of
cardiovascular disease or cancer in women.
Lonn E, Bosch J, Yusuf S, et al, for the HOPE
and HOPE-TOO Trial Investigators. Effects of
long-term vitamin E supplementation on
cardiovascular events and cancer: a randomized
controlled trial. JAMA 2005;293:1338–47.
The HOPE trial demonstrated a neutral effect
of vitamin E on cardiovascular outcomes over a
4.5-year period.  This trial, HOPE–The Ongoing
Outcomes (TOO), was an extension of the HOPE
trial.  The study investigated whether long-term
vitamin E therapy would prevent cardiovascular
events or cancer.  Patients were randomized to
receive either vitamin E 400 IU/day or placebo;
median follow-up was 7.0 years.  Study patients
were older than 55 years and had a history of
coronary or peripheral arterial disease, stroke, or
diabetes, plus one other cardiovascular risk
factor.  Primary outcome for cardiovascular
disease was a composite of myocardial infarction,
stroke, and cardiovascular death.  Secondary
outcomes were heart failure, unstable angina, and
revascularization procedures.  The results
demonstrated no significant difference in the
primary outcome variable (RR 1.04, 95% CI
0.96–1.14, p=0.34).  However, the patients
receiving vitamin E had a higher risk of heart
failure (RR 1.13, 95% CI 1.01–1.26, p=0.03).
Vitamin E also had no effect on occurrence of
cancer.  These results in a relatively high-risk
patient population suggest that vitamin E
supplementation should not be routinely
prescribed; in fact, the risk of developing heart
failure may be increased.  The obvious strengths
of this trial were its duration and dosage of
vitamin E used.  The mechanism behind
increased occurrence of heart failure with vitamin
E administration is not clear.  Despite this, the
study shows that the role of vitamin E in
decreasing cardiovascular disease in this patient
population is now relatively clear—it does not
prevent the disease.
Monocyte Chemotactic Protein-1
Martinez-Gonzalez J, Alfon J, Berrozpe M,
Badimon L. HMG-CoA reductase inhibitors
reduce vascular monocyte chemotactic protein-1
expression in early lesions from hypercholes-
terolemic swine independently of their effect on
plasma cholesterol levels. Atherosclerosis
2001;159:27–33.
This study investigated the role of statins on
vessel wall expression of monocyte chemotactic
protein-1 (MCP-1) and the inducible form of
nitric oxide synthase beyond lipid reduction.
The authors used an atherosclerotic pig model
and equivalent doses of atorvastatin and pravastatin.
Results demonstrated that MCP-1 expression was
significantly reduced by both statins regardless of
lipid-lowering effects and type of statin
administered (lipophilic vs hydrophilic).  No
effect on nitric oxide synthase was noted.
Results also demonstrated that statins may have
an important effect on MCP-1, and this effect
may be independent of degree of lipid reduction.
Statins may be important in attenuating the
inflammation process associated with athero-
sclerosis in part by affecting MCP-1 expression.
Parissis JT, Venetsanou KF, Kalantzi MV,
Mentzikof DD, Karas SM. Serum profiles of
granulocyte-macrophage colony-stimulating
factor and C-C chemokines in hypertensive
patients with or without significant hyperlipidemia.
Am J Cardiol 2000;85:777–9.
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This small but interesting study investigated
whether certain markers thought to be associated
with the atherosclerotic inflammatory process are
elevated in patients with hypertension with and
without significant hyperlipidemia.  The study
evaluated 46 patients with mild-to-moderate
hypertension and 18 healthy volunteers.  Of the
46 with hypertension, one group (22 patients)
had total cholesterol levels greater than 240
mg/dl or LDL levels greater than 160 mg/dl (or
both); the other group (24 patients) had total
cholesterol and LDL levels lower than those of
the first group.  Results demonstrated that
compared with healthy controls, patients with
hypertension had higher serum concentrations of
MCP-1, macrophage inflammatory protein-1a,
and granulocyte-macrophage colony-stimulating
factor.  In addition, these levels were higher in
patients with the highest cholesterol levels.  Both
MCP-1 and granulocyte-macrophage colony-
stimulating factor were significantly correlated
with LDL level.  These results suggest that these
markers of inflammation may be useful for
detection of the early inflammatory process
associated with atherosclerosis, and that LDL
level may play an important role in this process.
Chen YL, Chang YJ, Jiang MJ. Monocyte
chemotactic protein-1 gene and protein
expression in atherogenesis of hypercholes-
terolemic rabbits. Atherosclerosis 1999;143:
115–23.
This study is significant in that it established in
an animal model the relationship between
cholesterol and MCP-1 expression and the
pathophysiologic consequence of upregulation of
MCP-1 expression.  Specifically, MCP-1 may be a
key player responsible for the initial development
of atherosclerosis.  This study’s findings help
validate the importance of MCP-1 in athero-
sclerosis and provide a premise for the
importance of reducing cholesterol levels with
regard to MCP-1.
Homocysteine
Homocysteine Studies Collaboration. Homocys-
teine and risk of ischemic heart disease and
stroke: a meta-analysis. JAMA 2002;288:2015–22.
Debate continues regarding the significance of
the relationship between homocysteine
concentrations and cardiovascular disease.  This
study used meta-analysis statistics to determine
the relationship between homocysteine concen-
tration and vascular disease risk.  The analysis
included 30 prospective or retrospective studies
involving 5073 ischemic heart disease events and
1113 stroke events.  Evaluation of blood
concentrations of homocysteine indicated that
the association with outcome variables was
stronger in retrospective studies involving
patients with disease than in prospective studies
involving patients with no history of cardio-
vascular disease.  A 25% lower homocysteine
level was associated with 11% lower ischemic
heart disease risk and 19% lower stroke risk.  The
authors suggested that an elevated homocysteine
concentration may be a modest independent
predictor of the outcomes measured in this study.
Limitations of the study were those generally
associated with meta-analyses; another limitation
was that data only up to 1999 were included.
However, the study provided evidence that an
increased homocysteine concentration may be an
important risk factor for cardiovascular disease,
although the appropriate patient population at
risk needs to be determined.
Toole JF, Malinow MR, Chambless LE, et al.
Lowering homocysteine in patients with ischemic
stroke to prevent recurrent stroke, myocardial
infarction, and death: the vitamin intervention
for stroke prevention (VISP) randomized
controlled trial. JAMA 2004;291:565–75.
This double-blind, randomized, controlled trial
evaluated the effect of high doses of folic acid,
pyridoxine, and cobalamin to reduce the risk of
events in 3680 patients with nondisabling
cerebral infarction.  Patients were randomized to
receive a daily high-dose formulation of
pyridoxine 25 mg, cobalamin 0.4 mg, and folic
acid 2.5 mg (1827 patients), or a low-dose
formulation of pyridoxine 200 µg, cobalamin 6
µg, and folic acid 20 µg (1853 patients).  Primary
outcome was recurrent cerebral infarction;
secondary outcomes were CHD events and death
over a 2-year follow-up.  The high-dose group
had a 2-µmol/L greater reduction in total
homocysteine level than the low-dose group.  No
significant difference between the two groups
was noted in events for the primary or secondary
outcome measurements.  However, baseline
levels were still associated with risk.  In this
population, high-dose folic acid and vitamin
therapy had no effect in reducing outcomes.
However, the association seen between events
and homocysteine levels warrants further
investigation.  Trials of longer duration are
needed to further evaluate homocysteine therapy.
In addition, the appropriate patient population, if
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any, that would benefit from treatment with folic
acid still needs to be determined.
Schnyder G, Roffi M, Pin R, et al. Decreased rate
of coronary restenosis after lowering of plasma
homocysteine levels. N Engl J Med 2001;345:
1593–1600.
This prospective, double-blind, randomized
trial evaluated whether lowering plasma
homocysteine levels affected restenosis rates after
coronary angioplasty.  Daily folate treatment with
folic acid 1 mg, vitamin B12 400 µg, and
pyridoxine 10 mg was compared with placebo in
205 patients after coronary angioplasty.  Primary
end point was restenosis within 6 months;
secondary end point was a composite of major
adverse cardiac events.  Compared with placebo,
folate treatment significantly reduced homo-
cysteine levels, restenosis rates, and need for
revascularization.  Folate treatment as defined
above may be an important therapy for patients
undergoing percutaneous coronary angioplasty.
The authors commented that this inexpensive
therapy should be considered as an adjunct
therapy for patients undergoing percutaneous
coronary angioplasty.  A similar number of
patients received glycoprotein IIb-IIIa inhibitors
and statin therapy.  Dosages were not included,
nor was the number of patients receiving aspirin,
heparin, ticlodipine, or clopidogrel.  In addition,
due to the combination product administered, a
question may remain as to whether the outcomes
were due to lowering homocysteine levels or to
other factors.
Ridker PM, Shih J, Cook TJ, et al, for the Air
Force/Texas Coronary Atherosclerosis Prevention
Study (AFCAPS/TexCAPS) Investigators. Plasma
homocysteine concentration, statin therapy, and
the risk of first acute coronary events. Circulation
2002;105:1776–9.
This primary prevention trial, AFCAPS/TexCAPS,
evaluated the ability of homocysteine concentration
to predict coronary events in 5569 patients
receiving either lovastatin or placebo.  Results
demonstrated that baseline homocysteine level
was an independent predictor for a first acute
coronary event.  Patients at highest risk were
those with elevated levels of both LDL and
homocysteine.  However, homocysteine concen-
tration was not useful for predicting events in
patients whose LDL level was below the median
study level.  This study questioned the utility of
using homocysteine concentration as a marker to
identify initial cardiac events in low-risk patients
as determined by LDL level.  In other words, the
data suggest that homocysteine levels should not
be measured for primary prevention of first
cardiovascular events in patients with normal
LDL levels.
Anderson JL, Muhlestein JB, Horne BD, et al.
Plasma homocysteine predicts mortality
independently of traditional risk factors and C-
reactive protein in patients with angiographically
defined coronary artery disease. Circulation
2000;102:1227–32.
This prospective study evaluated risk associated
with plasma homocysteine levels in 1412 patients
with established CAD.  Findings indicated that
after a mean follow-up of 3 years, homocysteine
level was a significant predictor of mortality and
was independent of C-reactive protein and
genotype status for folate metabolism.  Patients
in the tertile with the highest homocysteine
levels had the greatest risk.  This study is
important because it further established elevated
homocysteine concentration as an independent
risk factor in patients with known CAD.
However, the study did not address whether
treatment that would lower this concentration
would alter outcomes.
Liem A, Reynierse-Buitenwerf GH, Zwinderman
AH, Jukema JW, van Veldhuisen DJ. Secondary
prevention with folic acid: effects on clinical
outcomes. J Am Coll Cardiol 2003;41:2105–13.
The effect of folic acid on outcomes in patients
with stable CAD receiving statin therapy is not
known.  This open-label study evaluated the
effect of folic acid 0.5 mg/day in 300 patients and
293 controls.  Primary end point was all-cause
mortality and a composite of vascular events;
mean follow-up was 24 months.  All patients had
stable CAD and had been receiving statin therapy
for a mean of 3.2 years.  Mean ± SD homocysteine
levels were significantly decreased by 18% (from
12 ± 4.8 to 9.4 ± 3.5 µmol/L) in the folic acid
group compared with controls.  No significant
differences were observed for the primary end
point.  Low-dose folic acid treatment and
corresponding homocysteine level reduction
were not effective in reducing clinical end points
in this patient cohort.  Results from this study
call into question the usefulness of folic acid
therapy for secondary prevention in patients with
stable coronary disease receiving statin therapy.
Of importance, baseline homocysteine levels
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were in the range where risk to the patient is
likely (Nygard O, Nordrehaug JE, Refsum H, et
al. Plasma homocysteine levels and mortality in
patients with coronary artery disease. N Engl J
Med 1997;337:230–6).  Thus, the reduction seen
in homocysteine levels should have demonstrated
benefit.  An obvious question from the trial is
whether a greater reduction in homocysteine
concentrations or higher baseline concentrations
would have made a difference.  In addition,
results may have been different with a longer
follow-up period.
Adhesion Molecules
Malik I, Danesh J, Whincup P, et al. Soluble
adhesion molecules and prediction of coronary
heart disease: a prospective study and meta-
analysis. Lancet 2001;358:971–6.
This study investigated whether soluble
adhesion molecules predict risk for CHD.  Study
patients were 643 men with CAD and 1278
controls; they were selected from a prospective
study of 5661 men who were followed for 16
years.  Serum concentrations of intracellular
adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1), E-selectin, and
P-selectin were measured.  In addition, the
authors performed a meta-analysis of other
relevant studies.  The ORs and 95% CIs for CHD
after adjustment for other coronary risk factors
and socioeconomic status were noted for ICAM-1
(OR 1.11, 95% CI 0.75–1.64), VCAM-1 (OR
0.96, 95% CI 0.66–1.4), E-selectin (OR 1.13,
95% CI 0.78–1.62), and P-selectin (OR 1.2
0.81–1.76).  The authors concluded that
measurement of these adhesion molecules
probably is not useful for predicting risk beyond
that of the more established risk factors.  As
presented in the article’s discussion section,
results of the meta-analysis appear to support
their conclusion.  These study data concern
chronic disease and cannot be extrapolated to the
acute coronary process.  Of note, epidemiologic
study samples may have been stored for nearly 20
years at -20°C.  Whether degradation of the
samples occurred and thus influenced the results
is not known.
de Lemos JA, Hennekens CH, Ridker PM.
Plasma concentration of soluble vascular cell
adhesion molecule-1 and subsequent cardiovascular
risk. J Am Coll Cardiol 2000;36:423–6.
This nested, case-control study investigated
whether soluble VCAM-1 is a marker for
increased cardiovascular risk in men with
confirmed myocardial infarction.  Baseline
plasma VCAM-1 samples were obtained from 474
men who experienced confirmed myocardial
infarction during the 9-year follow-up period of
the Physicians’ Health Study.  Their samples were
compared with those obtained from a similar
number of controls.  No significant difference
between the two groups was observed for median
baseline VCAM-1 concentration.  The data
suggest that soluble VCAM-1 concentrations in
apparently healthy men do not predict first
coronary event.  The study did not address
secondary events.
Blankenberg S, Rupprecht HJ, Bickel C, et al.
Circulating cell adhesion molecules and death in
patients with coronary artery disease. Circulation
2001;104:1336–42.
This prospective study was conducted to
determine whether soluble VCAM-1, ICAM-1,
and E-selectin are risk markers for future
cardiovascular events in patients with documented
CAD.  Baseline samples from a cohort of 1246
patients with CAD were obtained, and the rate of
cardiovascular events was documented over a
mean of 2.7 years.  Baseline soluble VCAM-1,
ICAM-1, and E-selectin predicted death from
cardiovascular causes in these patients.  When
the data were controlled for other markers
measured, such as C-reactive protein, only
soluble VCAM-1 remained independently
significant for fatal cardiovascular events (2.8-
fold increase in risk, p=0.003).  Circulating cell
adhesion molecules predicted cardiovascular
deaths in this patient population with
documented CAD.  Soluble VCAM-1 appeared to
be the most predictive.  Data concerning soluble
adhesion molecules are sparse.  Of note, this was
a nonrandomized, observational study with
inherent limitations.  Based on the data from this
trial, it appears that using soluble adhesion
molecules as markers to predict events may be
valuable in patients with established CAD.
Ridker PM, Buring JE, Rifai N. Soluble P-selectin
and the risk of future cardiovascular events.
Circulation 2001;103:491–5.
This study investigated whether P-selectin, a
cell surface adhesion molecule, predicts cardio-
vascular events.  Baseline plasma samples were
obtained from 115 apparently healthy women
who developed a cardiovascular event while
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participating in the Women’s Health Study.  These
samples were compared with those from 230
matched participants who remained event free
during a 3.5-year follow-up period.  Findings
indicated that women who experienced a
cardiovascular event had a higher mean P-
selectin level than matched controls (83.2 vs 69.3
ng/ml, p=0.003).  The greatest risk was observed
at the highest quartile (2.2 times higher than that
observed at the lowest quartile).  The increased
risk observed with increased P-selectin level was
independent of traditional risk factors.  This
study demonstrated that elevated soluble P-
selectin levels are a risk factor for primary
vascular events in women.
High-Sensitivity C-Reactive Protein
Ridker PM, Cushman M, Stampfer MJ, Tracy RP,
Hennekens CH. Inflammation, aspirin, and the
risk of cardiovascular disease in apparently
healthy men. N Engl J Med 1997;336:973–9.
This early landmark study demonstrated the
potential use of C-reactive protein as a risk
marker for future cardiovascular events.  This
was an observational study based on 543 healthy
men from the Physicians’ Health Study who
experienced a vascular event.  These men were
compared with 543 who did not experience a
vascular event.  The study found that increased
C-reactive protein level was an independent
predictor, with the greatest risk occurring at the
highest quartile.  Of interest, the effectiveness of
aspirin for lowering the risk of first myocardial
infarction was directly related to C-reactive
protein level.  This study helps establish
increased C-reactive protein level as a potential
risk factor for primary events in men.
Ridker PM, Glynn RJ, Hennekens CH. C-
reactive protein adds to the predictive value of
total and HDL cholesterol in determining risk of
first myocardial infarction. Circulation
1998;97:2007–11.
Drawing from the Physicians’ Health Study, the
authors evaluated the role of C-reactive protein
in concert with total cholesterol and HDL levels
in predicting first myocardial infarction.  This
classic article demonstrated not only the
independent value, but more important, the
additive value of evaluating C-reactive protein
and either total cholesterol level or total
cholesterol:HDL ratio for determining risk of first
myocardial infarction in healthy men.  In other
words, this article showed that the risk is greatest
when both total cholesterol and C-reactive
protein levels are elevated.
Ridker PM, Hennekens CH, Buring JE, Rifai N.
C-reactive protein and other markers of inflam-
mation in the prediction of cardiovascular disease
in women. N Engl J Med 2000;342:836–43.
The previous studies by these authors
demonstrated the value of C-reactive protein in
predicting risk in apparently healthy men.  In
this study, the authors evaluated C-reactive
protein and other markers of inflammation for
predicting risk for first cardiovascular event in
apparently healthy women.  This was a prospec-
tive, nested, case-control study involving subjects
from the Women’s Health Study.  Twelve markers
were evaluated in 122 case subjects (women with
cardiovascular events) and 244 control subjects
(women free of cardiovascular disease).  Results
demonstrated that C-reactive protein was the
strongest univariate predictor of risk, which was
4.4 times greater in the highest versus the lowest
quartile.  Other markers for risk were serum
amyloid A, soluble ICAM-1, interleukin-6,
homocysteine, total cholesterol, LDL, apolipo-
protein B-100, HDL, and total cholesterol:HDL
ratio.  Prediction of risk was significantly
improved in models that incorporated markers of
inflammation in addition to lipids.  Also, in a
subgroup of patients with LDL levels below 130
mg/dl, increased C-reactive protein and serum
amyloid A levels predicted risk.  When the
markers were evaluated by multivariate analysis,
C-reactive protein and total cholesterol:HDL ratio
were the only markers that independently
predicted risk.  Overall, this study demonstrated
the importance of C-reactive protein in
predicting risk of cardiovascular disease in
apparently healthy women.
Ridker PM, Rifai N, Clearfield M, et al, for the
Air Force/Texas Coronary Atherosclerosis
Prevention Study Investigators. Measurement of
C-reactive protein for the targeting of statin
therapy in primary prevention of acute coronary
events. N Engl J Med 2001;344:1959–65.
Previous data have shown that patients are at
risk for coronary events when C-reactive protein
levels are elevated even in those with lipid levels
that may be considered normal.  This study
investigated whether statin therapy could reduce
risk in patients with elevated C-reactive protein
levels but without overt hyperlipidemia.  C-reactive
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protein levels were obtained at baseline and 1
year in 5742 patients enrolled in AFCAPS/
TexCAPS.  Results demonstrated that lovastatin
was effective in patients with a total
cholesterol:HDL ratio below the median and C-
reactive protein level above the median.  Similar
results were seen for LDL level.  The number
needed to treat for 5 years to prevent one event
was 43 and 48 patients for each respective
analysis.  The data also demonstrated that the
changes in C-reactive protein level were probably
unrelated to the changes in lipid levels.  This
study helps confirm previous studies demon-
strating the importance of C-reactive protein to
predict risk independently and when added to
lipid levels.  The study also demonstrated that,
similar to pravastatin in the CARE trial,
lovastatin also lowers C-reactive protein level,
apparently independent of lipid level.  Finally,
these data suggest that patients may benefit from
statin therapy, at least for primary prevention,
when C-reactive protein level is elevated but lipid
levels are normal.
Albert MA, Danielson E, Rifai N, Ridker PM, for
the PRINCE Investigators. Effect of statin
therapy on C-reactive protein levels: the
pravastatin inflammation/CRP evaluation
(PRINCE): a randomized trial and cohort study.
JAMA 2001;286:64–70.
Previous data suggest that lowering C-reactive
protein level with statin therapy is independent
of LDL level; this prospective trial investigated
whether this is true with pravastatin in particular.
Results demonstrated that pravastatin did,
indeed, reduce C-reactive protein levels.  Also,
this study confirmed previous findings that no
significant association exists between C-reactive
protein and LDL levels.  This suggests that statins
may have both an antiinflammatory and a lipid-
lowering effect.  Clinically, this also suggests that
the effects of statin therapy in preventing
cardiovascular events may go beyond lipid
lowering alone.
Ridker PM, Cannon CP, Morrow D, et al, for the
Pravastatin or Atorvastatin Evaluation and
Infection Therapy-Thrombolysis in Myocardial
Infarction 22 (PROVE IT–TIMI 22) Investigators.
C-reactive protein levels and outcomes after
statin therapy. N Engl J Med 2005;352:20–8.
This study investigated the relationship
between LDL and C-reactive protein levels in
reducing the risk of recurrent myocardial
infarction or death from coronary causes in 3745
patients with ACS.  Study patients were drawn
from the PROVE IT–TIMI 22 study.  The authors
evaluated the effect of atorvastatin 80 mg/day
(intensive therapy) and pravastatin 40 mg/day
(moderate therapy) on cardiovascular outcomes
in patients with ACS.  For this aspect of the
study, the authors showed that when C-reactive
protein level was decreased to less than 2 mg/L,
event-free survival was improved.  The improve-
ment was seen with LDL levels less than 70
mg/dl and 70 mg/dl or greater.  Also, less than 3%
of the variation in C-reactive protein levels was
explained by the variation seen in LDL level after
statin therapy.  The authors also found that once
target levels were reached for C-reactive protein
(< 2 mg/L) and LDL (< 70 mg/dl) levels, the type
of statin administered did not seem important.
This study has a number of important impli-
cations.  First, in patients with ACS, the authors
confirmed findings from earlier primary
prevention studies demonstrating the importance
of C-reactive protein level in identifying risk.
Also, they showed that lowering C-reactive
protein levels with statin therapy is not directly
associated with LDL level reduction.  The results
from this study may suggest a pathophysiologic
role for C-reactive protein.  In addition, with data
from other trials, these results suggest that
monitoring and treatment may be necessary for
C-reactive protein as well as LDL levels.  Finally,
the results suggest that the type of statin
administered may not be important, but the
decrease in both LDL and C-reactive protein
levels is important.
Interleukin-6
Ridker PM, Rifai N, Stampfer MJ, Hennekens
CH. Plasma concentration of interleukin-6 and
the risk of future myocardial infarction among
apparently healthy men. Circulation 2000;101:
1767–72.
The authors used a prospective, nested, case-
control design to draw patients from the
Physicians’ Health Study to determine whether
interleukin-6 (IL-6) is a risk marker for
myocardial infarction in apparently healthy men.
A total of 202 patients who had a myocardial
infarction were identified and matched with 202
subjects who did not have a myocardial
infarction during a 6-year follow-up.  Baseline
median IL-6 levels were significantly higher in
patients who had a myocardial infarction.  Risk
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increased with each increasing quartile (p<0.001
for trend).  Men in the highest quartile had a
relative risk 2.3 times higher than those in the
lowest quartile (p=0.005).  After adjusting for
other cardiovascular risks, the relationship
remained significant.  These data indicate that
increased IL-6 level is associated with an
increased risk for myocardial infarction in
apparently healthy men.  The authors suggested
that cytokine-mediated inflammation may play
an important role in the development and
progression of atherosclerosis.
Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated
levels of interleukin-6 in unstable angina.
Circulation 1996;94:874–7.
This early study documented increased IL-6
levels in patients with unstable angina.  Levels
were measured in 38 patients with unstable
angina and in 29 with stable angina.  Interleukin-
6 levels were detectable in 23 of 38 patients with
unstable angina but in only 6 of 29 with stable
angina.  Significant correlation was seen between
IL-6 and C-reactive protein levels.  This study
demonstrated significant increased IL-6 levels in
patients with unstable versus those with stable
angina.  The data suggest that cytokine
production and the resultant influence on acute-
phase reactants contributed to cardiac events.  Of
note, the detection range was much less sensitive
in this study than in a previous study by the same
authors.  This accounts for the finding that only
six patients with stable angina had detectable IL-
6 levels.  The important finding in this study is
the significant rise from a probably already
activated cytokine state to an even higher state
during an acute process such as unstable angina.
Matrix Metalloproteinase
Aikawa M, Rabkin E, Okada Y, et al. Lipid
lowering of diet reduces matrix metalloproteinase
activity and increases collagen content of rabbit
atheroma: a potential mechanism of lesion
stabilization. Circulation 1998;97:2433–44.
This study, in which experimental atheromas
were induced in rabbits, tested whether lipid
lowering by diet alters macrophage accumulation
and matrix metalloproteinase (MMP) expression
in atherosclerotic lesions.  Results demonstrated
that a lipid-lowering diet reduced macrophage
content and MMP expression.  In addition,
interstitial collagen appeared to increase,
suggesting greater stabilization of fibrous caps.
This study establishes a mechanism by which
lipid lowering may prevent plaque rupture and
subsequent cardiovascular events.
Aikawa M, Rabkin E, Sugiyama S, et al. An
HMG-CoA reductase inhibitor, cerivastatin,
suppresses growth of macrophages expressing
matrix metalloproteinase and tissue factor in vivo
and in vitro. Circulation 2001;103:276–83.
This study investigated whether 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA)
reductase inhibition with cerivastatin decreases
macrophage accumulation and MMP expression
in a heritable hyperlipidemia rabbit model.
Results demonstrated that HMG-CoA reductase
inhibition decreased macrophage accumulation
and MMP expression in this model.  Further,
these results demonstrate that lipid lowering with
an HMG-CoA reductase inhibitor may prevent
cardiovascular events by decreasing plaque
instability through alterations in macrophage
accumulation and MMP activity.
Plasminogen Activator Inhibitor-1
Bourcier T, Libby P. HMG CoA reductase
inhibitors reduces plasminogen activator
inhibitor-1 expression by human vascular smooth
muscle and endothelial cells. Arterioscler
Thromb Vasc Biol 2000;20:556–62.
This study investigated whether HMG-CoA
reductase inhibitors affect the fibrinolytic system.
Specifically, the authors evaluated the effect of
HMG-CoA reductase inhibition on plasminogen
activator inhibitor-1 and tissue plasminogen
activator expression in cell cultures (inflam-
matory stimulated vascular smooth cells and
endothelial cells).  Results demonstrated that
simvastatin inhibited the expression of
plasminogen activator inhibitor-1 in both types
of cells and increased expression of tissue
plasminogen activator in endothelial cells.  These
data suggest that the benefit of HMG-CoA
reductase inhibition may relate in part to an
alteration in the fibrinolytic system that may
have favorable outcomes, perhaps by reducing
thrombotic risk after plaque rupture.  The effect
on the fibrinolytic system may be another
mechanism beyond lipid lowering in which
HMG-CoA reductase inhibitors may be beneficial
in treating patients with CAD.
CD40 System
Garlichs CD, John S, Schmeisser A, et al.
Upregulation of CD40 and CD40 ligand (CD154)
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in patients with moderate hypercholesterolemia.
Circulation 2001;104:2395–400.
Some researchers have suggested that the
CD40 system located in part on endothelial cells
or monocytes may promote expression of
proinflammatory cytokines, adhesion molecules,
and other factors that may contribute to
atherosclerotic development and progression.
This study investigated whether the CD40 system
is upregulated in patients with hypercholes-
terolemia and whether HMG-CoA reductase
inhibition affects this system.  The study
included 15 patients with hypercholesterolemia
and 15 healthy matched subjects.  At baseline
and after 3 weeks of treatment with cerivastatin
0.3 mg/day in the hypercholesterolemia group,
CD40, CD154, P-selectin, and MCP-1 were
evaluated.  Results demonstrated that at baseline,
before cerivastatin therapy, platelets of CD154
and P-selectin were significantly increased and
CD40 on monocytes was increased in the
hypercholesterolemia group.  Also, MCP-1 was
elevated in a platelet cell model and in the serum
of the hypercholesterolemia group.  After
cerivastatin therapy, CD40 was significantly
downregulated and serum MCP-1 levels were
decreased.  Implications of this study include the
possible role of the CD40 system to contribute to
the pathophysiology of atherosclerosis.  In
addition, a possible mechanism for
antiinflammatory effects of statins may be related
to modulation of this system.
Noncholesterol Sterols
Miettinen TA, Gylling H, Strandberg T, Sarna S,
for the Finnish 4S Investigators. Baseline serum
cholestenol as predictor of recurrent coronary
events in subgroup of the Scandinavian
simvastatin survival study. BMJ 1998;316:
1127–30.
Cholestenol, the 5-α-saturated derivative of
cholesterol, is formed from endogenous
cholesterol by enzymatic action.  The
cholestenol:cholesterol ratio, which is negatively
related to cholesterol synthesis in humans, may
help predict which patients may benefit from
statin therapy in terms of coronary event
reduction.  This study assessed baseline
cholestenol:cholesterol ratios in a Finnish
subgroup of 868 patients from the Scandinavian
Simvastatin Survival Study who were originally
randomized to receive simvastatin or placebo.
Patients were stratified into quartiles according to
their cholestenol:cholesterol ratio.  In each
quartile, relative risk of a major coronary event
(coronary death, nonfatal myocardial infarction,
revascularization procedure) were calculated for
patients in both simvastatin and placebo patients.
Risk reduction with simvastatin was seen with
increasing quartiles of cholestenol:cholesterol
ratios.  The authors suggested that measurement
of the cholestenol:cholesterol ratio may help in
identifying patients who might not benefit from
statin monotherapy.
Salem G, Horak I, Rothkopf M, et al. Lethal
atherosclerosis associated with abnormal plasma
and tissue sterol composition in sitosterolemia
with xanthomatosis. J Lipid Res 1985;26:
1126–33.
This report compared tissue sterol composition
in two 18-year-old patients; one had severe
atherosclerosis and died suddenly, the other had
minimal atherosclerosis and died accidentally.
The patient with severe atherosclerosis had
increased levels in plasma and tissue of
cholesterol, sitosterol, campesterol, and 5-a-
saturated stanols; the patient who died
accidentally had trace amounts of noncholesterol
sterols.  The authors endorsed cholestyramine
treatment for reducing plant sterol concentration
in patients with sitosterolemia.  Cholestyramine
enhances conversion of cholesterol and other
sterols to bile acids, thereby reducing plasma
concentrations.
Sudhop T, Gottwald BM, Bergmann KV. Serum
plant sterols as a potential risk factor for
coronary heart disease. Metabolism 2002;51:
1519–21.
Patients with sitosterolemia have extremely
elevated plant sterol levels and a high rate of
premature CHD.  This study investigated
whether plant sterol concentrations were a risk
factor for CHD in those without sitosterolemia.
Baseline levels of campesterol, sitosterol,
lathosterol, desmosterol, cholestenol, and serum
lipid were determined in consecutive patients
admitted for coronary bypass surgery.  Compared
with patients with no family history of CHD,
those with this history had significantly higher
concentrations of campesterol (0.5 ± 0.17 vs 0.38
± 0.16 mg/dl, p=0.011) and sitosterol (0.4 ± 0.11
vs 0.31 ± 0.11 mg/dl, p=0.004).  Other CHD risk
factors were similar between the two groups.
The authors concluded that plant sterols may be
an additional CHD risk factor.
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Myopathy, Hepatotoxicity, and Peripheral
Neuropathy Associated with Lipid-Lowering
Agents
Gaist D, Jeppesen U, Andersen M, Garcia
Rodriguez LA, Hallas J, Sindrup SH. Statins and
risk of polyneuropathy: a case-control study.
Neurology 2002;58:1333–7.
This nested, case-control study of a patient
registry in Denmark used outpatient visits or
hospital discharges recorded from January 1,
1994–December 31, 1998, to identify the first-
recorded cases of idiopathic polyneuropathy in a
single county.  Cases were excluded if diagnostic
codes or testing indicated other possible causes
of neuropathy (diabetes, renal insufficiency,
excessive alcohol intake, hypothyroidism, cancer,
monoclonal gammopathy of undetermined
significance, acquired immunodeficiency
syndrome, Lyme disease, connective tissue
disease, heavy metal intoxication, cobalamine or
folic acid deficiency, familial polyneuropathy, or
chronic inflammatory idiopathic polyneuropathy).
Only case patients with clinical data and
electrophysiologic tests (abnormal conduction in
at least two peripheral nerves, with at least one a
leg nerve) confirming the diagnosis were
included.  A neurologist masked to drug
exposure identified 166 cases with a first
diagnosis of idiopathic polyneuropathy.  Of these
cases, 35 were classified as definite, with no other
apparent cause of neuropathy; 54 as probable,
with sufficient information to rule out excessive
alcohol intake, diabetes, and renal insufficiency;
and 77 as possible, with insufficient evidence to
determine presence or absence of other exclusion
criteria.  Each case patient was matched with 25
controls based on age, sex, and calendar time.
Prescription records were used to assess exposure
to drugs and estimate the OR for administration
of statins for both groups.  Eight case patients
were taking statins (five simvastatin, two
pravastatin, one lovastatin, and one fluvastatin);
one had taken lovastatin previously. The OR
linking idiopathic polyneuropathy with statin
therapy was 3.7 (95% CI 1.8–7.6) for all cases
and 14.2 (95% CI 5.3–38.0) for definite cases.
The OR in patients taking statins was 4.6 (95%
CI 2.1–10.0) for all cases and 16.1 (95% CI
5.7–45.4) for definite cases, and 26.4 (95% CI
7.8–45.4) for those patients who had been taking
statins for 2 or more years.
Hsu I, Spinler SA, Johnson NE. Comparative
evaluation of the safety and efficacy of HMG-CoA
reductase inhibitor monotherapy in the treatment
of primary hypercholesterolemia. Ann Pharmacother
1995;29:743–59.
This comprehensive review compared the
efficacy and safety of fluvastatin, lovastatin,
pravastatin, and simvastatin in the treatment of
primary hypercholesterolemia.  Results from
placebo-controlled and comparative studies of
statin monotherapy are discussed; the
comparative trials are summarized in Table 3 of
the review.  The safety evaluation section
includes information on increased hepatic
transaminase kinase concentration, increased
creatine kinase and myopathy, lens opacity, and
sleep disturbances.  The authors concluded that
the long-term safety of statin therapy has been
established in clinical trials.  The most common
adverse events associated with statin therapy
were asymptomatic increased hepatic transaminase
and creatine kinase concentrations.  However,
symptomatic hepatic impairment and myopathy
were rare.  In the comparative trials, the adverse-
effect profiles of statins were similar.
Omar, MA, Wilson DP, Cox TS. Rhabdomyolysis
and HMG-CoA reductase inhibitors. Ann
Pharmacother 2001;35:1096–107.
The authors provide an overview of
rhabdomyolysis and the role of statins in patients
with rhabdomyolysis.  Case reports of statin-
associated rhabdomyolysis were identified by a
PubMed/MEDLINE search (January 1985–
October 2000).  This review has several useful
tables.  Table 1 compares pharmacokinetic
properties of statins, Table 2 lists drugs
associated with rhabdomyolysis due to
interaction with statins, Table 3 provides the
frequency of case reports associated with statin
monotherapy and combination therapy, and
Table 4 lists case reports of therapy.  No
information about rosuvastatin is provided.
Omar MA, Wilson JP. FDA adverse event reports
on statin-associated rhabdomyolysis. Ann
Pharmacother 2002;36:288–95.
The authors identified 871 (601 unique)
domestic and foreign cases of statin-associated
rhabdomyolysis using the FDA’s Adverse Event
Reporting System (November 1997–March
2000).  Outcome measures were the total number
of reports (initial plus follow-up), the number of
unique cases, patient age and sex, percentages of
report codes and role codes, frequencies of
concomitant interacting drugs that may have
984
KEY ARTICLES IN THE TREATMENT OF DYSLIPIDEMIAS  Ito et al
precipitated rhabdomyolysis, outcome codes, and
report source codes.  Numbers and percentages of
cases were associated with each statin as follows:
215 (35.8%) simvastatin, 192 (32.0%)
cerivastatin, 73 (12.2%) atorvastatin, 71 (11.8%)
pravastatin, 40 (6.7%) lovastatin, and 10 (1.7%)
fluvastatin.  No information was provided for
rosuvastatin.  Men had a higher rate of statin-
associated rhabdomyolysis than women (51.2%
vs 46.5%).  The most commonly reported
interacting drugs (more than 10 cases reported
for each) were mibefradil, fibrates, cyclosporine,
macrolide antibiotics, warfarin, digoxin, and
azole antifungals.  The most common outcome
listed was hospitalization; 38 cases resulted in
death.  Statin therapy was the primary suspect of
rhabdomyolysis in 72.0% of cases.  The authors
recognized the potential flaws in using the FDA
reporting system to determine the frequency of
statin-associated rhabdomyolysis.
Smith CC, Bernstein LI, Davis RB, Rind DM,
Shmerling RH. Screening for statin-related
toxicity: the yield of transaminase and creatine
kinase measurements in a primary care setting.
Arch Intern Med 2003;163:688–92.
These authors determined the frequency of
screening of transaminase and creatine kinase
levels in 1194 patients in a primary care practice
in 1998.  The patients were identified by use of a
computerized medical record.  During the study,
1014 (85%) patients had at least one monitoring
test.  Of these 1014 patients, 10 (1.0%) had a
significant transaminase level elevation (> 120
U/L) and five (0.5%) had a moderate elevation
(81–120 U/L); the elevations were not attributed
to statin therapy. Six (0.9%) patients had at least
one significantly abnormal creatine kinase level
elevation (> 5 times the upper limit of normal);
these elevations were attributed to statin therapy.
Fourteen (2.1%) patients had moderate creatine
kinase level elevations (2.5–5 times the upper
limit of normal); two of these elevations were
possibly related to statin therapy.  The frequency
of transaminase and creatine kinase level
elevations was lower than that reported in the
major statin trials.  No documented adverse
events were associated with any of the abnormal
laboratory test results.  Patients were taking
atorvastatin (37%), lovastatin (23%), pravastatin
(20%), and simvastatin (20%).  This study
included patients who would have been excluded
from the major clinical trials due to preexisting
medical conditions or concomitant drug
therapies.  The authors questioned the need for
routine monitoring of transaminase and creatine
kinase levels.
Staffa JA, Chang J, Green L. Cerivastatin and
reports of fatal rhabdomyolysis [letter]. N Engl J
Med 2002;346:539–40.
The writers of this letter to the editor evaluated
the frequency of fatal rhabdomyolysis associated
with atorvastatin, cerivastatin, fluvastatin,
lovastatin, pravastatin, and simvastatin using the
Adverse Event Reporting System of the FDA and
the National Prescription Audit Plus.  The letter
was written after Bayer voluntarily withdrew
cerivastatin from the U.S. market.  The reporting
rate of rhabdomyolysis fatalities was less than 1
death/million statin prescriptions compared with
1.9 deaths/million prescriptions for cerivastatin
monotherapy.  Thirty-one deaths due to
rhabdomyolysis were reported with cerivastatin.
Of these, 19 were associated with monotherapy
(12 and six patients with cerivastatin 0.8 and 0.4
mg, respectively; dose was not reported for one
patient).  Twelve fatalities were associated with
combined cerivastatin and gemfibrozil.  The
authors urge clinicians to warn patients taking
any statin to report symptoms of myopathy.
Thompson PD, Clarkson P, Karas RH. Statin-
associated myopathy. JAMA 2003;289:1681–90.
This review article provides a clinical summary
of statin-related myopathy and the frequency of
statin-associated rhabdomyolysis.  With a
PubMed/MEDLINE search, articles concerning
statin-related myopathy (through December
2002) and randomized, controlled clinical trials
involving statins (through January 2003) were
identified.  Rates of myalgia in the placebo- and
statin-treated groups in the clinical trials are
reported in Table 1 of the article.  Rates of
myopathy in placebo- and statin-treated groups
as reported in the randomized controlled statin
trials are compared in Table 3.  The authors
report the type of patients, duration of study,
statin dosage, number of patients, number with
cases of rhabdomyolysis, number with cases of
myositis, percentage of patients with elevated
creatine kinase levels, and percentage with
myalgia.  The incidence of statin-associated
rhabdomyolysis was determined using the FDA
MedWatch database (January 1, 1990–March 31,
2002).  In Table 2, rates of rhabdomyolysis with
atorvastatin, cerivastatin, fluvastatin, lovastatin,
pravastatin, and simvastatin are summarized
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according to age groups and outcomes (death,
disability, hospitalization, life-threatening
disorder, other).
Hodel C. Myopathy and rhabdomyolysis with
lipid-lowering drugs. Toxicol Lett 2002;128:
159–68.
Using published literature and unpublished
personal experiences with animal and clinical
cases, this author provided a 30-year review of
myopathy associated with fibrates and myopathy
and rhabdomyolysis associated with statins.  The
mechanism of action of myopathy in humans and
in the animal models for myopathy are discussed.
The author suggests that electrophysiologic
studies involving patients taking drugs known to
be or suspected of being myotoxic will allow
determination of the true incidence of drug-
induced myopathy.
Huynh T, Cordato D, Yang F, et al. HMG-CoA
reductase-inhibitor–related myopathy and the
influence of drug interactions. Intern Med J
2002;32:486–90.
This article presents four case reports involving
elderly women who developed rhabdomyolysis
and severe, disabling myopathy.  Patient no. 1
had been taking simvastatin 80 mg/day with
gemfibrozil 600 mg twice/day for over 6 months.
Rhabdomyolysis developed after roxithromycin
was added to treat an upper respiratory infection.
Patient no. 2, who had type 2 diabetes and
chronic renal failure, developed rhabdomyolysis
after taking simvastatin 20 mg/day for 3 months.
Patient no. 3, who had chronic renal failure, had
been taking simvastatin 40 mg/day for 5 years.
Muscle biopsy confirmed necrotizing myopathy
and the presence of inclusion bodies, which may
indicate underlying muscle disease.  Patient no.
4, who had diabetes, had been taking cerivastatin
for 1 month before hospital admission.  Muscle
symptoms resolved in three patients; the
exception was patient no. 3.  These case reports
illustrate the need to consider drug interactions
and comorbid disease states when selecting lipid-
lowering therapy.
Kiortsis DN, Nikas S, Hatzidimou K, Tsianos E,
Elisaf MS. Lipid-lowering drugs and serum liver
enzymes: the effects of both weight and baseline
enzyme levels. Fundam Clin Pharmacol
2003;17:491–4.
This study examined the effects of statins and
fibrates on liver enzyme levels in patients who
were obese, overweight, and lean, based on body
mass index.  Over 24 weeks, 263 men and
women aged 31–74 years received atorvastatin
10–20 mg/day (62 patients), ciprofibrate 100
mg/day (44), micronized fenofibrate 200 mg/day
(45), fluvastatin 40 mg/day (103), and gemfibrozil
900 mg/day (9).  Serum transaminase concen-
trations were obtained at baseline, after 8 weeks
of treatment, and at the end of the study; these
levels were compared based on body mass index.
At baseline, 8 weeks, and 24 weeks, more obese
than lean patients had elevated transaminase
levels; however, the differences were not statis-
tically significant.  No statistically significant
changes in transaminase levels were observed in
any patient group.
Punthakee Z, Scully LJ, Guindi MM, Ooi TC.
Liver fibrosis attributed to lipid lowering
medications: two cases. J Intern Med 2001;250:
249–54.
Two case reports describe patients with chronic
active hepatitis and liver fibrosis associated with
statins and fibrates; other possible causes were
ruled out.  The first report describes a 39-year-
old man originally treated inadequately with
gemfibrozil and cholestyramine.  His therapy was
changed to lovastatin, which was discontinued
after 9 months because of myalgia without
creatine kinase level elevation.  Nine months
after lovastatin discontinuation, pravastatin
therapy was started, and 9 months later the
patient came to the hospital complaining of fever
and asthenia.  His elevated liver enzyme levels
were consistent with acute liver injury; when
these levels returned to normal, simvastatin
therapy was started.  After 22 months of
simvastatin therapy, the patient returned to the
hospital with the same symptoms and elevated
liver enzyme levels.  Simvastatin was stopped,
and his elevated enzyme levels returned to the
normal range.  Findings from needle biopsy of
the liver 2 weeks after simvastatin discontin-
uation were consistent with drug-induced
chronic active hepatitis.  Six years after the
patient stopped taking simvastatin, hepatitis had
not recurred.
The second case report describes an obese, 63-
year-old woman whose transaminase concen-
trations were elevated to more than 11 times the
upper limit of normal on routine monitoring.
The patient had been taking fenofibrate for 2
years and simvastatin for 4 years at the time of
her laboratory test.  Liver enzyme concentrations
returned to normal within 2 months after
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discontinuation of the simvastatin and
fenofibrate.  Results of a liver biopsy 7 weeks
after the patient stopped taking these drugs
indicated that she had chronic active hepatitis
with severe fibrosis.
Sinzinger H, Wolfram R, Peskar BA. Muscular
side effects of statins. J Cardiovasc Pharmacol
2002;40:163–71.
This review article discusses the muscle-related
side effects of statins.  The authors did not
describe their literature search or specify the
period covered.  Coenzyme Q10 depletion and
oxidation injury are presented as possible
mechanisms of muscle symptoms.  The article
provides a general overview of pain (type, time of
onset, duration, and localization), creatine kinase
concentration, physical activity, statin dose-
dependency, predisposing factors, risk associated
with different statins, pathophysiology, and
treatment.
van Puijenbroek EP, Du Buf-Vereijken PW,
Spooren PF, van Doormaal JJ. Possible increased
risk of rhabdomyolysis during concomitant use
of simvastatin and gemfibrozil. J Intern Med
1996;240:403–4.
Two case reports describe rhabdomyolysis
development during concomitant treatment with
simvastatin and gemfibrozil.  The first patient, a
62-year-old man with diabetes, atherosclerosis,
and hyperlipidemia, was taking simvastatin 20
mg/day with gemfibrozil 600 mg/day.  The second
patient, a 50-year-old woman with diabetes,
hyperlipidemia, chronic renal failure with
nephrotic syndrome, and obesity, was taking
simvastatin 80 mg/day with gemfibrozil 600
mg/day.
Wortmann RL. Lipid-lowering agents and
myopathy. Curr Opin Rheumatol 2002;14:643–7.
This review article discusses the muscle-related
side effects of statins, fibrates, and nicotinic acid.
Clinical features, epidemiology, risk factors, and
mechanisms are presented in short sections.  In
Table 4, drug-drug interactions resulting from
cytochrome P450 (CYP) systems are listed by
statin.  Certain references are marked “of special
interest” or “of outstanding interest.”
Ballantyne CM, Corsini A, Davidson MH, et al.
Risk for myopathy with statin therapy in high-
risk patients. Arch Intern Med 2003;163:553–64.
This comprehensive review article focuses on
statin-associated myopathy.  The authors identify
drug-drug interactions as a potential cause of
increased risk of myopathy.  Statin-cyclosporine,
statin-fibrate, statin-niacin, and statin–calcium
channel antagonist interactions are discussed in
subsections of the article.  In Table 5, the authors
list advisory statements as safety considerations
in prescribing statins in primary care settings.
This table could be easily posted in clinics or
used by clinicians as a pocket-card reference.
The bibliography for the article is much more
extensive than for other review articles we
present in this section.
Bannwarth B. Drug-induced myopathies. Expert
Opin Drug Saf 2002;1:65–70.
This review article discusses drug-induced
myopathies, including those associated with
lipid-lowering therapy. Drug-induced myopathies
are divided into five categories:  necrotizing
(mainly associated with lipid-lowering therapy),
inflammatory, mitochondrial, corticosteroid, and
various painless myopathies.  Risk factors for
statin-induced myopathy include high plasma
concentrations of statin as a result of high doses
or impaired metabolism; low levels of intestinal
and hepatic CYP, particularly CYP3A4 subclass;
and coadministration of CYP3A4 inhibitors.
Other statin-related causes of rhabdomyolysis or
potentiators of myotoxicity are certain viral
infections; endocrine, metabolic, and electrolyte
disturbances; major trauma; seizures; hypo-
thermia; hypoxia; and misuse of amphetamines,
cocaine, ecstasy, lysergide, or alcohol.  Preventive
measures against statin myopathy are listed.
Table 1 in the article provides a partial list of
drugs associated with myalgia.  Certain
references are marked “of special interest” or “of
outstanding interest.”
Chazerain P, Hayem G, Hamza S, Best C, Ziza
JM. Four cases of tendinopathy in patients on
statin therapy. Joint Bone Spine 2001;68:430–3.
Four patients (three men, one woman) with
statin-associated tendinopathy are described.
Patient no. 1 was diagnosed with extensor
tenosynovitis of the hands, patient no. 2 with
tenosynovitis of the tibialis anterior tendon, and
patients nos. 3 and 4 with Achilles tendinopathy.
Two patients were taking atorvastatin, two
simvastatin.  In all four patients, symptoms
resolved within 2 months of drug discontin-
uation.  The only patient who showed possible
statin causality was treated with a nonsteroidal
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antiinflammatory drug and recovered within 2
weeks after atorvastatin discontinuation.  Two
patients had other risk factors for tendinopathy.
One patient was rechallenged with a lower dose
of simvastatin and experienced no recurrence of
tendinopathy.
Federman DG, Hussain F, Walters AB. Fatal
rhabdomyolysis caused by lipid-lowering therapy.
South Med J 2001;94:1023–6.
This case report describes a 68-year-old man
with fatal rhabdomyolysis caused by the
combination of simvastatin and gemfibrozil.  The
patient had type 2 diabetes with diabetic
nephropathy, hypertension, peripheral vascular
disease, and dyslipidemia.  His baseline serum
creatinine level was 3.4 mg/dl.  Four weeks
before his hospital admission, gemfibrozil 600
mg twice/day was added to his drug regimen,
which included simvastatin 80 mg/day. The
patient’s condition worsened, and he died on day
7 of his hospital stay. Autopsy showed significant
myositis on microscopic examination.  The
authors warn against administration of high-dose
statins in combination with fibrates in patients
with renal insufficiency.
Kamaliah MD, Sanjay LD. Rhabdomyolysis and
acute renal failure following a switchover of
therapy between two fibric acid derivatives.
Singapore Med J 2001;42:368–72.
Two case reports describe bezafibrate-induced
rhabdomyolysis in two men with coronary artery
disease and preexisting renal impairment.  The
patients were affected several days after their
drug therapy was changed from gemfibrozil to
bezafibrate.  Both had been taking gemfibrozil
600 mg twice/day for a year; neither was
receiving other lipid-lowering therapy.  Both
patients required dialysis.  One patient developed
an acute coronary event and died on day 7 of his
hospital stay; the other recovered and was
discharged.  The authors suggest that fibrates
may have different degrees of propensity for
myotoxicities, and they urge clinicians to use
caution when prescribing these drugs for patients
with renal impairment.
Le Quintrec JS, Le Quintrec JL. Drug-induced
myopathies. Baillieres Clin Rheumatol 1991;5:
21–38.
This article reviews major drug-induced
generalized myopathies.  Painless myopathies are
categorized as those without neuropathy, with
neuropathy, and with abnormal neuromuscular
transmission.  Painful myopathies are categorized
as those without neuropathy (polymyositis or
other painful myopathies) and with neuropathy.
Drug-induced myokymia and hypotonia are not
discussed.  Myopathy associated with lipid-
lowering agents is described as painful myopathy
without polymyositis.  Clofibrate and its
derivatives, fenofibrate, gemfibrozil, nicotinic
acid, and statins have all been associated with
myopathies.  The authors note that combinations
of fibrate-fibrate or fibrate-statin may be
myotoxic.  Clofibrate-induced myopathy is
described in enormous detail:  it occurs 36
hours–2 years after the start of therapy; patients
with renal disease, low serum albumin levels, and
hypothyroidism may be at greater risk than
others; the myopathy has a syndrome of muscle
pain, weakness and tenderness, and increased
serum creatine kinase levels with normal results
on reflex and sensory examination; electro-
myogram of the proximal upper and lower limb
muscles shows a mixed myopathic picture; and
muscle biopsy may show atrophy, degeneration,
fragmentation, hyalinization, vacuolization,
deranged mitochondria and phagocytosis by
macrophages, without inflammatory infiltrates.
The authors suggest the following criteria for
associating myopathy with drug therapy:  lack of
preexisting muscular symptoms, a lag time
between the start of treatment and start of symp-
toms, lack of other possible cause of myopathy,
and partial or complete resolution of symptoms
after the treatment drug is discontinued.
Mantel-Teeuwisse AK, Klungel OH, Herings
RM, van Puijenbroek EP, Porsius AJ, de Boer A.
Myopathy due to statin/fibrate use in the
Netherlands. Ann Pharmacother 2002;36:1957–60.
This study compared the estimated number of
expected cases of myopathy to the number of
observed cases of myopathy due to statin or
fibrate treatment in the Netherlands in 1 year.
The expected number of cases was calculated by
multiplying the total number of person-years of
statin or fibrate treatment by the excess rate of
myopathy due to those statins and fibrates as
reported in the literature.  The observed number
of cases was obtained from PHARMO and the
Dutch Pharmacovigilance Foundation Lareb.
PHARMO links drug histories with hospital
discharges, so it would not capture myopathy
that did not require hospitalization.  The Dutch
Pharmacovigilance Foundation Lareb relies on
reporting by health professionals, so it has the
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same limitations as the Adverse Event Reporting
System of the FDA.  The number of observed
cases was less than the estimated number of
expected cases of myopathy.
Shanahan RL, Kerzee JA, Sandhoff BG, Carroll
NM, Merenich JA. Low myopathy rates
associated with stains as monotherapy or
combination therapy with interacting drugs in a
group model health maintenance organization.
Pharmacotherapy 2005;25:345–51.
The authors determined the rate of statin-
related myopathy in a group-model health
maintenance organization (HMO) with
approximately 360,000 members.  Computer
data were used to identify 468 patients with a
diagnosis of myopathy during a 4-year period.
Medical record review determined that 61 (13%)
patients received statin therapy before their
diagnosis of myopathy; 41 (67%) of the 61 had
confirmed myopathy with creatine kinase level
elevations above 1000 IU/L.  Of the 41 patients,
17 (41%) had statin-related myopathy.  Prevalence
of statin-related myopathy was 0.12% with
monotherapy and 0.22% when the statin was
combined with interacting drugs; however, the
difference was not statistically significant.  None
of the cases resulted in death.  The authors noted
that myopathy occurred more frequently in
patients with a precipitating event (addition of an
interacting drug, increased statin dose in the
presence of an interacting drug, or other events
not related to therapy) or concurrent risk factors.
In this HMO, all patients prescribed a statin
receive intensive education, which includes
information about the possibility of increased
risk of myopathy and rhabdomyolysis.  This
HMO’s patients may be more motivated to report
possible myopathy symptoms earlier than
patients who do not receive this education.  The
authors urge practitioners to use caution in
applying these results to health care settings that
lack a structured program for monitoring
patients.
Ziajka PE, Wehmeier T. Peripheral neuropathy
and lipid-lowering therapy. South Med J
1998;91:667–8.
This case report describes a patient who
experienced peripheral neuropathy that was
induced and exacerbated by atorvastatin,
lovastatin, pravastatin, simvastatin, and niacin.
After taking lovastatin 20 mg/day for 4 years, the
patient noted the start of symptoms (burning
dysesthesia in both feet progressing to gait
disability); nerve conduction studies confirmed
polyneuropathy.  Lovastatin was discontinued
and the symptoms improved.  Twenty months
later, the patient was prescribed pravastatin 20
mg/day.  Symptoms worsened over the next 2
weeks, and the pravastatin therapy was changed
to simvastatin 10 mg/day.  The patient’s
neuropathic pain worsened over the next month.
Simvastatin was discontinued and the symptoms
improved.  A brief trial of low-dose niacin 50 mg
3 times/day and then atorvastatin 10 mg/day also
caused recurrence and worsening of neuropathic
symptoms.  In addition to this case report, the
authors provide a brief review of other statin-
associated peripheral neuropathy case reports.
The authors speculate that the mechanism of
statin-associated neuropathy may not be caused
by ubiquinone depletion since niacin does not
affect ubiquinone production.
Davidson M. Does differing metabolism by
cytochrome P450 have clinical importance? Curr
Atheroscler Rep 2000;2:14–19.
Drug metabolism by CYP enzyme is described.
The impact of fibrates, cyclosporine, potent
CYP3A4 inhibitors, and grapefruit juice on statin
therapy is discussed only briefly since this
information is available in the individual statin
package inserts.  Genetic polymorphisms of CYP
isoenzymes are noted as possible causes of
interindividual variation of drug effects.  No
evidence of CYP3A4 polymorphisms is cited;
CYP2C9 has been associated with polymor-
phisms in Caucasians and African-Americans,
but the clinical significance with fluvastatin
therapy is not known.
Corsini A, Bellosta S, Baetta R, Fumagalli R,
Paoletti R, Bernini F. New insights into the
pharmacodynamic and pharmacokinetic proper-
ties of statins. Pharmacol Ther 1999;84:413–28.
This comprehensive article discusses the
possible direct effects statins may have on the
arterial wall and explains drug interactions in
terms of pharmacokinetic properties of statins.
Table 2 provides a brief summary with references
for possible mechanisms of the direct vascular
action of statins.  The bibliography is extensive.
Studies Assessing Alternate-Day Dosing
Graham MR, Lindsey CC, Kennedy JA.
Maintenance of low-density lipoprotein goal with
step-down pravastatin therapy. Pharmacotherapy
2002;22:21–6.
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This prospective, randomized, open-label study
involved 104 men who were taking pravastatin
once/day and had maintained their NCEP ATP II
goal LDL level for at least 3 months.  Patients
were randomized to two pravastatin treatment
groups:  53 who received their original dose
every other day and 51 who received half their
original daily dose.  Fasting lipid profiles and
liver function were checked at baseline, 2
months, and 4 months; compliance was assessed.
Only 49% of patients remained at their LDL goal
(42% of those receiving their original dose every
other day, 57% of those receiving half their
original daily dose).  Concentrations of LDL were
statistically significantly higher at 2 and 4
months in the group receiving the original dose
of pravastatin every other day.  The authors
concluded that giving pravastatin daily at half the
original daily dose is more effective than giving
the original dose every other day.
Copher HR, Stewart RD. Daily dosing versus
alternate-day dosing of simvastatin in patients
with hypercholesterolemia. Pharmacotherapy
2002;22:1110–16.
This nonrandomized, before-after comparison
trial involved 15 men who were taking
simvastatin once/day and had attained their
NCEP ATP II goal LDL level.  Efficacy of the
original daily simvastatin dose was compared
with alternate-day therapy at double the original
daily dose.  Laboratory values were obtained
before and 8 weeks after the alternate-day
therapy was started.  All patients received an 8-
week supply of prefilled pillboxes.  Concen-
trations of LDL remained at goal in 12 of the 14
patients who completed the study. One patient,
whose LDL level did not remain at goal, was not
compliant with the alternate-day therapy. No
statistically significant differences were noted
between prestudy and poststudy levels of total
cholesterol, LDL, HDL, triglycerides, liver
transaminases, or creatine kinase.  Therapy with
double the original simvastatin dose every other
day was as safe and effective as with the original
dose taken daily.
Matalka MS, Ravnan MC, Deedwania PC. Is
alternate daily dose of atorvastatin effective in
treating patients with hyperlipidemia? The
alternate day versus daily dosing of atorvastatin
study (ADDAS). Am Heart J 2002;144:674–7.
This double-blind, placebo-controlled trial
compared the efficacy of alternate-day dosing of
atorvastatin with once-daily dosing in 35 patients
who met the NCEP ATP II guidelines for drug
treatment.  Patients were randomly assigned to
receive atorvastatin 10 mg once/day or once
every other day.  Laboratory values were obtained
at 6 and 12 weeks, and the atorvastatin dose was
doubled if LDL was not at goal level.  The initial
dose of atorvastatin was doubled at the 6-week
follow-up period in 17% of patients in the daily
group and in 79% of those in the alternate-day
group.  At the end of the 12-week study period,
the average atorvastatin dose was 12 mg in the
daily group and 18 mg (9 mg/day) in the
alternate-day group (p<0.001).  Target LDL goal
was attained in 75% of the daily group and 43%
of the alternate-day group; however, the
alternate-day group had more secondary
prevention patients.  Both groups had similar
LDL reductions (38% and 35% in the daily and
alternate-day groups, respectively).  The authors
estimated that alternate-day therapy could reduce
annual drug costs by 34%.
Studies Assessing Adherence to Guidelines
Stafford RS, Blumenthal D, Pasternak RC.
Variations in cholesterol management practices of
U.S. physicians. J Am Coll Cardiol 1997;29:
139–46.
This study evaluated the cholesterol
management practices of 2332 physicians during
1991–1992 based on data from the National
Ambulatory Medical Care Surveys conducted by
the National Center for Health Statistics.
Randomly selected, office-based, patient care
physicians reported specific clinical services
provided during a sample of patient visits.
Patient demographics, diagnoses, current drug
therapies, physician characteristics, and visit
characteristics were reported.  Physicians also
indicated whether they provided cholesterol
counseling (which included any advice related to
cholesterol) or ordered laboratory tests for either
a cholesterol panel or total cholesterol level
alone.  The study evaluated the effects of
independent variables—including physician
specialty; patient sex, age, and race; presence of
cardiovascular disease and its risk factors;
expected payment source; and census region—on
the odds that patients received cholesterol
management services.  The authors combined
estimates from the National Ambulatory Medical
Care Surveys with data from the third National
Health and Nutrition Examination Survey
(NHANES III) and the Atherosclerosis Risk in
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Communities Study.  In this manner, they
demonstrated that 42 million (3.8%) of the 1.12
billion estimated visits to U.S. office-based
physicians in 1991–1992 included cholesterol
counseling (95% CI 40–45 million) and 49
million (4.4%) visits included cholesterol testing
(95% CI 46–52 million).  Study results showed
that nonclinical, clinical, and demographic
factors—such as physician specialty, presence of
cardiovascular disease or risk factors, and
payment source—strongly influenced patterns of
cholesterol management.  Overall, this study
demonstrated that rates of hyperlipidemia
screening and treatment were lower than
expected, and many factors contributed to the
underuse of clinical services.
McBride P, Schrott HG, Plane MB, Underbakke
G, Brown RL. Primary care practice adherence to
National Cholesterol Education Program
guidelines for patients with coronary heart
disease. Arch Intern Med 1998;158:1238–44.
This study examined the patterns of
cholesterol screening and management by
primary care physicians after publication of the
NCEP ATP II guidelines.  The authors reported
the dietary counseling and drug therapy provided
for patients with cardiovascular disease in
primary care practice, their patients’ level of
success in meeting ATP-II  treatment goals, and
factors that influenced cholesterol screening and
management.  Data were collected from medical
records and patient and physician questionnaires
from practices near four regional centers in
Wisconsin, Minnesota, and Iowa from
1993–1995.  The medical record review yielded
lipid panel results for 579 patients; only 84
(14.5%) had an LDL level below 100 mg/dl.
Logistic regression analysis showed that
physician time in practice, patient education
level, and cholesterol level predicted the dietary
counseling and drug therapy provided.  The
study data suggested that physicians are more
likely to treat hyperlipidemia aggressively when
they perceive that patients are at higher risk, and
they do not consider cardiovascular disease a
requirement for targeting LDL goal levels of less
than 100 mg/dl.  These factors may be related to
the lack of adherence to NCEP ATP II guidelines
and may contribute to the number of patients
who do not have a lipid panel obtained and are
not treated to reach the recommended LDL goals.
Straka RJ, Taheri R, Cooper SL, Tan AWH,
Smith JC. Assessment of hypercholesterolemia
control in a managed care organization.
Pharmacotherapy 2001;21:818–27.
This retrospective study assessed 124,971
members of a managed care organization for their
degree of lipid control according to the NCEP
ATP II guidelines.  Of 6538 patients with a
history of coronary disease, 2170 (33%) did not
have a fasting lipid profile recorded.  Of 4368
with a recorded lipid measurement, 2632 (60%)
did not meet their goal LDL level of less than 100
mg/dl.  Only 35% of patients with a history of
CHD attained their LDL goal.  The group without
CHD but with two or more risk factors had
17,267 patients.  Of these, 10,131 (59%) had no
fasting lipid profile recorded.  Of the 7136
patients with a recorded lipid measurement, 3276
(46%) did not achieve their LDL goal of less than
130 mg/dl.  Therefore, only 46% of all patients
who had a recorded lipid measurement, had no
history of CHD, and had two or more risk factors
achieved their LDL goals.
This study also assessed the ability to treat
patients with diabetes to their LDL goal.  Of 4995
patients with diabetes but no history of CHD,
2152 (43%) did not have a recorded fasting lipid
profile.  Of the 2843 remaining patients, only 588
(21%) achieved their LDL goal of less than 100
mg/dl.  Possible reasons for failure to achieve
LDL goal in all groups were inadequate use of
pharmacologic agents (39%–80% of patients in
each group were not receiving drug therapy) and
lack of appropriate follow-up (as evidenced by
large populations without a fasting lipid profile).
Possible limitations of the study were inadequate
capturing of patients’ smoking history and family
history of heart disease.  Also, the large
percentage of patients without a fasting lipid
profile may have contributed to overestimation of
the percentages of patients achieving goal.
Jackevicius CA, Mamdani M, Tu JV. Adherence
with statin therapy in elderly patients with and
without acute coronary syndromes. JAMA
2002;288:462–7.
This Canadian population-based cohort study
assessed 2-year adherence to statin therapy in
three groups:  22,379 patients with recent ACS,
36,106 with chronic CAD, and 85,020 receiving
primary prevention.  Within 6 months, approxi-
mately 25% of patients in all three groups had
discontinued their statin therapy. At 2 years,
adherence rates were 61.7% in the ACS group,
58.5% in the CAD group, and 46.8% in the
primary prevention group.  Factors associated
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with increased adherence were comorbidities,
such as hypertension and diabetes, and increased
physician visits.  Factors associated with
decreased adherence were lower disease severity,
male sex, increased number of prescriptions, and
increased number of different physicians.  Many
patients in the lower risk groups may have
discontinued their statin therapy because they
could not perceive its benefit.  Patients should be
reminded to adhere to their statin therapy in
order to receive the benefits seen in controlled
trials.
Schectman G, Hiatt J. Drug therapy for
hypercholesterolemia in patients with cardio-
vascular disease: factors limiting achievement of
lipid goals. Am J Med 1996;100:197–204.
This retrospective cohort study assessed
whether NCEP goals were being achieved in
clinical settings.  The study involved 244 patients
with either CAD or peripheral vascular disease
who were receiving treatment for hypercholes-
terolemia at a large Veterans Affairs medical
center.  Results showed that the lipid-lowering
drug therapy reduced LDL levels 25%– 42% from
baseline in patients with mild-to-severe
hypercholesterolemia.  Also, approximately 72%
of those with baseline LDL levels of 160 mg/dl or
less achieved their LDL target goal of 130 mg/dl
or less with the drug therapy.  On the other hand,
less than 50% of patients whose baseline LDL
level was 160 mg/dl or greater achieved target
goal.  Multivariate analysis indicated that factors
associated with achieving study target goals were
baseline LDL and triglyceride levels, adherence,
and combination therapy versus monotherapy.
The benefit of this study is that it affirmed the
use of NCEP guidelines for providing adequate
treatment to patients with hypercholesterolemia
who also have cardiovascular disease.
Pearson TA, Laurora I, Chu H, Kafonek S. The
lipid treatment assessment project (L-TAP): a
multicenter survey to evaluate the percentages of
dyslipidemic patients receiving lipid-lowering
therapy and achieving low-density lipoprotein
cholesterol goals. Arch Intern Med 2000;160:
459–67.
Whether patients with dyslipidemia receiving
lipid-lowering therapy achieve LDL goals has
been a concern.  Using NCEP guidelines as a
gauge for therapeutic outcomes, the multicenter
L-TAP assessed 4888 adults with dyslipidemia
who had been receiving consistent lipid-lowering
therapy for at least 3 months.  Of the 4888
patients, 23% were at low risk (fewer than two
risk factors and no evidence of CHD), 47% were
at high risk (two or more risk factors and no
evidence of CHD), and 30% had CHD.  Patients
were assessed at study enrollment and end point.
The overall success rate for achieving NCEP-
specified LDL target levels was 38%; low-risk
patients had the highest success rate (68%), and
those with established CHD had the lowest rate
(18%).  Although drug therapy was significantly
more effective than nondrug therapy in all risk
groups, large proportions of patients treated with
lipid-lowering drugs did not achieve their LDL
target level.  This suggests the need for a more
aggressive approach to therapy in these patients.
Fonarow GC, Gawlinski A, Moughrabi S,
Tillisch JH. Improved treatment of coronary
heart disease by implementation of a cardiac
hospitalization atherosclerosis management
program (CHAMP). Am J Cardiol 2001;87:
819–22.
In patients with CAD, a secondary prevention
medical therapy such as a cardiac hospitalization
atherosclerosis management program (CHAMP)
has been hypothesized to reduce mortality by
starting treatment with several agents—aspirin,
cholesterol-lowering agents, β-blockers, and ACE
inhibitors—along with diet and exercise
counseling, before hospital discharge.  This study
followed patients discharged after myocardial
infarction 2 years before and 2 years after the
CHAMP. Across the board, patients after the
CHAMP had much better treatment rates and
clinical outcomes, which persisted throughout
successive follow-up visits.  Outcomes after the
CHAMP were a 24% increase in therapy with
aspirin, 50% increase in β-blocker use, 52%
increase in ACE inhibitor use, and 80% increase
in statin use.  In addition, achievement of an LDL
level of 100 mg/dl or less increased by 52%.  The
significant improvements in clinical outcomes
after the CHAMP further substantiate the need
for secondary prevention medical therapy in
patients after hospitalization for acute myocardial
infarction.
Studies Assessing Combination
Pharmacotherapy
Statin and Fibrate
Garg A, Grundy SM. Gemfibrozil alone and in
combination with lovastatin for treatment of
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hypertriglyceridemia in NIDDM. Diabetes
1989;38:364–72.
This randomized, double-blind, placebo-
controlled study assessed the effectiveness of
lipid-lowering drugs in patients with non–
insulin-dependent diabetes mellitus and
hypertriglyceridemia despite good glycemic
control.  The study included six patients with
moderate hypertriglyceridemia (plasma
triglyceride level 250–500 mg/dl) and 10 with
marked hypertriglyceridemia (triglyceride level
above 500 mg/dl).  In phase I of the study,
patients were given gemfibrozil 600 mg twice/day
or placebo for 28 days; these two treatments were
then crossed over for the next 28-day period.  In
phase II, patients were given either gemfibrozil
600 mg twice/day plus lovastatin 20 mg/day or
matched placebo for 28 days; these treatments
were crossed over for the last 28-day period.  In
patients with marked hypertriglyceridemia,
gemfibrozil alone compared with placebo
significantly reduced triglyceride and VLDL
levels and increased LDL and HDL levels.  In
phase II, the combination of gemfibrozil and
lovastatin further reduced total cholesterol, LDL,
triglyceride, and VLDL levels compared with
gemfibrozil alone, but did not change HDL levels.
Patients with marked versus moderate hyper-
triglyceridemia also experienced significant
reductions in triglyceride and VLDL levels with
gemfibrozil monotherapy, but to a lesser degree.
Increases in LDL were not statistically significant,
and HDL levels did not change.  In phase 2,
combination therapy produced significant
reductions in total cholesterol, LDL, triglyceride,
and VLDL levels compared with gemfibrozil
monotherapy, but the extent of these reductions
were similar to those seen in patients with
marked hypertriglyceridemia.  Again, HDL levels
remained unchanged.
Overall, this study showed that gemfibrozil
alone did not produce benefits in overall
lipoprotein profiles but effectively decreased
triglyceride and VLDL levels.  Addition of
lovastatin to gemfibrozil further reduced
atherogenic apolipoprotein B–containing
lipoproteins, especially in the marked
hypertriglyceridemia group, but did not result in
additional increases in HDL.  Therefore, the
authors concluded that combination therapy can
be a reasonable therapeutic choice for patients
with marked triglyceride levels.
Kayikcioglu M, Ozerkan F, Soydan I.
Effectiveness and safety of alternate-day
simvastatin and fenofibrate on mixed hyper-
lipidemia. Am J Cardiol 1999;83:1135–7.
To minimize the adverse effects often
associated with combination therapy with a statin
and fibric acid, the authors evaluated the safety
and efficacy of simvastatin and fenofibrate
administered on alternate days.  The study
enrolled 74 patients with mixed hyperlipidemia
who were receiving monotherapy but were not
meeting their lipid goals according to NCEP
guidelines.  Patients were randomized to receive
either simvastatin 10 mg and fenofibrate 250 mg
every other day or simvastatin 10 mg and
fenofibrate 250 mg every day with dinner.  After
6 weeks of follow-up, plasma total cholesterol,
LDL, triglyceride, and apolipoprotein B levels
decreased from baseline by 31%, 34%, 55%, and
20%, respectively, in the alternate-day group;
HDL and apolipoprotein A-I levels increased by
18% and 12%, respectively.  In the every-day
group, decreases in total cholesterol, LDL,
triglyceride, and apolipoprotein B levels were
31%, 36%, 54%, and 18%, respectively; HDL and
apolipoprotein A-I levels increased by 18% and
12%, respectively.  In addition, fewer adverse
events occurred in the alternate-day group.  No
patients had increased liver enzyme or creatine
kinase levels, whereas four patients in the every-
day group had increased creatine kinase levels
and five had increased alanine aminotransferase
levels.  This study—the first to investigate the
effects of alternate-day administration of lipid-
lowering agents—found equal efficacy and
improved safety of this administration schedule
compared with every-day administration.
Farnier M, Dejager S. Effect of combined
fluvastatin-fenofibrate therapy compared with
fenofibrate monotherapy in severe primary
hypercholesterolemia: French fluvastatin study
group. Am J Cardiol 2000;85:53–7.
This 16-week, double-blind study assessed the
safety and efficacy of combination therapy with
fluvastatin and fenofibrate compared with
fenofibrate monotherapy in 102 patients with
severe primary hypercholesterolemia.  Patients
were randomized to receive micronized
fenofibrate 200 mg plus placebo once/day,
micronized fenofibrate 200 mg plus fluvastatin
20 mg once/day, or micronized fenofibrate 200
mg plus fluvastatin 40 mg once/day.  Of the 102
patients, 96 finished the study.  At week 16, the
mean decrease in LDL level was 21% with
fenofibrate alone, 32% with fenofibrate plus
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fluvastatin 20 mg, and 41% with fenofibrate plus
fluvastatin 40 mg (p<0.001).  Triglyceride levels
decreased by 29% with fenofibrate alone, by 39%
with fenofibrate plus fluvastatin 20 mg, and by
40% with fenofibrate plus fluvastatin 40 mg
(p<0.05).  The HDL levels were moderately
increased in all treatment groups, but increases
were largest in patients receiving fenofibrate plus
fluvastatin 20 mg due to hyperresponders in that
group.  In all lipid parameters except apolipo-
protein A-I, the combination therapy groups had
significantly better responses than those
receiving fenofibrate alone.
In terms of safety, the frequency of adverse
events was similar among the three treatment
groups.  One patient receiving fenofibrate plus
fluvastatin 40 mg was withdrawn from the study
due to elevated liver enzyme levels, but this
patient had similar reactions to other statins and
fenofibrate alone.  No patients were withdrawn
from the study due to elevated creatine kinase
levels.  This study addressed the fear that
combination therapy poses excessive risk of
adverse events.  Results demonstrated that
addition of fluvastatin to fenofibrate produced
marked improvement in LDL, total cholesterol,
apolipoprotein B, and triglyceride levels in a
dose-dependent manner without increasing
myopathy rates.
Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J.
Gemfibrozil-lovastatin therapy for primary
hyperlipoproteinemias. Am J Cardiol 1992;70:
1–9.
This retrospective, observational study assessed
the safety and efficacy of long-term combination
therapy with gemfibrozil 1.2 g/day and lovastatin
20–40 mg/day in 80 patients with primary mixed
hyperlipidemia who did not reach their lipid
goals while receiving monotherapy.  Patients
included in the study had been receiving
combination therapy for at least 6 months.  With
the combination therapy, no significant changes
occurred in glucose, blood urea nitrogen,
creatinine, liver function, or creatine kinase
levels between baseline and the final visit
(p<0.01).  The frequency of liver function test
levels that were 3 times the upper normal limit or
greater was 0.02%; the frequency of creatine
kinase levels that were 3 times the upper normal
limit or greater was 0.1%.  After a mean of 21
months of combination therapy, decreases were
noted in total cholesterol (22%), LDL (26%),
triglycerides (35%), and total cholesterol:HDL
ratio (24%).  Combination therapy was
discontinued in 3% of study patients due to
muscle symptoms or high creatine kinase
concentration, or both.  No rhabdomyolysis,
myoglobinuria, or renal failure was reported.
Overall, this study supports other similar trials
demonstrating that gemfibrozil in combination
with lovastatin effectively modified lipid profiles
with infrequent adverse events and no cases of
rhabdomyolysis.
Eliav O, Schurr D, Pfister P, Friedlander Y,
Leitersdorf E. High-dose fluvastatin and
bezafibrate combination treatment for hetero-
zygous familial hypercholesterolemia. Am J
Cardiol 1995;76(2):76A–9.
This 88-week, open-label study evaluated the
combination of bezafibrate and high-dose
fluvastatin in patients with severe heterozygous
familial hypercholesterolemia who did not reach
their target LDL level with combination therapy
in a previous study.  Patients received fluvastatin
40 mg twice/day for 6 weeks; bezafibrate 200
mg/day, was then added for 6 weeks in patients
who did not reach their LDL goal.  Dosages were
then titrated to fluvastatin 80 mg/day and slow-
release bezafibrate 400 mg/day for 66 weeks.
Interim results up to week 36 are presented in
this article.  Mean LDL levels were reduced from
300 to 205 mg/dl (32%) with fluvastatin
monotherapy; the  addition of bezafibrate 200 mg
further reduced LDL levels to 193 mg/dl.
Increasing bezafibrate to 400 mg for 24 weeks
reduced the mean LDL level to 184 mg/dl.  From
week 0 to week 36, mean total cholesterol level
was reduced from 365 to 245 mg/dl, triglyceride
level from 136 to 94 mg/dl.  In addition, mean
HDL level increased from 38 to 42 mg/dl.  To this
point, no significant elevations were seen in liver
function enzyme or creatine kinase levels.
Overall, the interim results of this study
demonstrate that fluvastatin can be safely and
effectively added to bezafibrate to produce
favorable results in LDL, total cholesterol,
triglyceride, and HDL levels.
Spence JD, Munoz CE, Hendricks L, Latchinian
L, Khouri HE. Pharmacokinetics of the
combination of fluvastatin and gemfibrozil. Am J
Cardiol 1995;76:80A–3.
This open-label, crossover, single-center study
involving 6 weeks of active treatment after a 4-
week washout period was conducted to
determine whether any pharmacokinetic
994
KEY ARTICLES IN THE TREATMENT OF DYSLIPIDEMIAS  Ito et al
interaction occurred between fluvastatin and
gemfibrozil.  Seventeen patients were randomized
to receive fluvastatin 20 mg/day or gemfibrozil
600 mg twice/day for 2 weeks, followed by both
drugs in combination for 2 weeks.  Then, for
another 2 weeks, patients received monotherapy
with the agent they did not receive in the first 2-
week phase.  Of the 17 study patients, 16
completed the study.  No significant changes
were noted in any of the safety laboratory test
results for any treatment.  No significant
differences occurred in area under the curve,
maximum plasma concentration, or time to
maximum concentration when the two drugs
were taken together versus alone.  Therefore, the
study results suggest that no clinically significant
pharmacokinetic interaction would be expected
when patients take these two drugs together.
Leitersdorf E, Muratti EN, Eliav O, Peters TK.
Efficacy and safety of triple therapy (fluvastatin-
bezafibrate-cholestyramine) for severe familial
hypercholesterolemia. Am J Cardiol 1995;76:
84A–8.
This 60-week, open-label, extension study
evaluated the safety and efficacy of combination
therapy with three lipid-lowering drugs
administered to patients with severe hetero-
zygous familial hypercholesterolemia who
completed three previous studies.  The patients
initially received fluvastatin monotherapy, then
double therapy with fluvastatin and bezafibrate,
and finally triple therapy with fluvastatin,
bezafibrate, and cholestyramine.  At the end of
the study, 13 patients were still receiving the
triple therapy.  Adding bezafibrate to fluvastatin
reduced total cholesterol levels by 8.2%
(p<0.002), LDL levels by 9% (p<0.001), and
triglyceride levels by 26.4% (p<0.001), and
increased HDL levels by 13.3% (p<0.01).  Adding
cholestyramine reduced LDL by another 5.2%,
for a total reduction of 35.4% with triple therapy
from drug-free baseline level.  No notable
abnormalities were seen in liver function enzyme
or creatine kinase levels.  This study showed that
triple therapy with fluvastatin, bezafibrate, and
cholestyramine reduced lipid levels to a greater
extent than single or double therapy (which
patients with severe familial hypercholes-
terolemia require) without increasing the risk of
adverse events.
Smit JW, Jansen GH, de Bruin TW, Erkelens
DW. Treatment of combined hyperlipidemia with
fluvastatin and gemfibrozil, alone or in
combination, does not induce muscle damage.
Am J Cardiol 1995;76:126A–8.
This prospective, double-blind, placebo-
controlled study assessed the effects of fluvastatin
and gemfibrozil on muscle in patients with
combined hyperlipidemia.  Of 21 study patients,
seven each were randomized to receive
fluvastatin 40 mg/day, gemfibrozil 600 mg
twice/day, or both for 6 weeks.  Before and after
the 6-week treatment period, patients underwent
an exercise muscle-provocation test.  Serum
creatine kinase and myoglobin levels were
determined before exercise testing and 1 and 8
hours after testing.  In all groups, preexercise
creatine kinase and myoglobin levels were not
affected by any of the three treatments.  At 48
hours after exercise testing, a muscle needle
biopsy obtained from the quadriceps muscle was
classified as normal, abnormal, or indeter-
minable.  Abnormal muscle histology was seen in
two patients before therapy, whereas one patient
in each monotherapy group had abnormal
histology after treatment.  Study results suggested
that fluvastatin and gemfibrozil as monotherapy
or combination therapy did not induce muscle
damage in these patients.  This study was unique
in that it evaluated the possibility of muscle
damage and myopathy based on muscle biopsies
and histologic data.
Ellen RL, McPherson R. Long-term efficacy and
safety of fenofibrate and a statin in the treatment
of combined hyperlipidemia. Am J Cardiol
1998;81:60B–5.
This study evaluated the long-term safety and
efficacy of fenofibrate in combination with low-
dose simvastatin or pravastatin in 80 patients
with combined hyperlipidemia and high risk for
CAD.  Patients had normal hepatic and renal
function and no other significant disease or
laboratory abnormality that would compromise
their safety. Baseline laboratory tests were
conducted while patients were receiving
monotherapy—39 with a statin and 41 with
fenofibrate.  After the second agent was added,
63 patients received pravastatin 20 mg/day plus
regular fenofibrate 300 mg/day or micronized
fenofibrate 200 mg/day; 17 received simvastatin
10 mg/day plus fenofibrate 200 mg/day.  After a
mean of 2 years of combination therapy,
triglyceride levels decreased by 41% from
baseline (p<0.001), LDL levels decreased by 28%
(p<0.001), and HDL levels increased by 22%
(p<0.001).  None of the patients experienced
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clinically significant increases in liver function
enzyme or creatine kinase levels during this
study, and none reported muscle symptoms or
malaise.  Overall, the study showed that
combination therapy with low-dose statin and
fibrate resulted in greater improvements in lipid
profiles than monotherapy with either agent.
Also, the combination therapy was safe in
patients with good general health and normal
renal function.  Despite the fears of myopathy
with combination therapy, this study adds
support that statins and fibrates can be
administered together with favorable results and
should remain a consideration for certain high-
risk patients.
Leitersdorf E, Muratti EN, Eliav O, Peters TK.
Efficacy and safety of a combination fluvastatin-
bezafibrate treatment for familial hypercholes-
terolemia: comparative analysis with a
fluvastatin-cholestyramine combination. Am J
Med 1994;96:401–7.
This short-term, double-blind, randomized,
parallel-group study compared the efficacy and
safety of the combination of fluvastatin 20 or 40
mg/day plus bezafibrate 400 mg/day with the
combination of fluvastatin 40 mg/day plus
cholestyramine 8 g/day in 38 patients with
familial hypercholesterolemia.  After 12 weeks of
monotherapy with fluvastatin 40 mg/day,
bezafibrate was added to fluvastatin 20 mg/day
and cholestyramine was added to fluvastatin 40
mg/day for 6 weeks.  Cholestyramine decreased
LDL level by 12.9%, whereas bezafibrate
decreased LDL by 7.5% (p=NS).  Triglyceride
levels increased by 24.1% with cholestyramine
but decreased by 14.5% with bezafibrate
(p<0.01).  The HDL level increased in both
groups, but to a larger extent with bezafibrate
(20.2% vs 7.5% with cholestyramine, p<0.01).
After another period of fluvastatin monotherapy,
bezafibrate and cholestyramine were again added
to fluvastatin, but the dosage of fluvastatin was
40 mg/day in both groups.  This time, bezafibrate
and cholestyramine reduced LDL levels by 12.6%
and 13.8%, respectively (p=NS).  Again,
triglyceride levels increased by 26% with
cholestyramine and decreased by 26.4% with
bezafibrate (p<0.001); HDL increases were
similar in the two groups.  No notable
abnormalities in liver enzyme or creatine kinase
levels were seen in the two groups.  Overall,
combination therapy was safe, effective, and well
tolerated.  The bezafibrate-fluvastatin combination
produced a larger reduction in LDL levels with
fluvastatin 40 mg/day compared with fluvastatin
20 mg/day.  The study showed that the combi-
nation of bezafibrate and fluvastatin is superior
to the combination of cholestyramine and
fluvastatin in reducing triglyceride and increasing
HDL levels.
Wiklund O, Angelin B, Bergman M, et al.
Pravastatin and gemfibrozil alone and in
combination for the treatment of hypercholes-
terolemia. Am J Med 1993;94:13–20.
This study was the first to evaluate the safety
and efficacy of a combination of pravastatin and
gemfibrozil in patients with primary hyper-
cholesterolemia.  The study enrolled 290 patients
who were randomized to receive 12 weeks of
pravastatin 40 mg/day, gemfibrozil 600 mg
twice/day, a combination of both drugs, or
placebo.  Combination therapy reduced total
cholesterol levels by 29%, LDL by 37%, VLDL by
50%, triglycerides by 42%, and apolipoprotein B
by 31%, and increased HDL by 17% and
apolipoprotein A-I by 6% (all p≤0.01).  The
combination was more effective in altering these
lipid parameters than either drug alone.  The
frequency of musculoskeletal pain and creatine
kinase level elevation was slightly higher in the
combination therapy group.  Two patients from
this group were removed from the study due to
asymptomatic creatine kinase level elevation.
However, no severe myopathy or rhabdomyolysis
was reported in any of the study groups.  Overall,
the study showed that combination therapy
could be safe and helpful in normalizing the lipid
pattern in patients with mixed hyperlipidemia
without risk of serious adverse events.
Illingsworth DR, Bacon S. Influence of lovastatin
plus gemfibrozil on plasma lipids and lipo-
proteins in patients with heterozygous familial
hypercholesterolemia. Circulation 1989;79:590–6.
This study examined the effects of lovastatin
alone and in combination with gemfibrozil in 12
patients with heterozygous familial hypercholes-
terolemia.  Patients first received lovastatin 40
mg twice/day for 10 weeks, then gemfibrozil 600
mg twice/day was added for another 12 weeks.
Mean total cholesterol level decreased from 395
mg/dl at baseline to 274 mg/dl with lovastatin
monotherapy (p<0.001) and then to 259 mg/dl
with combination therapy (p=NS).  The LDL
response was similar, with mean levels decreasing
from 321 mg/dl at baseline to 207 mg/dl with
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lovastatin (p<0.01) and then to 194 mg/dl with
combination therapy (p=NS).  However, LDL
levels increased in three patients when
gemfibrozil was added.  The HDL levels increased
with each addition, but differences were not
statistically significant.  Triglyceride levels
decreased from 145 to 105 mg/dl with lovastatin
and then to 80 mg/dl (p<0.05) with combination
therapy.  One patient experienced muscle pain
and increased creatine kinase concentration
during combination therapy, necessitating
discontinuation of both drugs.  This patient was
later treated with lovastatin and colestipol
without recurrence of symptoms.  None of the
other patients experienced significant increases
in creatine kinase or transaminase levels.  Similar
to other studies, this trial demonstrated that the
addition of gemfibrozil to a statin resulted in
small and variable effects on total cholesterol,
and especially on LDL level.  In patients with
heterozygous familial hypercholesterolemia with
very high levels of total cholesterol and LDL, this
small benefit may not outweigh the increased
risk of myopathy with combination therapy.
Therefore, the authors did not support treatment
with the combination in this patient population.
Murdock DK, Murdock AK, Murdock RW, et al.
Long-term safety and efficacy of combination
gemfibrozil and HMG-CoA reductase inhibitors
for the treatment of mixed lipid disorders. Am
Heart J 1999;138:151–5.
This study evaluated the safety and efficacy of
long-term combination therapy with gemfibrozil
and any statin in patients with CAD, peripheral
vascular disease, or carotid arterial disease and
mixed dyslipidemia not controlled with a single
agent.  A total of 252 patients from a lipid clinic
were prospectively tracked for a mean of 2.4
years.  Treatment with gemfibrozil was started in
148 patients who had markedly elevated
triglyceride levels (> 400 mg/dl) or depressed
HDL levels (< 30 mg/dl).  In these patients,
gemfibrozil alone had little effect on total
cholesterol, but combination therapy decreased
baseline total cholesterol from 222 to 181 mg/dl
(p<0.001), increased HDL from 30 to 36 mg/dl
(p<0.01), and decreased triglyceride levels from
361 to 212 mg/dl (p<0.03).  Statin therapy was
started first in 104 patients due to markedly
elevated baseline total cholesterol levels (> 300
mg/dl).  In these patients, the changes in HDL
and triglyceride levels from statin alone were not
significant.  However, combination therapy
reduced baseline total cholesterol from 246 to
192 mg/dl (p<0.01), increased HDL from 33 to
38 mg/dl (p<0.03), and decreased triglycerides
from 314 to 183 mg/dl (p<0.001).  Of 68 patients
whose combination therapy was terminated, six
experienced myalgia, one had an asymptomatic
5-fold rise in alanine aminotransferase, and one
had myalgia and a creatine kinase level 12 times
the upper limit of normal.  Overall, the
combination of a statin and gemfibrozil improved
lipid profiles to a greater extent than either agent
alone in patients with mixed lipid disorders.  In
this study, the benefit of combination therapy in
the high-risk population outweighed the low risk
of toxicity.  Unfortunately, the study was not
powered to distinguish differences in adverse-
event rates between different statins, which
would have been useful information.
East C, Bilheimer DW, Grundy SM. Combination
drug therapy for familial combined hyper-
lipidemia. Ann Intern Med 1988;109:25–32.
This prospective trial compared the efficacy of
gemfibrozil and colestipol with gemfibrozil and
lovastatin in patients with familial combined
hyperlipidemia with types 2b and 4 hyper-
lipoproteinemia.  Patients with type 2b hyper-
lipoproteinemia are characterized by elevated
VLDL, LDL, triglyceride, and cholesterol  levels,
whereas those with type 4 have elevated VLDL
and triglyceride levels.  In the first of two study
phases, patients received 8 weeks of dietary
therapy and then 8 weeks of gemfibrozil 600 mg
twice/day.  In the second phase, gemfibrozil was
continued, but patients also were randomized to
receive either colestipol 10 g twice/day or
lovastatin 20 mg twice/day for 8 weeks and then
crossed over to receive the other drug for another
8 weeks.  The first 4 weeks of each period were
considered washout, and samples were taken
during the second 4 weeks.
Nine patients with type 2b were analyzed
separately from eight with type 4 hyper-
lipoproteinemia.  Although gemfibrozil reduced
triglyceride and VLDL levels in type 4 patients, it
failed to lower total cholesterol or apolipoprotein
B levels and even increased LDL.  However, the
combination of lovastatin and gemfibrozil in both
groups produced greater reductions in LDL and
apolipoprotein B levels and significantly
increased HDL compared with gemfibrozil and
colestipol, as well as gemfibrozil alone.  The
addition of colestipol to gemfibrozil appeared to
partially reverse the action of gemfibrozil alone in
lowering triglycerides and VLDL and in raising
HDL levels.  Clinical side effects during drug
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therapy were relatively minor, and no
abnormalities in blood chemistry profiles were
reported.  Overall, the study suggested that
gemfibrozil alone may not be adequate therapy
for lowering LDL and apolipoprotein B levels in
patients with type 2b and 4
hyperlipoproteinemia.  In this short-term study,
the addition of lovastatin to gemfibrozil generally
provided more favorable outcomes than the
addition of colestipol, without incidence of
myalgia, myopathy, or rhabdomyolysis.
Statin and Niacin
Arntz HR, Agrawal R, Wunderlich W, et al.
Beneficial effects of pravastatin (± cholestyra-
mine/niacin) initiated immediately after a
coronary event (the randomized lipid-coronary
artery disease [L-CAD] study). Am J Cardiol
2000;86:1293–8.
This study compared cholesterol-lowering
therapy begun immediately after myocardial
infarction or balloon angioplasty with usual
outpatient treatment on the course of coronary
atherosclerosis and clinical outcomes.  Patients
aged 75 years or younger who had experienced
either acute myocardial infarction or emergency
balloon angioplasty and whose baseline LDL
level was 130–300 mg/dl were randomized to
receive intensive hypolipidemic therapy (group
A) or usual care (group B).  Intensive therapy
included pravastatin alone or in combination
with either niacin or cholestyramine to achieve
an LDL goal level of less than 130 mg/dl.
Pravastatin was started a mean ± SD of 6 ± 5 days
after the qualifying event.  Analysis was
performed by quantitative angiography at
baseline, 6 months, and 24 months.  However, a
complete series of evaluable angiographs was
available for fewer than half of the randomized
patients in each group.  Mean baseline LDL level
was 176 mg/dl in group A (70 patients) and 172
mg/dl in group B (56 patients).
An LDL level less than 130 mg/dl was achieved
in 40 patients with pravastatin alone and in eight
with combination therapy; the remaining group
A patients did not reach goal and could not
tolerate niacin or cholestyramine.  No group B
patients maintained LDL at goal level, and only
13 received any lipid treatment.  Mean LDL
reduction in group A was 28%, and the mean
LDL level at 6 months was 122 mg/dl.  A
clinically significant increase in lumen diameter
was measured in 23 of 77 stenoses in group A
compared with 7 of 72 stenoses in group B.
Group B also had a statistically significantly
higher rate of diameter decreases over the 24-
month study period.  No significant effect on
angioplasty restenoses was noted.  Clinical event
rates were also significantly lower in group A.
Although this study was designed to evaluate
combination therapy, most patients who required
the addition of niacin or cholestyramine were
unable to tolerate it and thus were receiving
pravastatin monotherapy and did not achieve
LDL goal.  Additional limitations of the study
were its small sample size and high dropout rate.
However, despite less than optimal LDL reduc-
tion, progression of coronary atherosclerosis
appeared to be slowed and clinical outcomes
improved.
O’Keefe JH Jr, Harris WS, Nelson J, et al. Effects
of pravastatin with niacin or magnesium on lipid
levels and postprandial lipemia. Am J Cardiol
1995;76:480–4.
This 18-week,  parallel-design study compared
the effects of pravastatin 20 mg/day plus either
niacin 1 g 3 times/day, magnesium 800 mg 3
times/day, or placebo once/day on lipid lowering
in patients with low HDL levels and hyper-
triglyceridemia.  Magnesium supplementation
had previously been reported to improve HDL,
triglycerides, insulin resistance, and blood
pressure.  The study enrolled 65 patients, and
although placebo control was attempted, the
niacin-treated patients usually developed adverse
effects (e.g., flushing and pruritis) and thus
disclosed.  Major study end points were LDL3
(the more atherogenic, small, dense LDL), HDL,
and triglyceride levels; exaggerated postprandial
lipemia; and total cholesterol:HDL ratios.
Randomization allowed for the 22% dropout rate
seen in the pravastatin-niacin group; therefore,
21 patients in the pravastatin-niacin group and
18 in each of the other two treatment groups
completed the study.
The LDL level decreased 25% in the
pravastatin-niacin group compared with 13% in
the pravastatin-magnesium group and 14% in the
pravastatin-placebo group; these percentages are
less than would usually be expected with
pravastatin 20 mg alone.  The LDL3 level
decreased by 43% in the pravastatin-niacin
group, which was significantly greater than the
change seen in the other groups.  The HDL level
was significantly increased (29%) and triglyceride
levels were decreased (42%) in the pravastatin-
niacin group.  The only significant change in the
other groups was a 15% reduction in triglyceride
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levels in the pravastatin-placebo group.  The only
significant change in characteristics of
postprandial lipemia was a decrease in
triglyceride content of remnant lipoprotein
particles in the pravastatin-niacin group.  In this
small study, niacin in combination with
pravastatin was superior to magnesium or
placebo in improving non-LDL lipid risk factors.
Jacobson TA, Chin MM, Fromell GJ, Jokubaitis
LA, Amorosa LF. Fluvastatin with and without
niacin for hypercholesterolemia. Am J Cardiol
1994;74:149–54.
This double-blind study investigated the
addition of immediate-release niacin titrated to a
maximum of 3 g/day with fluvastatin 20 mg or
placebo.  Seventy-four patients with LDL levels of
160 mg/dl or greater were randomized to receive
fluvastatin 20 mg/day or placebo for 6 weeks.
Immediate-release niacin was then added to both
treatment regimens for an additional 9 weeks.
The LDL levels decreased by 21% with fluvastatin
monotherapy (p<0.001 vs placebo), and by 40%
after the addition of niacin, compared with 25%
for the niacin control group (p<0.001).
Lipoprotein(a) decreased by 37% in patients
receiving fluvastatin-niacin but was unaltered in
those receiving fluvastatin alone.  No clinically
significant adverse events were seen with
monotherapy or combination therapy.  This study
was limited by its small sample size and short
duration, but it demonstrated the effectiveness of
this combination on the lipoprotein profile.
Davignon J, Roederer G, Montigny M, et al.
Comparative efficacy and safety of pravastatin,
nicotinic acid and the two combined in patients
with hypercholesterolemia. Am J Cardiol
1994;73:339–45.
This placebo-controlled, randomized trial
compared pravastatin 40 mg twice/day, extended-
release niacin 1000 mg twice/day, and the
combination of both agents in patients with type
IIa or IIb hyperlipidemia.  The study consisted of
a short-term phase of 8 weeks (158 patients) and
a long-term phase (143 patients) of up to 88
weeks.  The primary efficacy criterion was
absolute reduction in LDL compared with
baseline level.  Mean baseline LDL level ranged
from 227.1–234.8 mg/dl in all groups.  Reduction
in LDL level at 8 weeks was greatest with the
combination therapy (41.5%) versus pravastatin
alone (32.72%) and niacin alone (16.11%).
Increases in HDL were statistically significantly
different from baseline and placebo in all groups.
Triglyceride level reduction was best in the
combination group (34.85%).  Of interest,
reductions in the niacin-alone group (11.43%)
were less than expected given the known
characteristics of the drug.  Similar results were
seen during the long-term phase.  Clinical
adverse events were more common in the niacin
and combination groups, where flushing and
gastrointestinal complaints predominated.
Statistically but not clinically significant increases
in hepatic enzyme and creatine kinase levels were
more frequent in the niacin-containing regimens;
combination therapy was discontinued in one
patient during the long-term phase due to
chemical hepatitis.  Although of interest in
characterizing the effects on lipoproteins of this
drug combination in comparison with
monotherapy with each component, this study
was limited by its small sample size and the
inclusion of a niacin preparation that is in limited
use today.
Heudebert GR, Van Ruiswyk J, Hiatt J,
Schectman G. Combination drug therapy for
hypercholesterolemia: the trade-off between cost
and simplicity. Arch Intern Med 1993;153:
1828–37.
This article was published before the results of
clinical outcome trials with the statins and was
guided by NCEP ATP II recommendations for
administration of niacin and/or sequestrants as
first-line therapy to achieve the target LDL level
of less than 130 mg/dl.  The authors compared
this recommendation with administration of
lovastatin as initial therapy if multidrug regimens
were required to achieve goal LDL level.
Prospective data regarding tolerance and
effectiveness of niacin, sequestrants, and
lovastatin were collected, and a decision tree was
used to compare the complexity and cost of three
sequential drug algorithms used for initial LDL
levels of 160, 190, 220, and 250 mg/dl.  Actual
drug and laboratory costs were used.  Sensitivity
analyses were performed on the tolerance and
effectiveness of each drug as well as drug and
laboratory cost estimates.  The authors were not
surprised to find that the algorithm using
lovastatin first achieved goal more often and with
fewer concurrent drugs; in addition, it was
relatively less expensive as the initial LDL level
increased.  Although the direct clinical
applicability of this information is now limited by
the acceptance of statins as the standard for
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initial therapy in most patients, this article may
be useful for practitioners attempting to develop
algorithms for combination drug therapies.
Bays HE, Dujovne CA, McGovern ME, et al.
Comparison of once-daily, niacin extended-
release/lovastatin with standard doses of
atorvastatin and simvastatin (the ADvicor Versus
Other Cholesterol-Modulating Agents Trial
Evaluation [ADVOCATE]). Am J Cardiol
2003;91:667–72.
This 16-week, randomized, open-label, dose-
comparison study compared the lipid-altering
effects of extended-release niacin 1000–2000 mg
once/day plus lovastatin 40 mg/day with standard
doses of simvastatin 10–40 mg/day and
atorvastatin 10–40 mg/day.  Special emphasis was
placed on comparison of starting doses of all
agents.  Inclusion criteria were an LDL level 160
mg/dl or greater in patients with CAD,
triglyceride levels less than 300 mg/dl, and HDL
levels less than 45 mg/dl in men and less than 50
mg/dl in women.  Patients with a fasting blood
glucose level above 115 mg/dl and those with
diabetes were excluded.  Mean age of the 315
study patients was 53 years, and most were
overweight Caucasian men.  Mean baseline LDL
level was 191 mg/dl, triglycerides 170 mg/dl,
HDL 38 mg/dl, and lipoprotein(a) 21 mg/dl.
Patients were randomized to one of four
treatment groups, and treatment was titrated over
12 weeks to the maximum dose tolerated.
Patients who did not tolerate titration were
withdrawn from the study; no dosage reductions
were allowed.
Extended-release niacin 1000 mg–lovastatin 40
mg lowered LDL level as effectively (38%) as
atorvastatin 10 mg (38%) and simvastatin 20 mg
(35%), and increased HDL level and lowered
triglycerides and lipoprotein(a) levels signifi-
cantly more.  Extended-release niacin 2000
mg–lovastatin 40 mg lowered LDL 42%,
increased HDL 32%, and lowered lipoprotein(a)
21% compared with 49%, 6%, and 0% with
atorvastatin 40 mg and 39%, 7% and 2% with
simvastatin 40 mg, respectively.  Dizziness and
flushing occurred more frequently in the
extended-release niacin–lovastatin groups and
accounted for more dropouts from the study.
Otherwise, the frequency of adverse effects was
low and was similar among treatment groups.
This study demonstrated that a combination
extended-release niacin–lovastatin product can
produce LDL reductions similar to those
achieved with low doses of atorvastatin and low-
to-moderate doses of simvastatin, with superior
improvement in other lipid risk factors.
Kashyap ML, McGovern ME, Berra K, et al.
Long-term safety and efficacy of a once-daily
niacin/lovastatin formulation for patients with
dyslipidemia. Am J Cardiol 2002;89:672–8.
This study evaluated the long-term safety of
once-daily extended-release niacin–lovastatin by
meeting regulatory guidelines for minimum
exposure to lipid-modifying agents (at least 600
patients had been exposed for 6 months, 200 for
12 months).  Eligible patients were aged 21 years
or older and had type IIa or IIb hyperlipidemia;
the NCEP ATP II target LDL guidelines were used
for the enrollment criteria.  Mean age of the
study patients was 59 years (range 25–84 yrs),
and most were Caucasian men; 37% had CAD
and 11% reported a history of diabetes.
Extended-release niacin 500 mg–lovastatin 10 mg
was started for 1 month and was then increased
monthly by niacin 500–lovastatin 10 mg up to
niacin 2000–lovastatin 40 mg, which was
maintained through week 52 if tolerated.  Of the
814 patients who received study drug, 604 were
evaluable at 28 weeks and 226 at 52 weeks,
meeting the study goals for minimum drug
exposure.
Over 52 weeks, changes in lipoprotein profiles
were dose related, with LDL level reduction
ranging from 25–45%, HDL level increase
11–41%, triglyceride level reduction 16–42%,
and lipoprotein(a) level reduction 2–25%.  The
predominant adverse effect was flushing, which
caused 105 patients to withdraw. Dyspepsia was
reported in 6–8% of patients; headache (7%),
dizziness (5%), and hyperglycemia (5%) also
occurred.  One 58-year-old, obese man with
hypertension and CAD developed diabetes.
Three patients were withdrawn from the study
after experiencing serious gastrointestinal
disorders that were considered at least possibly
drug related.  Creatine kinase level elevations of
more than 10 times the upper limit of normal
occurred in two patients, both of whom
experienced exercise-related injuries; one
withdrew from the study.  Overall, extended-
release niacin–lovastatin was well tolerated over
52 weeks in this controlled study of relatively
healthy patients.
Statin and Resin
Denke MA, Grundy SM. Efficacy of low-dose
cholesterol-lowering drug therapy in men with
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moderate hypercholesterolemia. Arch Intern Med
1995;155:393–9.
This study investigated the efficacy of a low-
dose combination of a resin (cholestyramine)
with a statin (lovastatin) in reducing LDL
concentration.  Three drug regimens were tested
in 26 men with moderate hypercholesterolemia:
cholestyramine 8 g/day, cholestyramine 8 g/day
plus lovastatin 5 mg/day, and lovastatin 20
mg/day.  Cholestyramine 8 mg/day reduced LDL
level from 173 to 151 mg/dl (p<0.005); the
cholestyramine-lovastatin combination further
reduced LDL level to 131 mg/dl (p<0.005),
similar to results with lovastatin 20 mg.  This
study is significant because it demonstrated that
a low-dose resin-statin combination resulted in a
significant reduction in LDL level, similar to
results with a higher statin dose.  Thus, a low-
dose resin-statin combination is a viable option
for management of elevated LDL concentrations.
Ito MK, Shabetai R. Pravastatin alone and in
combination with low-dose cholestyramine in
patients with primary hypercholesterolemia and
coronary artery disease. Am J Cardiol 1997;80:
799–802.
Another important study demonstrated the
efficacy of low-dose combination therapy with a
resin and a statin in addition to demonstrating
the cost-effectiveness of combination therapy.
This randomized, open-label, parallel-design
study evaluated 59 patients who received
pravastatin 10 mg/day in combination with
cholestyramine 5 g/day or pravastatin 20 mg/day.
If LDL concentration remained greater than 100
mg/dl after 6 weeks of this therapy, pravastatin
was increased to 20 mg/day in the combination
group and to 40 mg/day in the monotherapy
group.  The results demonstrated that the lower-
dose combination treatment had similar effects
on lipoproteins as low- and high-dose
monotherapy.  In addition, the higher-dose
combination therapy had superior effects in
reducing LDL level compared with pravastatin 20
mg (p=0.0006) or 40 mg (p=0.033).  Cost-
effectiveness of the combination therapy was
similar to that of monotherapy with pravastatin
20 mg/day and superior to that of pravastatin 40
mg/day. Overall, this study is important because
it demonstrated that not only is low-dose resin-
statin combination therapy effective in treating
hypercholesterolemia but it also may be a cost-
effective alternative to higher-dose statin therapy.
Statin and Ezetimibe
Davidson MH, McGarry T, Bettis R, et al.
Ezetimibe coadministered with simvastatin in
patients with primary hypercholesterolemia. J
Am Coll Cardiol 2002;40:2125–34.
This randomized, single-blind study
determined the efficacy and safety of treatment
with both ezetimibe and simvastatin in patients
with primary hypercholesterolemia.  A total of
591 patients received one of 10 treatments:
ezetimibe 10 mg/day; simvastatin 10, 20, 40, or
80 mg/day; ezetimibe 10 mg/day plus simvastatin
10, 20, 40, or 80 mg/day; or placebo.  The
combination of ezetimibe and simvastatin
resulted in significantly greater reductions in
LDL level and significantly greater increases in
HDL levels compared with simvastatin alone.
When pooled doses were evaluated, ezetimibe
and simvastatin provided 13.8% and 7.5% greater
reductions in LDL and triglyceride levels,
respectively, and a 2.4% increase in HDL level
compared with pooled doses of simvastatin
alone.  The authors also noted that ezetimibe 10
mg in combination with simvastatin 10 mg
resulted in a 44% reduction in LDL level, similar
to that seen with simvastatin 80 mg alone.  An
incremental increase also was noted in LDL level
reduction when ezetimibe was added to
simvastatin 80 mg compared with simvastatin 80
mg alone.  All treatments had a similar safety
profile.  Addition of ezetimibe 10 mg to
simvastatin provided an incremental benefit in
LDL and triglyceride level reduction and in HDL
level increase.  Also, the combination was well
tolerated compared with statin therapy alone.
This study demonstrated that with all doses of
simvastatin, an incremental benefit on lipid
profile may occur when ezetimibe 10 mg/day is
added for treatment of primary hypercholes-
terolemia.  In addition, low-dose simvastatin in
combination with ezetimibe had effects similar to
those of high-dose simvastatin therapy. This
finding may have important clinical application,
especially for patients who cannot tolerate high-
dose statin therapy.  One important issue not
addressed by this study is the effect of the
ezetimibe-simvastatin combination on the
pleiotropic effects associated with statin therapy
compared with statin therapy alone, especially
across dose ranges.
Ballantyne CM, Houri J, Notarbartolo A, et al.
Effect of ezetimibe coadministered with
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atorvastatin in 628 patients with primary hyper-
cholesterolemia: a prospective, randomized,
double-blind trial. Circulation 2003;107:2409–15.
This study determined the efficacy and safety
of treatment with both ezetimibe and atorvastatin
in patients with primary hypercholesterolemia.  A
total of 628 patients were randomized to receive
one of 10 treatments:  ezetimibe 10 mg;
atorvastatin 10, 20, 40, or 80 mg; ezetimibe 10
mg plus atorvastatin 10, 20, 40, or 80 mg; or
placebo.  The combination of ezetimibe and
atorvastatin resulted in significantly greater
reductions in LDL, triglyceride, and CRP levels,
and significantly greater increases in HDL levels
compared with atorvastatin alone.  When pooled
doses were evaluated, ezetimibe and atorvastatin
provided 12%, 8%, and 10% greater reductions in
LDL, triglyceride, and CRP levels, respectively,
and a 3% increase in HDL level compared with
pooled doses of atorvastatin alone.  Ezetimibe
alone had no effect on CRP level.  The authors
also noted that ezetimibe 10 mg in combination
with atorvastatin 10 mg resulted in a 50%
reduction in LDL level, similar to the 51%
reduction seen with atorvastatin 80 mg alone.
However, a greater reduction (43%) in CRP level
was noted with atorvastatin 80 mg than with the
combination of ezetimibe 10 mg and atorvastatin
10 mg/day (25%).  An incremental increase also
was noted in LDL and CRP level reduction when
ezetimibe was added to atorvastatin 80 mg
compared with atorvastatin 80 mg alone.  All
treatments had a similar safety profile.  Addition
of ezetimibe 10 mg to atorvastatin provided an
incremental benefit in LDL and triglyceride level
reduction and in HDL level increase.  Similar
results in lowering CRP level were also observed
with atorvastatin doses greater than 10 mg.  Also,
the combination was well tolerated compared
with statin therapy alone.
This study and its results were nearly identical
to the preceding simvastatin study, except that
CRP level was also measured.  The nearly
identical results from these studies suggest that
with regard to effects on lipid levels, a class effect
seems to occur with the statins when ezetimibe is
added to the regimen.  Also of note, the addition
of ezetimibe further reduced CRP levels.  The
mechanisms for this effect on CRP level still need
to be elucidated.  This effect may be clinically
important in targeting CRP level reduction.  Also
of note, however, is that using a low-dose statin-
ezetimibe combination does not have the same
effect on CRP level (and perhaps other
pleiotropic effects) as high-dose monotherapy
with a statin.  This finding may be a factor when
selecting therapy for individual patients.
Gagne C, Gaudet D, Bruckert E. Efficacy and
safety of ezetimibe coadministered with
atorvastatin or simvastatin in patients with
homozygous familial hypercholesterolemia.
Circulation 2002;105:2469–75.
This randomized, double-blind study
determined the efficacy and safety of treatment
with both ezetimibe and either atorvastatin or
simvastatin in patients with homozygous familial
hypercholesterolemia.  Fifty patients receiving
open-label simvastatin 40 mg/day or atorvastatin
40 mg/day with or without concomitant LDL
apheresis were randomized to receive one of the
following treatments for 12 weeks:  atorvastatin
80 mg/day or simvastatin 80 mg/day (17
patients), ezetimibe 10 mg/day plus atorvastatin
40 mg/day or simvastatin 40 mg/day (16
patients), or ezetimibe 10 mg/day plus
atorvastatin 80 mg/day or simvastatin 80 mg/day
(17 patients).  Patients receiving ezetimibe and
either 40 mg or 80 mg of a statin had
significantly greater LDL level reductions than
those receiving 80 mg of a statin without
ezetimibe (20.7% vs 6.7%, p=0.007).  This study
demonstrated that in patients with homozygous
familial hypercholesterolemia, addition of
ezetimibe to statin therapy resulted in greater
LDL level reductions than with statin therapy
alone.
Ziajka PE, Reis M, Kreul S, King H. Initial low-
density lipoprotein response to statin therapy
predicts subsequent low-density lipoprotein
response to the addition of ezetimibe. Am J
Cardiol 2004;93:779–80.
The authors of this small (37 patients),
retrospective study explored the notion that
hyporesponders to statin therapy are hyper-
absorbers.  They speculated that ezetimibe added
to statin therapy would result in an inverse
correlation between the initial LDL response to
statin therapy and the response with combination
therapy.  In other words, hyporesponders to
statin therapy would be hyperresponders when
ezetimibe was added.  Linear regression analysis
showed a significant correlation with a negative
slope (r=0.77, p<0.001).  In eight of the 37
patients, LDL level reduction was greater than
40% when ezetimibe was added.  Overall, this
interesting study has a number of major
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limitations.  However, the authors have presented
enticing data to potentially explain exaggerated
responses that may occur when ezetimibe is
added to statin therapy.
Other Important Pharmacotherapy Studies
Niacin
McKenney JM, Proctor JD, Harris S, Chinchili
VM. A comparison of the efficacy and toxic
effects of sustained- vs immediate-release niacin
in hypercholesterolemic patients. JAMA 1994;
271:672–7.
This randomized, double-blind, parallel-group
trial compared immediate-release and sustained-
release niacin in 46 patients with hyper-
cholesterolemia across a dose range that started
at 500 mg/day and was titrated every 6 weeks to a
maximum of 3000 mg/day. The two treatment
groups (immediate- and sustained-release niacin)
were similar at baseline except for their HDL
levels.  Sustained-release niacin reduced LDL
level significantly more than immediate-release
niacin with daily doses above 1000 mg.  This
reduction, up to 50%, is greater than that seen in
other studies using sustained-release niacin; the
lack of success in other studies may be due to
hepatotoxicity that developed in the study
patients.  Immediate-release niacin resulted in
significantly higher HDL levels than sustained-
release niacin at all doses except 1500 mg.  No
significant differences between dosage forms were
noted with regard to triglyceride level reductions.
The most common adverse effect in the
immediate-release niacin group was vasodilatory,
such as flushing, prompting 39% of the patients
in that group to withdraw from the study.  The
most common adverse effect with sustained-
release niacin was hepatotoxicity, prompting 78%
of the patients in that group to withdraw before
achieving the target daily dose of 3000 mg.  Most
cases of hepatotoxicity occurred with daily doses
of 2000 mg or greater. A significant increase was
noted in liver enzyme levels with sustained-
release niacin at doses above 1500 mg (p<0.05).
Also, sustained-release niacin was associated with
significant increases in fasting glucose levels at
daily doses above 1500 mg (p=0.009).  The
increased toxicity of sustained-release niacin
precludes its widespread use in the treatment of
hypercholesterolemia.
Knopp RH, Ginsberg J, Albers JJ, et al.
Contrasting effects of unmodified and time-
release forms of niacin on lipoproteins in
hyperlipidemic patients: clues to mechanism of
action of niacin. Metabolism 1985;34:642–50.
This study compared immediate- and time-
release niacin in 65 patients over a 6-month
period to assess the differences in changes in
lipid indexes, lipoprotein subclasses, and adverse
events.  Thirty-four patients in the immediate-
release niacin group and 31 in the time-release
niacin group received 500 mg 3 times/day (1500
mg/day) during the first month and then 1000
mg 3 times/day (3000 mg/day) during months
2–6.  Dropout rates were similar among patients
in both groups—25% for those receiving
immediate-release and 18% for time-release
niacin.  Patients receiving immediate- versus
time-release niacin had significantly decreased
triglyceride levels (45.2 vs 15.2 mg/dl) and
significantly increased HDL levels (12.9 vs 4.1
mg/dl) when results were averaged over months
2–6 (p<0.05).  Both compounds significantly
increased HDL3, but only immediate-release
niacin significantly increased HDL2 (p<0.05).
The time-release group had less flushing than the
immediate-release group, but the difference was
not significant.  The time-release group had
significantly increased gastrointestinal adverse
reactions (p<0.05), which limited achievement of
the 3000-mg daily dose to a mean of 2000 mg.
Thus, immediate-release niacin was effective in
treating lipoprotein abnormalities and resulted in
similar rates of flushing compared with time-
release niacin in this study. Generally, sustained-
and extended-release forms of niacin minimize
the flushing adverse reactions.
Elam MB, Hunninghake DB, Davis KB, et al.
Effect of niacin on lipid and lipoprotein levels
and glycemic control in patients with diabetes
and peripheral arterial disease: the ADMIT study:
a randomized trial: arterial disease multiple
intervention trial. JAMA 2000;284:1263–70.
The effects of immediate-release niacin on
lipoproteins and glycemic control in 468 patients
(125 with diabetes) were assessed over 48 weeks
in the Arterial Disease Multiple Intervention Trial
(ADMIT).  Patients with hemoglobin A1c (A1C)
values above 9.0% were excluded from the trial.
One group of patients (237 patients—64 with
diabetes, 173 without) received immediate-
release niacin in doses up to 3000 mg/day or a
maximally tolerated dose.  The other group (231
patients—61 with diabetes, 170 without)
received placebo.  No significant differences
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between groups were noted at baseline, except
that the placebo-treated patients with diabetes
were older than the niacin-treated patients with
diabetes (p=0.04).  Niacin reduced total
cholesterol, triglyceride, and LDL levels, and
increased HDL levels in patients with and
without diabetes compared with placebo
(p<0.001 for all comparisons).  The reductions
were not significantly different between patients
with and without diabetes.  Niacin caused an
increase in plasma glucose level in patients with
diabetes (8.1 mg/dl, p=0.04) and without
diabetes (6.3 mg/dl, p≤0.001).  No change in
A1C was observed in niacin patients with
diabetes; however, A1C was decreased 0.3% in
placebo patients with diabetes, resulting in a
significant difference (p=0.05).  No significant
changes in A1C were noted in niacin- or placebo-
treated patients without diabetes (p=0.38).  The
changes in glucose level were mild, which may be
accounted for by the allowed titration in
antidiabetic drugs (increased insulin [p=0.09]
and oral hypoglycemics [p=0.94]).  However,
none of the changes reached statistical
significance.  Niacin also caused significant
increases in uric acid levels in patients with and
without diabetes (p<0.001), but did not
significantly increase alanine aminotransferase
levels (p=0.09).  Thus, niacin at dosages of 3000
mg/day or lower in patients with controlled type
2 diabetes is effective and can be used safely with
proper monitoring.
Grundy SM, Vega GL, McGovern ME, et al, for
the Diabetes Multicenter Research Group.
Efficacy, safety, and tolerability of once-daily
niacin for the treatment of dyslipidemia
associated with type 2 diabetes: results of the
assessment of diabetes control and evaluation of
the efficacy of Niaspan trial. Arch Intern Med
2002;162:1568–76.
The efficacy and safety of extended-release
niacin in 148 patients with diabetes over a 16-
week period was assessed in this double-blind,
placebo-controlled trial.  All patients had a
fasting blood glucose level of 200 mg/dl or less
and an A1C value of 9% or less.  Patients were
divided into three treatment groups:  placebo,
extended-release niacin 1000 mg/day, and
extended-release niacin 1500 mg/day.  The
significant differences in baseline characteristics
of the group receiving extended-release niacin
1000 mg/day versus the other groups were higher
weight, higher body mass index, and lower HDL
levels.  Compared with placebo, both niacin
groups had significantly increased HDL levels
(p<0.05).  Only extended-release niacin 1500
mg/day significantly reduced triglyceride and
LDL levels compared with placebo (p<0.05).
This may be explained by the higher weight and
body mass index in patients receiving extended-
release niacin 1000 mg/day.  A trend was noted in
favor of the 1500-mg niacin dose in reducing
lipoprotein(a) and CRP levels and in increasing
LDL particle size, but this did not reach
significance.  No significant changes were noted
in fasting blood glucose level between the three
groups, but the group receiving extended-release
niacin 1500 mg/day had significantly increased
A1C values compared with placebo (p=0.048).
All groups were similar with regard to uric acid
and liver enzyme levels, and episodes of flushing.
Thus, extended-release niacin can be used safely
and effectively in patients with diabetes.
Meyers CD, Carr MC, Park S, Brunzell JD.
Varying cost and free nicotinic acid content in
over-the-counter niacin preparations for
dyslipidemia. Ann Intern Med 2003;139:
996–1002.
This study assessed the differences between
various over-the-counter preparations of niacin
(immediate-release, sustained-release, and no-
flush) in terms of cost and free nicotinic acid
concentrations.  Ten brands of immediate-release
niacin, nine brands of sustained-release niacin,
and 10 brands of no-flush niacin, all at 500 mg/
tablet or capsule, were assessed.  Assessment was
based on high rates of sales deduced from
national sales figures and high rates of
recommendations from clinical lipidologists
quantified through an e-mail survey. Cost
analysis was determined by the following
equation:  monthly cost = ($/mg) x (2000
mg/day) x (30 days/month).  Immediate-release
niacin was the least expensive preparation at a
mean ± SD cost of $7.10 ± $1.13/month, and
sustained-release niacin was second at $9.76 ±
$1.74/month; no-flush niacin was the most
expensive at $21.70 ± $1.95/month (p<0.001, no-
flush niacin compared with both immediate-
release and sustained-release niacin).
Measurement of free nicotinic acid
concentrations showed that immediate-release
niacin and sustained-release niacin had similar
mean ± SD levels (520.4 ± 12.6 mg and 502.6 ±
19.3 mg, respectively) whereas no-flush niacin
had no detectable levels of free nicotinic acid.
No-flush niacin is composed of inositol
hexaniacinate, which is an inositol molecule
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esterified to six molecules of nicotinic acid.
Hydrolysis of the ester bonds to release free
nicotinic acid takes time and does not result in
therapeutic concentrations of nicotinic acid,
therefore resulting in no benefit of niacin therapy
to treat hyperlipidemia.  Over-the-counter
compounds that should be recommended are Slo-
Niacin (Upsher Smith, Minneapolis, MN) and
Enduracin (Endurance Products Co., Tigard, OR)
for sustained-release niacin, and Squibb
(Princeton, NJ) and Rugby (Westbury, NY) for
immediate-release niacin.
Fibrates
Chapman MJ. Fibrates in 2003: therapeutic
action in atherogenic dyslipidaemia and future
perspectives. Atherosclerosis 2003;171:1–13.
This comprehensive review article explores the
role of fibrates in correcting the atherogenic
dyslipidemias (low HDL and elevated triglyceride
levels) associated with type 2 diabetes, metabolic
syndrome, and type IIb (mixed) lipid phenotype.
Figures enhance understanding of the text.  The
lipid-lowering and pleiotropic effects of fibrates
are discussed.  The author concludes that the
lipid-modulating and antiinflammatory effects of
fibrate therapy alone or in combination may
decrease premature atherosclerosis and cardio-
vascular disease; however, more information is
needed regarding how fibrates change the
atherogenicity of LDL.
Prueksaritanont T, Zhao JJ, Ma B, et al.
Mechanistic studies on metabolic interactions
between gemfibrozil and statins. J Pharmacol Exp
Ther 2002;301:1042–51.
Dog and human liver microsomes were used to
explore the mechanism of the clinical pharmaco-
kinetic interactions between statins and
gemfibrozil.  Dogs were used as an animal model
for humans to study the interaction between
simvastatin and gemfibrozil because gemfibrozil
increases only the simvastatin hydroxyl acid
concentration (not the simvastatin concentration).
In addition, the interpatient variability of area
under the curve for simvastatin hydroxyl acid
exists in dogs as in humans.  The results suggest
that gemfibrozil modulates the pharmacokinetics
of simvastatin hydroxyl acid by inhibiting its
glucuronidation.  Tests conducted in human liver
microsomes suggest that gemfibrozil inhibited
glucuronidation of atorvastatin and simvastatin
hydroxyl acids to a greater extent than the
CYP3A4-mediated oxidation.  Gemfibrozil
inhibited the glucuronidation and the CYP2C8-
and CYP3A4-mediated oxidation pathways for
cerivastatin, which may explain the increased
susceptibility of gemfibrozil to interact with
cerivastatin.
Prueksaritanont T, Tang C, Qiu Y, Mu L,
Subramanian R, Lin JH. Effects of fibrates on
metabolism of statins in human hepatocytes.
Drug Metab Dispos 2002;30:1280–7.
This study used human hepatocytes to
investigate the effects of fibrates on the major
metabolic pathways of statin hydroxyl acids (b-
oxidation, glucuronidation, and CYP-mediated
oxidation).  The results suggest that the
pharmacokinetic interaction between gemfibrozil
and simvastatin is not due to the inhibitory effect
of gemfibrozil on b-oxidation of simvastatin
hydroxyl acid.  These findings substantiate the
results from a previous trial showing that
gemfibrozil interacts with simvastatin by
glucuronidation of simvastatin hydroxyl acid, not
the CYP3A-mediated oxidation.  Gemfibrozil
inhibited the oxidation of rosuvastatin and
cerivastatin, but not of atorvastatin.  Gemfibrozil
inhibited lactonization of the statin hydroxyl
acids in a concentration-dependent manner for
atorvastatin, cerivastatin, rosuvastatin, and
simvastatin.  Rosuvastatin hydroxyl acid
underwent glucuronidation.  Fenofibrate had
minimal effect on the metabolic pathways of
simvastatin hydroxyl acid.  The authors
concluded that these results provide a possible
explanation for the difference between
interactions observed among statin-fibrate
combinations.
Statins
Coons JC. Hydroxymethylglutaryl-coenzyme A
reductase inhibitors in osteoporosis management.
Ann Pharmacother 2002;36:326–30.
This literature review outlines the postulated
mechanism for statins as bone anabolic agents
and analyzes the data available through May
2001.  In vitro, statins act to promote osteoblast
proliferation and differentiation through their
stimulation of the expression of the bone
morphogenetic protein-2 (BMP-2) gene.  The
currently available evidence supporting a positive
relationship between statins and bone mineral
density and reduction of fractures is from
observational studies.  Three large case-control
studies indicated a reduction in fracture risk in
patients taking statins, whereas one found no
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evidence for that hypothesis.  Prospective studies
to evaluate this question have yet to be
published.
Jones P, Kafonek S, Laurora I, Hunninghake D.
Comparative dose efficacy study of atorvastatin
versus simvastatin, pravastatin, lovastatin, and
fluvastatin in patients with hypercholesterolemia
(the CURVES study). Am J Cardiol 1998;81:
582–7.
The CURVES study evaluated the comparative
dose efficacy of atorvastatin 10, 20, 40, and 80
mg; simvastatin 10, 20, and 40 mg; pravastatin
10, 20, and 40 mg; lovastatin 20, 40, and 80 mg;
and fluvastatin 20 and 40 mg in patients with
hypercholesterolemia after 8 weeks of treatment.
Mean age of the 534 patients randomized was 55
years (range 20–80 yrs); 59% were men, and
most were Caucasian.  Mean baseline LDL level
ranged from 192–244 mg/dl in each treatment
group.  Mean LDL level reductions were as
follows:  atorvastatin 10, 20, 40, and 80 mg—
38%, 46%, 51%, and 54%, respectively;
simvastatin 10, 20, and 40 mg—28%, 35%, and
41%, respectively; pravastatin 10, 20, and 40
mg—19%, 24%, and 34%, respectively; lovastatin
20, 40, and 80 mg—29%, 31%, and 48%,
respectively; and fluvastatin 20 and 40 mg—17%
and 23%, respectively.  Atorvastatin 10 mg was
statistically significantly more effective in
reducing LDL levels than the other drugs at all
doses except for simvastatin 20 and 40 mg,
pravastatin 40 mg, and lovastatin 80 mg.
Atorvastatin 20 mg was statistically significantly
more effective in reducing LDL levels than the
other drugs at all doses except for lovastatin 80
mg.
Jones PH, Davidson MH, Stein EA, et al, for the
STELLAR Study Group. Comparison of the
efficacy and safety of rosuvastatin versus
atorvastatin, simvastatin, and pravastatin across
doses (STELLAR trial). Am J Cardiol 2003;92:
152–60.
This 6-week, parallel-group, open-label,
randomized trial compared rosuvastatin 10, 20,
40, and 80 mg with atorvastatin 10, 20, 40, and
80 mg; pravastatin 10, 20, and 40 mg; and
simvastatin 10, 20 , 40, and 80 mg across dose
ranges for LDL level reduction.  The study, which
included 2431 patients, administered the doses of
drugs that were, except for rosuvastatin,
approved by the FDA at that time.  Eligible
patients had baseline LDL levels that were stable
at 160–250 mg/dl (mean baseline level ~190
mg/dl) and triglyceride levels less than 400
mg/dl.  The LDL level reductions were as follows:
rosuvastatin 10, 20, 40, and 80 mg—45.8%,
52.4%, 55%, and percentage not provided,
respectively; atorvastatin 10, 20, 40, and 80 mg—
36.8%, 42.6%, 47.8%, and 51.1%, respectively;
pravastatin 10, 20, and 40 mg—20.1%, 24.4%,
and 29.7%, respectively; and simvastatin 10, 20,
40, and 80 mg—28.3%, 35%, 38.8%, and 45.8%,
respectively.  Of patients meeting NCEP goals,
89% were receiving rosuvastatin 20 or 40 mg;
29% of patients had an LDL goal of less than 100
mg/dl.  Two patients receiving rosuvastatin 80 mg
developed acute renal failure of uncertain
etiology; this dose was never approved by the
FDA.  Otherwise, no differences were noted
among groups regarding reported adverse effects
or withdrawn treatment.  This study was well
powered and designed to characterize LDL level
reductions with a new agent, rosuvastatin,
compared with other available and widely
administered statin agents.
McGowan MP, for the Treating to New Target
(TNT) Study Group. There is no evidence for an
increase in acute coronary syndromes after short-
term abrupt discontinuation of statins in stable
cardiac patients. Circulation 2004;110:2333–5.
This article was a response to two previous
publications that found that risk of death and
myocardial infarction increased significantly
when statins were abruptly withdrawn after
hospital admission for ACS.  The data reported in
this article were derived from the washout and
open-label randomization phases of the TNT
study, which enrolled patients with stable CAD.
A total of 16,619 patients entered the dietary
lead-in drug-washout period; of these, 9395 were
receiving previous statin therapy.  On entry into
the washout period, mean ± SD LDL level was
106 ± 30.4 mg/dl; during this period, 24 primary
cardiac events occurred.  On entry into the open-
label run-in period, mean ± SD LDL level was
153 ± 37.8 mg/dl; 31 primary events were
recorded during this period.  Based on this
report, patients with stable CAD who discontinue
their statin therapy abruptly for up to 6 weeks do
not appear to have an increased risk of
precipitating ACS.  The report was not designed
to answer the question of whether patients with
ACS have an increased risk of death or
myocardial infarction when these drugs are
similarly withdrawn.
1006
KEY ARTICLES IN THE TREATMENT OF DYSLIPIDEMIAS  Ito et al
Resins
Konzem SL, Gray DR, Kashyap ML. Effect of
pharmaceutical care on optimum colestipol
treatment in elderly hypercholesterolemic
veterans. Pharmacotherapy 1997;17:576–83.
This small, prospective, randomized study
investigated whether pharmacist-physician
comanagement (pharmaceutical care group)
could improve patient adherence with colestipol
therapy and outcomes.  Forty men with
hypercholesterolemia were equally divided and
assigned to receive either pharmaceutical care or
usual care by a physician.  All patients were
followed for 52 weeks.  In the pharmaceutical
care group, a pharmacist provided education
about hypercholesterolemia, colestipol dosage
titration, adverse-effect management, and
instructions for follow-up.  Patients were given
an 8-week supply of colestipol, docusate sodium,
and psyllium.  The pharmacist phoned the
patients during weeks 2, 4, 6, 26, and 52, and
met with patients after 8 weeks to evaluate
fasting lipid panel results, assess acceptance of
therapy, and provide prescription refills.  After 52
weeks, the pharmaceutical care group achieved
greater LDL level reductions than the usual care
group (16.0% vs 9.4%), and more patients in the
pharmaceutical versus usual care group (29.4%
vs 5.0%, p<0.5) achieved their NCEP ATP II goal
LDL level.
Spence JD, Huff MW, Heidenheim P, et al.
Combination therapy with colestipol and
psyllium mucilloid in patients with hyper-
lipidemia. Ann Intern Med 1995;123:493–9.
This randomized, parallel-group, double-blind,
controlled trial evaluated the efficacy, safety, and
compliance of colestipol 5 g, colestipol 2.5 g plus
psyllium 2.5 g, psyllium 5 g, and cellulose
placebo 5 g in 121 patients who had primary
hypercholesterolemia and had followed a NCEP
step 2 diet for 1 year.  Fasting lipid levels,
apolipoprotein concentrations, and quality of life
were assessed at baseline, 4 weeks, and 10 weeks.
Packet counts were used to assess compliance.
No statistically significant differences were noted
between the colestipol group and the combi-
nation group with respect to individual lipid
parameters.  The psyllium-colestipol combination
was more effective in lowering the total
cholesterol:HDL ratio than either drug or placebo
alone (p<0.05).  The authors concluded that
quality of life was best with the combination
therapy and worst with placebo and with
psyllium alone, but no other information was
provided.  No statistically significant difference
was noted in compliance between treatment
groups.
Novel Targets
Bays H, Stein EA. Pharmacotherapy for
dyslipidaemia: current therapies and future
agents: review. Expert Opin Pharmacother
2003;4:1901–38.
This article reviews potential targets for
intervention of lipid metabolism that are in
development.  These include newer statins, bile
acid transport inhibitors, sterol regulatory
element binding protein cleavage-activating
protein-activating ligand, microsomal transport
protein inhibitors, cholesteryl ester transfer
protein (CETP) inhibitors and vaccines,
acylcoenzyme A cholesterol acyltransferase
inhibitors, mixed peroxisome proliferator
activated receptor agonists, and revival of
squalene inhibitors.  The authors comment that
many of these agents are being investigated with
available agents as fixed-dose combinations.
de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef
AF, Kastelein JJ, Kuivenhoven JA. A review of
CETP and its relation to atherosclerosis. J Lipid
Res 2004;45:1967–74.
Cholesteryl ester transfer protein promotes the
transfer of cholesteryl esters from HDL to
apolipoprotein B–containing lipoprotein
particles.  Thus, CETP action in most cases
directly relates to decreased HDL levels.  This
article reviews the role of CETP in lipoprotein
metabolism and cardiovascular risk.  In addition,
drug development studies of two CETP
inhibitors in animals and humans are reviewed.
In humans, phase I and II studies have shown
significant increases in HDL with CETP
inhibition.  Whether this has an antiatherogenic
effect is not known.  The authors acknowledge
the complexity of the relationship between CETP,
HDL, and atherogenesis, and thus conclude that
it is too early to predict whether these compounds
will be useful.
Kong W, Wei J, Abidi P, et al. Berberine is a
novel cholesterol-lowering drug working through
a unique mechanism distinct from statins. Nat
Med 2004;10:1344–51.
This study identifies berberine (a compound
isolated from a Chinese herb) as a potential
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cholesterol-lowering compound that increases
hepatic LDL receptor protein 2.6-fold in
hypercholesterolemic hamsters by a mechanism
different from that of statins.  Berberine does not
inhibit cellular cholesterol biosynthesis through
the sterol regulatory element binding protein
pathway that is the primary mechanism of
statins.  In this study, 91 humans with
hypercholesterolemia were randomized to receive
berberine 0.5 g or placebo for 3 months.
Berberine significantly reduced total cholesterol,
LDL, and triglyceride levels by 29%, 25%, and
35%, respectively.  No change in HDL level was
observed in the berberine-treated patients, and
no significant change was observed in any lipid
parameters in the placebo-treated patients.
Improved liver function was also observed in a
subgroup of patients randomized to receive
berberine compared with those who received
placebo.  The investigators speculate that this
may have been due to reduced fat storage in the
liver.  This hypothesis is supported by animal
data demonstrating reduced hepatic fat staining
in berberine-treated animals compared with
control animals.  This study identifies a potential
hypolipidemic substance with a mechanism of
action different from that of the statins.
Role of Lipid-Lowering Therapy in Patients
with Metabolic Syndrome
Hulthe J, Bokemark L, Wikstrand J, Fagerberg
B. The metabolic syndrome: LDL particle size,
and atherosclerosis: the atherosclerosis and
insulin resistance (AIR) study. Arterioscler
Thromb Vasc Biol 2000;20:2140–7.
This study assessed whether small, dense LDL
particles (pattern B) were related to metabolic
syndrome and subclinical atherosclerosis as
measured by intimal medial thickness in the
carotid and femoral arteries after ultrasound
testing in 391 clinically healthy men.  Patients
were divided into three groups:  62 with
metabolic syndrome, 252 with more than one
metabolic syndrome risk factor, and 77 with no
metabolic syndrome risk factors.  Patients with
metabolic syndrome had elevated body mass
index, blood pressure, heart rate, total
cholesterol, and apolipoprotein B compared with
the other two groups.  Significantly higher mean
values for intimal medial thickness were found in
the metabolic syndrome group than in the other
groups in the carotid artery (p<0.001) and
femoral artery (p=0.022).  However, no
significant differences were noted in plaque
occurrence and size between the groups.  Pattern
B patients had significantly elevated body mass
index, blood pressure, heart rate, total
cholesterol, triglyceride levels, and plasma
insulin levels compared with the larger LDL
subtype.  Patients with pattern B had a higher
prevalence of moderate-to-large plaques, and
decreasing LDL peak particle size was associated
with increasing intimal medial thickness of the
arteries.  Thus, patients with metabolic syndrome
are more likely to have small, dense LDL particles
and increased thickening of the carotid and
femoral arterial walls.
Ford ES, Giles WH, Dietz WH. Prevalence of the
metabolic syndrome among US adults: findings
from the third national health and nutrition
examination survey. JAMA 2002;287:356–9.
Data from the third National Health and
Nutrition Examination Survey were examined to
assess the prevalence of metabolic syndrome in
adults from the United States.  Metabolic
syndrome is defined as meeting three or more of
the following criteria:  abdominal obesity (waist
circumference > 102 cm in men, > 88 cm in
women), hypertriglyceridemia (triglyceride level
≥ 150 mg/dl), low HDL level (< 40 mg/dl in men,
< 50 mg/dl in women), hypertension (blood
pressure ≥ 130/85 mm Hg or receiving anti-
hypertensive drug therapy), and high fasting
glucose level (≥ 110 mg/dl or receiving anti-
diabetic drug therapy).  Roughly 24% of adults
(47 million patients) have metabolic syndrome,
and the prevalence increases with age to more
than 40% in patients older than 60 years.  In
men, Caucasians and Mexican-Americans have
higher rates of abdominal obesity, low HDL
levels, and hypertriglyceridemia; African-
Americans have higher rates of hypertension; and
Mexican-Americans have higher rates of
hyperglycemia.  In women, Mexican-Americans
and African-Americans have higher rates of
abdominal obesity; African-Americans have
higher rates of hypertension; and Mexican-
Americans have higher rates of low HDL levels,
hypertriglyceridemia, and hyperglycemia.
Prevalence was similar between men and women,
except that rates were higher in Mexican-
American women (26% higher) and African-
American women (57% higher) than their male
counterparts.  Thus, metabolic syndrome is
prevalent in American society and needs to be
reduced through intensive diet and exercise
programs as well as proper medical management.
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Lakka HM, Laaksonen DE, Lakka TA, et al. The
metabolic syndrome and total and cardiovascular
disease mortality in middle-aged men. JAMA
2002;288:2709–16.
This study assessed whether the presence of
metabolic syndrome increased the risk of death
due to CHD, cardiovascular disease, or any cause
in 1209 men with and without metabolic
syndrome who were followed for a median of
11.6 years.  During follow-up, 109 deaths
occurred, with 27 due to CHD and 46 due to
cardiovascular disease.  According to the NCEP
ATP III guidelines, metabolic syndrome was
associated with an age-adjusted increased risk of
death due to CHD (RR 3.40, 95% CI 1.37–8.43).
No significant association was found between the
NCEP ATP III criteria regarding cardiovascular
disease and all-cause mortality unless the model
was adjusted for other factors.  The WHO criteria
for metabolic syndrome were significantly
associated with death due to CHD, cardio-
vascular disease, and mortality across various
models.  When assessing unadjusted Kaplan-
Meier hazard curves, metabolic syndrome was
associated with an increased mortality in CHD
(RR 3.77, 95% CI 1.74–8.17), cardiovascular
disease (RR 3.55, 95% CI 1.96–6.43), and all-
cause mortality (RR 2.43, 95% CI 1.64–3.61).
Thus, metabolic syndrome is associated with
increased mortality in middle-aged men who are
initially free of cardiovascular disease and diabetes.
Robins SJ, Collins D, Wittes JT, et al. Relation of
gemfibrozil treatment and lipid levels with major
coronary events: VA-HIT: a randomized
controlled trial. JAMA 2001;285:1585–91.
The Veterans Affairs High-Density Lipoprotein
Intervention Trial (VA-HIT) showed a 22%
reduction in the combined rate of nonfatal
myocardial infarction and CHD death in 1264
men receiving gemfibrozil 1200 mg/day versus
1267 men receiving placebo over a 5.1-year
period.  This study assessed how well the
changes in each lipid variable correlated with
reduced outcomes.  Only HDL concentrations
significantly predicted nonfatal myocardial
infarction and CHD death at baseline and during
treatment (p=0.048 and 0.01, respectively).  Also,
after controlling for diabetes, hypertension,
smoking, age, and body mass index, HDL level
was the only lipid parameter to significantly
predict a reduction in CHD events.  For every 5-
mg/dl increase in HDL, there was an 11% relative
risk reduction in nonfatal myocardial infarction
or CHD death (95% CI 0.81–0.98).  No other
lipid parameter was predictive.  This benefit of
HDL level accounted for only 23% of the
treatment benefit.  The other major lipid
parameters did not contribute to treatment effect,
and perhaps other favorable effects of gemfibrozil
contribute to this reduction.  Thus, raising HDL
concentration can reduce the occurrence of new
coronary events independent of changes in LDL
concentration.
Laaksonen DE, Lakka H-M, Niskanen LK,
Kaplan GA, Salonen JT, Lakka TA. Metabolic
syndrome and development of diabetes mellitus:
application and validation of recently suggested
definitions of the metabolic syndrome in a
prospective cohort study. Am J Epidemiol
2002;156:1070–7.
This prospective cohort study assessed the
ability of different metabolic syndrome criteria
(from the NCEP ATP III and WHO) in predicting
the occurrence of diabetes in 1005 middle-aged
men followed for 4 years.  Patients who met the
WHO criteria for metabolic syndrome were
almost 9 times more likely to develop diabetes
over 4 years than those without the syndrome.
The WHO criteria had high sensitivity (0.83 for
prevalent, 0.67 for incident) and specificity
(0.78–0.80).  The NCEP ATP III criteria had
lower sensitivity for prevalent (0.61) and
incident (0.41) than the WHO criteria, but NCEP
ATP III had more specificity (0.89–0.90).  The
main difference between the criteria is the
definition of abdominal obesity.  The WHO
criteria uses waist:hip measurement ratios above
0.90 as indicative of abdominal obesity, whereas
the NCEP ATP III uses waist circumference above
102 cm.  All men who developed diabetes had a
waist:hip ratio above 0.90, whereas less than a
third of those who developed diabetes had a
waist circumference above 102 cm.  However,
most men who did not develop diabetes also had
a waist:hip ratio above 0.90, reducing specificity
of the measurement.  When the waist circum-
ference cutoff point was reduced to 94 cm or
greater, it captured 59% of the men who
developed diabetes.  Both sets of criteria were
valid in predicting the prevalence and occurrence
of diabetes, but perhaps the waist circumference
criteria in the NCEP ATP III guidelines should be
lowered to capture more individuals who are
likely to develop the disease.
Ford ES, Giles WH. A comparison of the
prevalence of the metabolic syndrome using two
1009
PHARMACOTHERAPY  Volume 26, Number 7, 2006
proposed definitions. Diabetes Care 2003;26:
575–81.
This study applied two different sets of criteria
for metabolic syndrome—those from the NCEP
ATP III and the WHO—to data from NHANES III
to assess whether differences existed between the
two for identifying patients with the syndrome.
For 8608 patients aged 20 years or older, NCEP
ATP III and WHO identified 23.9% and 25.1%,
respectively, as having metabolic syndrome.  The
two sets of criteria were similar for assessing the
population, but the WHO criteria identified more
African-American men (24.9%) than the NCEP
ATP III criteria (16.5%).  This may be due to the
different measurements of central adiposity
between the two sets of criteria; the WHO criteria
identified 3 times as many African-American
men.  Also, more African-American men were
captured due to the inclusion of microalbu-
minuria in the WHO criteria.  Both sets of criteria
associated increased serum insulin concentrations
with increased homeostasis model assessment
scores in patients with metabolic syndrome
versus those without the syndrome.  Both sets of
criteria predicted clinical end points of
cardiovascular disease, such as heart attack,
stroke, and chronic heart failure; the ORs derived
from the WHO criteria had higher numbers but
significant overlapping of the CIs with the ORs
derived from the NCEP ATP III criteria.  Thus,
both sets of criteria are adequate for assessing
most patients with metabolic syndrome, but
perhaps a more inclusive set of criteria can be
developed.
Grundy SM. Hypertriglyceridemia, atherogenic
dyslipidemia, and the metabolic syndrome. Am J
Cardiol 1998;81(4A suppl B):18B–25.
Hypertriglyceridemia plays a large role in the
development of atherogenic dyslipidemia and
may be atherogenic on its own.  Triglyceride-rich
lipoproteins are derived intestinally (chylomi-
crons) and hepatically (VLDL).  As these
particles are metabolized, they decrease in size
and may become atherogenic.  Particles richer in
cholesteryl esters tend to be more atherogenic
and may be seen in the setting of hyper-
triglyceridemia.  Thus, patients with high
triglyceride levels have atherogenic particles
outside their LDL, and they should have their
non-HDL as well as LDL assessed.  Their non-
HDL cholesterol goals are 30 mg/dl above their
LDL goals.  Hypertriglyceridemia also leads to
the lipid triad, or atherogenic dyslipidemia.  The
lipid triad consists of an elevated triglyceride
level, low HDL level, and small, dense LDL
particles.  When triglyceride-rich lipoproteins are
present (due to hypertriglyceridemia), they
exchange triglycerides for cholesteryl esters with
LDL and HDL particles.  This lowers the
cholesterol content in HDL particles, resulting in
low HDL levels.  Also, the triglycerides are
hydrolyzed from the LDL particles, decreasing
their size and producing small, dense LDL
particles.  Each component of the lipid trial
increases atherogenicity.
Metabolic syndrome is a metabolic disorder
consisting of the lipid triad, insulin resistance
(with or without glucose intolerance), hyper-
tension, and a prothrombotic state.  Treatment
should focus on weight loss and increased
physical activity initially.  Second, medical
management should begin with insulin-
sensitizing agents such as metformin or a
thiazolidinedione (glitazone).  Finally, individual
risk factors should be treated with statins
primarily to lower non-HDL cholesterol, niacin
or fibrates to modify the lipid triad, various
agents for treatment of hypertension, and aspirin
to modify the prothrombotic state.
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